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Inherited metabolic disorders (IMDs) are rare autosomal recessive disorders, showing 
a high allelic and phenotypic heterogeneity. The main therapeutic goal in these disorders is to 
restore the metabolic balance and, until now, most available therapies are not definitive and 
only alleviate the patients’ symptoms.  
In this work, three IMDs were analyzed, two organic acidurias, propionic and 
methylmalonic acidurias, and one aminoacidopathy, pyruvoyltetrahydropterin synthase.  
Organic acid disorders or organic acidurias (OAs) are characterized by the excretion of 
non-amino organic acids in urine. Two of the most common OAs are propionic and 
methylmalonic acidurias. These two disorders are caused by defects in the oxidation pathway 
of propionyl-CoA into succinyl-CoA that enters the tricarboxylic acid cycle. Propionic aciduria is 
caused by mutations affecting the PCCA or PCCB genes that encode the subunits of the 
propionyl-CoA carboxylase enzyme, while methylmalonic aciduria is caused by mutations 
affecting not only the MUT gene but also the genes encoding the proteins involved in the 
trafficking and synthesis of the enzyme cofactor, adenosylcobalamin (AdoCbl). Until now, 9 
different complementation groups have been identified, but only four, mut, cblA, cblB and 
cblD variant 2 are responsible for a phenotype of isolated methylmalonic aciduria. 
Pyruvoyltetrahydropterin synthase deficiency is caused by defects in the PTS gene that 
encodes the enzyme pyruvoyltetrahydropterin synthase (PTPS), which catalyzes the second 
step of the de novo tetrahydrobiopterin (BH4) synthesis.  
In this work four methylmalonic cblD variant 2 type, one methylmalonic mut type and 
two propionic patients of Spanish and Portuguese origin were genetically characterized, 
revealing the presence of three novel (c.165_166del2, c.170G>A and c.10-1G>C) and one 
already described (c.57_64del8) mutations in cblD variant 2 type patients, two novel mutations 
(c.244dupA and c.1408-10A>G) in the mut type patient and two already described mutations 
(c.1218del14ins12 and c.183+3G>C) in the propionic patients.  
The functional analysis of three missense mutations (p.His183Leu, p.Arg186Trp and 
p.Glu193Lys), and two in-frame mutations (p.Ile117_Gln118del and p.Arg190dup) affecting the 
MMAB gene (cblB complementation group) revealed that all are disease causing, since the in-
frame mutations are responsible for a complete lack of immunoreactive protein, while the 
missense mutations affect protein folding and stability. 
The p.His183Leu and p.Arg190dup are novel mutations and were identified in two 
siblings presenting phenotypic differences. Analysis of these patients using a customized high-
resolution comparative genomic hybridization assay (Metaboloarray®) and the analysis of the 
MMAB gene promoter regions did not reveal any other changes, while the analysis of 
fibroblasts derived from the patients revealed low protein levels when compared with 
ABSTRACT 
 
 
XXX 
controls, and also differences in the protein levels between the siblings. The study of the 
mitochondrial protein quality control revealed elevated levels of mitochondrial Hsp70 in both 
patients and reduced Lon protease levels in one of the siblings.  
Analysis of the mitochondrial function in these two cblB type patients, and also in two 
mut type patients, revealed mitochondrial impairment in all patients and, most importantly, a 
correlation between mitochondrial impairment and the phenotypic differences observed in 
the cblB type patients.  
Finally, two different therapeutic approaches were assessed. The use of a 
pharmacological chaperone, in vitro upon missense mutations (p.His183Leu, p.Arg186Trp and 
p.Glu193Lys) affecting MMAB gene, and also in vivo, upon the wild-type protein. In vitro 
treatment with compound V increased the mutants’ stability, and the in vivo treatment 
stabilized the wild-type protein in brain and liver without toxic effects.  
A comparison of the stabilizing effect of the pharmacological chaperone and 
hydroxocobalamin (OHCbl) was also performed, showing a synergistic effect of both 
compounds upon the stability of wild-type and p.Ile96Thr mutant proteins in a cellular model.  
The antisense therapy targeting pseudoexon inclusion in PTPS deficient patients was 
tested, and successfully restored the normal PTS splicing profile, immunoreactive protein 
levels, enzymatic activity and metabolic pathway in the three patients analyzed.  
The results obtained with this work allowed the expansion of the known mutational 
spectrum in isolated methylmalonic aciduria, the characterization of novel mutants, as well as 
the identification of novel therapeutic targets.  
 
 
Key words: Inherited metabolic disorders, mitochondrial impairment, pharmacological 
chaperone, antisense therapy.  
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As Doenças Metabólicas Hereditárias (DHMs) são doenças raras, transmitidas na sua 
maioria de forma autossómica recessiva, e que afetam o metabolismo intermediário. Embora a 
frequência individual de cada DHM seja baixa, quando analisadas no seu conjunto, estas 
doenças afetam cerca de 8% da população europeia. 
As DHMs caracterizam-se por uma elevada heterogeneidade fenotípica e, até ao 
momento, as opções terapêuticas não corrigem as causas e apenas aliviam a sintomatologia 
dos doentes. Os recentes avanços científicos ampliaram o conhecimento das bases genéticas 
bem como da patofisiologia subjacente às DHMs, permitindo a procura e identificação de 
novas abordagens terapêuticas.  
A classificação das DHMs é feita de acordo com a via metabólica afetada. Neste 
trabalho foram estudadas duas acidúrias orgânicas, acidúria propiónica e metilmalónica e uma 
aminoacidopatia, deficiência no enzima 6-piruvoil-tetrahidropterina sintase (PTPS).  
As acidúrias propiónica e metilmalónica são duas das acidúrias orgânicas mais comuns 
e são causadas por defeitos na via metabólica que catalisa a oxidação do propionil-CoA em 
succinil-CoA, um intermediário do ciclo dos ácidos tricarboxílicos. A acidúria propiónica é 
causada por mutações nos genes PCCA ou PCCB que codificam as subunidades do enzima 
propionil-CoA carboxilase (PCC). Este enzima é responsável pela carboxilação do propionil-CoA 
em D-metilmalonil-CoA. Os doentes afetados apresentam um amplo espectro de 
manifestações clínicas caracterizado por acidose metabólica, cetose, hipoglicémia e 
hiperamonémia devido à acumulação de ácido propiónico e à depleção dos níveis de carnitina. 
O diagnóstico bioquímico consiste na deteção de níveis urinários elevados de 2-metilcitrato, 
ácido propiónico e 3-hidroxi-propionato, entre outros metabolitos, sendo a confirmação do 
diagnóstico realizada através de estudos enzimáticos ou de caracterização genética. O 
tratamento destes doentes passa pela restrição alimentar de aminoácidos percursores do 
propionil-CoA, administração de carnitina, biotina e cabamilglutamato, e também de 
metronidazol para reduzir a produção de propionato pela flora intestinal.  
Por sua vez, a acidúria metilmalónica pode ter diversas causas: mutações no gene MUT 
que codifica o enzima metilmalonil-CoA mutase (MUT), responsável pela síntese de succinil-
CoA a partir de L-metilmalonil-CoA, ou mutações em genes que codificam as proteínas 
responsáveis pela síntese e transporte do cofactor, adenosilcobalamina.  
Até ao momento, foram identificados 9 grupos de complementação distintos, de 
acordo com as proteínas afetadas e o fenótipo apresentado pelos doentes, mas apenas quatro, 
mut, cblA, cblB e cblD variante 2, são responsáveis por um fenótipo de acidúria metilmalónica 
isolada. O grupo de complementação cblA é causado por mutações no gene MMAA, enquanto 
RESUMO 
 
 
XXXIV 
mutações no gene MMAB são responsáveis pelo grupo cblB. O grupo de complementação cblD 
variant 2 é causado por mutações nos exões iniciais do gene MMADHC. 
O diagnóstico de acidúria metilmalónica consiste na determinação de perfis 
metabólicos, em estudos enzimáticos e, finalmente, na caracterização genética. Estes doentes 
apresentam níveis elevados de ácido metilmalónico, 3-hidroxipropionato, 2-metilcitrato, 
lactato, propionilglicina e creatinina, tanto na urina como no plasma. O tratamento destes 
doentes passa também pela restrição alimentar, administração de vitamina B12 e 
carbamilglutamato, bem como suplementação com carnitina.  
Mutações no gene PTS causam deficiência do enzima PTPS, responsável pela catálise 
do segundo passo da via de síntese de novo da tetrahidrobiopterina (BH4). Estes doentes 
podem apresentar três fenótipos clínicos, classificados de acordo com a gravidade 
apresentada: central (deficit de BH4 e neurotransmissores no sistema nervoso central e órgãos 
periféricos), periférico (deficit de BH4 e neurotransmissores nos órgãos periféricos) e 
transitório.  
Neste trabalho, realizou-se a caracterização molecular de vários doentes de origem 
espanhola e portuguesa: quatro doentes com acidúria metilmalónica pertencentes ao grupo 
cblD variante 2, um doente metilmalónico pertencente ao grupo mut e dois doentes com 
acidúria propiónica. Os resultados levaram à identificação de três mutações novas 
(c.165_166del2, c.170G>A e c.10-1G>C) e uma mutação já descrita (c.57_64del8) nos doentes 
tipo cblD variante 2, duas mutações novas (c.244dupA e c.1408-10A>G) no doente tipo mut e 
duas mutações já descritas (c.1218del14ins12 e c.183+3G>C) nos doentes propiónicos. Todas 
as mutações identificadas foram caracterizadas, tendo os resultados revelado que são muito 
provavelmente patogénicas e responsáveis pelo fenótipo clínico observado nos doentes.  
A caracterização funcional das mutações no gene MMAB, que codifica o enzima 
adenosilcobalamina transferase (ATR), responsável pela síntese do cofactor do enzima MUT, 
adenosilcobalamina, revelou resultados dependentes do tipo de mutação. Assim, as três 
mutações missense (p.His183Leu, p.Arg186Trp e p.Glu193Lys) revelaram uma diminuição da 
estabilidade proteica, sugerindo uma possível deficiência no mecanismo de folding. As duas 
mutações in-frame (p.Ile117_Gln118del e p.Arg190dup) revelaram ser responsáveis por uma 
diminuição drástica dos níveis de proteína.  
As mutações p.Arg183Leu e p.Arg190dup não se encontravam descritas na literatura e 
foram detetadas em dois irmãos pertencentes ao grupo cblB que, apesar do mesmo genótipo, 
apresentam diferenças fenotípicas significativas, sendo um deles assintomático e o outro 
apresentando níveis ligeiramente elevados de ácido metilmalónico. A sequenciação da região 
promotora do gene MMAB, bem como uma análise por hibridização genómica comparativa 
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(Metaboloarray®), não revelou nenhuma outra alteração genética. A análise dos níveis da 
proteína ATR nestes doentes revelou uma redução significativa em comparação com os 
controlos, bem como diferenças entre os dois irmãos. A análise indireta da atividade da 
proteína ATR em condições de stress (42°C) revelou uma redução significativa da mesma no 
irmão assintomático, indicando que as diferenças entre os dois irmãos poderiam estar 
relacionadas com diferenças na expressão de proteínas envolvidas no sistema de controlo de 
qualidade proteico. A análise posterior da expressão dos chaperones mitocondriais Hsp60, 
Hsp70 e da protease Lon, revelou níveis significativamente elevados do chaperone Hsp70 nos 
dois irmãos em comparação com o controlo e uma redução dos níveis da protease Lon foi 
observada no caso do irmão assintomático.  
O conhecimento prévio da existência de disfunção mitocondrial em doentes com 
acidúria metilmalónica levou à análise da função mitocondrial nos dois irmãos tipo cblB e 
também em dois doentes pertencentes ao grupo de complementação mut. A análise dos níveis 
de espécies reativas de oxigénio (ROS), morfologia mitocondrial, função bioenergética e, por 
último, da formação/abertura do poro mitocondrial, revelou que todos os doentes apresentam 
uma redução da função mitocondrial quando comparados com os controlos. Observou-se uma 
correlação positiva entre a disfunção mitocondrial e as diferenças fenotípicas entre os dois 
irmãos, embora não se tenha detetado uma correlação entre os níveis de ácido metilmalónico 
e a diminuição da função mitocondrial.  
Neste trabalho foram também estudadas duas abordagens terapêuticas diferentes, de 
acordo com o tipo de mutação presente. O uso de um chaperone farmacológico em doentes 
com acidúria metilmalónica tipo cblB causada por mutações missense, e de terapia antisense 
em doentes com deficiência no enzima PTPS causadas por mutações de splicing.  
Estudos in vitro do efeito estabilizador de uma molécula, composto V, em mutantes 
missense (p.His183Leu, p.Arg186Trp e p.Glu193Lys), previamente caracterizados, revelaram 
um aumento da estabilidade proteica. O efeito do composto V foi também estudado in vivo 
sobre a proteína nativa, e observou-se um aumento dos níveis da proteína ATR em órgãos 
chave desta doença, como o fígado e o cérebro, e sem efeitos tóxicos aparentes. A 
comparação do efeito estabilizador obtido com o chaperone e o efeito estabilizador obtido 
com hidroxocobalamina (OHCbl), o cofator atualmente utilizado para tratamento, demonstrou 
um efeito sinergístico sobre a proteína nativa e o mutante missense, p.Ile96The, inicialmente 
utilizado para estudar o efeito do composto V.  
A presença de mutações que afetam o mecanismo de splicing levando à introdução de 
pseudoexões, tal como se observou em doentes com deficit no enzima PTPS, levou ao uso de 
terapia antisense para recuperar o mecanismo normal de splicing. As abordagens passaram 
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pela utilização de vários tipos de sondas oligonucleotídicas antisense, tais como antisense 
morfolino oligonucleotides (AMOs), bem como VIVO-morfolinos e locked antisense 
oligonucleotides (LNAs), sendo o perfil normal de splicing recuperado com todos os 
oligonucleótidos utilizados. Para além da recuperação do perfil normal de splicing, foi possível 
recuperar ainda os níveis normais de proteína e atividade enzimática, bem como a 
normalização dos diversos compostos intermediários da via metabólica.  
Os resultados obtidos com este trabalho permitiram, assim, a expansão do espectro 
mutacional da acidúria metilmalónica isolada, a caracterização funcional de novas proteínas 
mutantes, bem como a identificação de novas alternativas terapêuticas. 
 
Palavras-chave: Doenças metabólicas hereditárias, disfunção mitocondrial, novas 
aproximações terapêuticas, chaperones, terapia antisense.  
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1.1. INHERITED METABOLIC DISORDERS 
Metabolism is the sum of all the biochemical processes and pathways in the body in 
which enzymes play a crucial role. Errors of metabolism are caused by congenital or acquired 
defects in the genes encoding those enzymes (genotype) causing an impaired function that 
leads to a disruption of the physiological homeostasis and, consequently, to clinical 
manifestations (phenotype). When the defect is hereditary we have inherited metabolic 
disorders (IMDs).  
The term “inborn error of metabolism (IEM)” was coined more than a century ago by 
Sir Archibald E. Garrod during his studies on alkaptonuria (Garrod, 1975). The number of 
uncovered IEM has increased and, since then, more than five hundred different IEM have been 
identified (Martins, 1999). 
The alterations found in hereditary metabolic disorders can be caused by substrate 
accumulation and/or its derivatives and also the shortage of a certain reaction product (Rao et 
al, 2009). The differences in the phenotypic manifestations observed depend on the severity of 
the alteration observed in the gene, the type and function of the affected enzyme, post 
translational mechanisms, cellular processes, genes in other loci that may also be affected and 
environmental factors. Due to all these factors, patients with IMD present a complex assembly 
of symptoms (Dipple and McCabe, 2000). 
IMDs are considered rare disorders and, according to the European Organization for 
Rare Disease (EURORDIS), a disease is considered rare when 1 in every 2,000 inhabitants is 
affected (Orphan Drug Regulation 141/2,000). About 6,000 to 8,000 rare disorders are 
described and although the individual frequencies are low, collectively IMDs attain around 6 to 
8% of the EU population.  
IMDs are monogenic disorders with 67% displaying an autosomic recessive, 21% an 
autosomic dominant and 6% an X-linked pattern of inheritance; moreover, about 6% are 
related with defects in mitochondrial genome. In general, a high allelic heterogeneity is 
observed and the kind and intensity of clinical manifestations are related to the type of 
mutations detected (Pampols, 2010). 
The major therapeutic goal in IMD is to re-establish the metabolic balance and, several 
strategies can be applied, either isolated or in combination. The first step is to either eliminate 
the accumulating substrate from the diet or to inhibit the enzymatic activity. The fast 
elimination of the toxic products from the body is also a common strategy. An increase of the 
residual enzymatic activity and the administration of the reaction end product in shortage are 
also therapeutic approaches (Raghuveer et al, 2006; Schwartz et al, 2008; Knerr et al, 2012). 
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In terms of medical care, treatment of IMD represents a significant challenge to the 
public health system and, until now, the majority of the available therapies are not definitive 
and only ameliorate the patient’s symptoms.  
The scientific achievements of the last years allowed uncovering more and more 
disorders, and also made possible a broader knowledge on the genetic and pathophysiological 
processes underlying IMD, thus paving the way to novel therapeutic strategies.  
IMD can be classified according to the metabolic pathway in which the affected 
enzyme is involved. IMD can be divided into three major categories according to the 
pathophysiology; disorders that give rise to intoxication, disorders involving energy 
metabolism and disorders involving complex molecules (Saudubray et al, 2006a; Saudubray et 
al, 2006b). The first group is characterized by an acute or progressive intoxication due to a 
metabolic block and accumulation of toxic compounds, and includes inborn errors of amino 
acid metabolism, most organic acidurias, congenital urea cycle defects, sugar intolerances, 
metal intoxication and porphyrias (Saudubray et al, 2006a).  
Organic acid disorders or organic acidurias (OAs) are characterized by the excretion of 
non-amino organic acids in urine. The majority of classic OAs are caused by abnormal amino 
acid catabolism of branched-chain amino acids or lysine (Deodato et al, 2006; Seashore, 2009). 
The oxidation pathway of propionyl-CoA into succinyl-CoA is achieved by two 
mitochondrial enzymes, propionyl-CoA carboxylase and methylmalonyl-CoA mutase. Defects in 
the function of these enzymes are responsible for two of the most common OAs: propionic 
and methylmalonic acidurias (Figure 1) (Fenton et al, 2001; Pérez-Cerdá et al, 2004).  
 
 
Figure 1– Oxidation pathway of propionyl-CoA into succinyl-CoA. Propionyl-CoA carboxylase catalyses 
the synthesis of D-methylmalonyl-CoA from propionyl-CoA and methylmalonyl-CoA converts L-
methylmalonyl-Ca into succinyl-CoA. Methylmalonyl-CoA Epimerase catalyses the D to L dimerization. 
Defects in these enzymes are responsible for propionic and methylmalonic acidurias, respectively.  
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1.2. PROPIONIC ACIDURIA  
 
Propionic aciduria (PA, MIM #606054) affects approximately one in every 30,000 new-
borns around the world, although in some areas it can reach a higher incidence, and is caused 
by defects in the mitochondrial biotin-dependent enzyme propionyl-CoA carboxylase (PCC, E.C. 
6.4.1.3) (Hofherr et al, 2009). Propionyl-CoA, originated from the catabolism of amino acids 
like valine, isoleucine, methionine and threonine, the catabolism of fatty acids and cholesterol, 
as well as from intestinal flora, is carboxylated to D-methylmalonil-CoA by propionyl-CoA 
carboxylase (Figure 1) (Campeau et al, 1999). 
PCC is a heteropolimer composed of non-identical subunits α and β arranged in a α6β6 
structure (Stankovics and Ledely, 1993). Each subunit is encoded by a different gene. The 
larger α subunit contains the union site to biotin and is synthesized by the PCCA gene (MIM 
*232000) located in chromosome 13q32 (Desviat et al, 2004; Ballhausen et al, 2009). This gene 
is composed of 24 exons ranging from 37 to 335 bp and the coding mRNA has an open reading 
frame of 2184 nucleotides that encodes a 728 amino acid protein (Kennerkcht et al, 1992; 
Campeau et al, 2001; Ballhausen et al, 2009). 
The β subunit is encoded by the PCCB gene (MIM *232050) located in chromosome 
3q13.3-q22 and is composed of 15 exons ranging from 57 to 183 bp. The coding mRNA has an 
open reading frame of 1617 nucleotides encoding a 539 amino acid protein (Ohura et al, 1993; 
Rodriguez-Pombo et al, 1998). 
Mutations in any of the genes can cause PA and cells from patients with mutations in 
PCCA belong to the pccA complementation group, while those from patients with alterations in 
the PCCB gene belong to the pccB complementation group (Deodato et al, 2006). To date, 91 
mutations have been described in PCCA and 95 different mutations in PCCB gene, being 
missense variants the prevalent type in both cases (HGMD® Professional 2013.1). Mutations 
are distributed along the gene sequence, although some clustering is observed in exon 13 in 
the PCCA gene and in exons 12 and 15 in PCCB gene, suggesting a hot spot for mutations 
(Desviat et al, 2004). None of the mutations detected in PCCA gene is predominant in 
Caucasians, while in PCCB gene a few mutations account for most cases and the mutation 
c.1218del14ins12 is the most common among Caucasians. Mutations c.1172_1173insT and 
p.Glu168Lys are also frequent, specifically in Spanish and Latin American populations (Desviat 
et al, 2004). 
Clinical manifestations can present a neonatal-onset form or a late-onset form, but 
most of the affected individuals show a neonatal clinical onset of the disease (Pérez-Cerdá et 
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al, 2004; Deodato et al, 2006). Patients present a variable phenotype, characterized by mild to 
severe metabolic acidosis, ketosis, hyperlactacidemia, hypoglycemia and hyperammonemia 
due to the accumulation of propionate and low levels of free and total carnitine. Biochemical 
diagnosis is based on the characteristic profile of urinary organic acids that show elevations of 
3-hydroxy-propionate, 2-methylcitrate and propionyl and tiglyl-glycine (Pérez-Cerdá et al, 
2004; Desviat et al, 2004; Schwab et al, 2006).  
Confirmation of the diagnosis can be achieved by enzymatic studies in lymphocytes 
and/or cultured fibroblasts or by molecular genetics (Pérez-Cerdá et al, 2004). 
The treatment consists on dietary restriction of the precursor amino acids of 
propionyl-CoA, increase of caloric intake, avoidance of long-fasting periods, administration of 
carnitine to buffer intramitochondrial accumulation of propionyl-CoA, biotin and 
carbamylglutamate to improve hyperammonemia and metronidazole to reduce gut propionate 
produced by intestinal bacteria (Miyazaki et al, 2001; Deodato et al, 2006).  
PA is a severe disorder with a poor survival rate on patients presenting an early-onset 
form and survivors may have developmental delay, nutritional problems and neurological 
impairment (Desviat et al, 2004). 
 
1.3. ISOLATED METHYLMALONIC ACIDURIA 
 
Methylmalonic aciduria (MMA) is caused by a complete or partial defect in the 
conversion of L-methylmalonyl-CoA into succinyl-CoA catalysed by the mitochondrial enzyme 
methylmalonyl-CoA mutase (MUT, EC 5.4.99.2), and also by defects in the genes encoding the 
proteins involved in the synthesis and transport of its cofactor, adenosylcobalamin (AdoCbl) 
(Figure 1) (Fowler et al, 2008; Takahashi-Iñiguez et al, 2012). 
MUT is a dimer of identical subunits each containing two main functional domains. The 
amino terminal domain is composed by the leader sequence (residues 1 to 32) which targets 
the protein to the mitochondrion and a (βα)8 barrel (TIM-barrel) that spans residues 88 to 422 
and contains the substrate binding site, and the carboxyl terminal domain that consists of a 
(βα)5 barrel, encompassing residues 578 to 750, and containing the cobalamin binding site. The 
two functional domains are connected by a linker region of 160 amino acids (Fenton et al, 
2001; Acquaviva et al, 2005). 
The MUT enzyme is encoded by the MUT gene (MIM *609058) located on 
chromosome 6p21 and is structured in 13 exons spanning more than 35 kb of genomic DNA 
(Jansen et al, 1989). The full-length messenger encodes a 750 amino acid protein with a 
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molecular weight of 88.2 kDa. The mature form of the protein lacks the mitochondrial leading 
sequence and has about 79 kDa (Thomä and Leadlay, 1996).  
Until now, 242 different mutations have been described in the MUT gene being 68% of 
the missense type (HGMD® Professional 2013.1). Mutations have been found in all exons, but 
there seems to be a higher incidence in exons 2, 3, 6, 11 and 12, and some mutations have 
been found to be population specific. For example, the mutation p.Asn219Tyr is common in 
Caucasian patients and the c.671-678dup is found in many patients with Spanish origin 
(Acquaviva et al, 2005; Martinez, 2005; Worgan L et al, 2006). 
As referred, MUT is dependent on adenosylcobalamin, a cofactor synthesized from 
cobalamin, an essential nutrient for cellular development (Padovani and Banerjee, 2009). 
Cobalamin is a complex organometallic cofactor with a corrin ring that donates four hydrogen 
atoms to a central cobalt atom and a bulky dimethylbenzimidazole (DMB) group. It can exist in 
the cell under three different conformational states: base-on or base-off according to the 
coordination state of the DMB group with cobalt, and base-off/His-on when the cobalt 
interacts with a histidine residue on the C-terminal of the MUT protein (Banerjee, 2006). The 
states base-off and base-off/His-on are the prevalent conformations and also the most 
physiologically relevant.  
In mammals, only two proteins use cobalamin as cofactor, the mitochondrial MUT 
protein ,as already described, and the cytosolic enzyme, methionine synthase (MS EC 2.1.1.13) 
that uses methylcobalmin (MeCbl) to convert homocysteine into methionine (Yamanishi et al, 
2005; Banerjee et al, 2009). Cobalamin is obtained from the diet and enters the cellular 
environment via a complex carrier-mediated import system that involves several different 
proteins. Somatic complementation studies using patients’ cells allowed the establishment of 
nine different complementation groups: cblA, cblB, cblC, cblD (variant 1 and 2), cblE, cblF, cblG, 
cblJ and mut (Figure 2) (Gherasim et al, 2013a). The mut complementation group can be 
divided in two different categories according to the response to B12 supplementation by the 
patients’ cells: mut0 and mut-. Patients belonging to the mut0 group present very low or null 
MUT enzymatic activity and do not respond to B12 supplementation, while patients who belong 
to mut- display some residual enzymatic activity and may respond to treatment with 
hydroxycobalamin (Fowler et al, 2008). Among the nine complementation defects, only four 
are responsible for a phenotype of isolated MMA: mut, cblA, cblB and cblD variant 2. Patients 
that belong to the cblE, cblG and cblD variant 1 present a biochemical phenotype of isolated 
homocysteinuria, while patients belonging to the cblF, cblJ, cblC and cblD groups present a 
combined phenotype of methylmalonic aciduria with homocysteinuria (Morel et al, 2005; 
Fowler et al, 2008; Kim et al, 2012). 
PART 1 INTRODUCTION and OBJECTIVES 
 
 
8 
 
Figure 2 – Representation of the cobalamin trafficking pathway. The question marks denote the 
uncertainty of mechanism of cobalamin import to the mitochondrion and loading to the ATR protein. 
Adapted from Gherasim et al, 2013a.  
 
 
1.3.1. Cobalamin defects causing isolated methylmalonic aciduria 
 
Cellular cobalamin processing can be divided into two major pathways, cytosolic and 
mitochondrial. The protein responsible for cobalamin sorting for each of these pathways is 
MMADHC (for MethylMalonic Aciduria type D and HomoCysteinuria) (Figure 2). The MMADHC 
cDNA has an ORF of 891 bp that is translated into a 296 amino acid protein with a predicted 
molecular mass of 32.8 kDa (Coelho et al, 2008). The protein presents a mitochondrial leader 
sequence (residues 1-11), a weakly conserved putative B12-binding motif (GXXXHXD, residues 
81-86) and a homologous region to the ATPase component of a bacterial ATP-binding cassette 
transporter (residues 78-168) (Coelho et al, 2008). 
This protein is encoded by the MMADHC gene (MIM *611935), located in chromosome 
2q23.2, and mutations affecting its function are responsible for the cblD complementation 
defect. This complementation group is the most complex of all because the patients present a 
clinical heterogeneity that can range from isolated homocystinuria (cblD variant 1), or isolated 
methylmalonic aciduria (cblD variant 2), to methylmalonic aciduria combined with 
homocystinuria (cblD) (Suormala et al, 2004). This heterogeneity provides strong evidence for 
its dual function in the cytoplasmatic and the mitochondrial pathways for cobalamin 
processing and assimilation, and is related with the location and type of the mutations 
affecting the gene (Coelho et al, 2008; Stucki et al, 2011). Mutations causing a premature 
translation stop codon toward the N-terminal of the protein are found in patients with cblD 
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variant 2, missense mutations located in the C-terminal of the protein are related to cblD 
variant 1, while nonsense and missense mutations affecting the middle and the C-terminal of 
the protein are related to cblD combined phenotype (Coelho et al, 2008; Stucki et al, 2011). 
The observation of the three different phenotypes is explained by the existence of two 
additional initiation codons in the protein, located at positions 62 (methionine 62) and 116 
(methionine 116). Therefore, mutations affecting residues located before Met62 or even 
Met116 only affect the protein region responsible for AdoCbl synthesis, originating a protein 
fully capable of MeCbl synthesis. Mutations downstream Met116 abolish the MeCbl synthesis, 
leaving AdoCbl synthesis intact. Mutations affecting patients with the combined phenotype are 
located in a short stretch of 14 amino acids towards the C-terminal of the protein. According to 
recent studies, this small region is one of the five putative sites of interaction between 
MMADHC and MMACHC protein (cblC complementation group) (Stucki et al, 2011). 
It has been demonstrated that MMACHC interacts mainly with the C-terminal domain 
of MMADHC in the cytosol, indirectly assisting the transfer of cob(II)alamin to methionine 
synthase (Plesa et al, 2011).  
The patients’ clinical presentations are variable. Patients with the cblD combined 
phenotype present developmental delay, seizures, hypotonia, lethargy and megaloblastic 
anemia; patients with the cblD variant 1 present developmental delay, ataxia and 
megaloblastic anemia; and patients with the cblD variant 2 have respiratory distress, cranial 
hemorrhage, seizures and abnormal electroencephalograms (Miousse et al, 2009). 
Until now, only 17 cblD patients have been described in the literature, making it the 
rarest complementation defect so far (Stucki et al, 2011). 
 
The inactive cob(II)alamin then enters the mitochondrion and is adenosylated to its 
active AdoCbl form by ATP:Cob(I)alamin adenosyltransferase (ATR) (Maurice et al, 2008). ATR 
is encoded by the gene MMAB (for MethylMalonic Aciduria type B) located in chromosome 
12q23.3 (Dobson et al, 2002a). Mutations affecting the correct processing of MMAB gene 
(MIM *607568) are responsible for the cblB defect (MIM #251110) (Dobson et al, 2002b). The 
most common mutation found in MAAB gene in European patients is p.R186W (about 33% of 
the mutant alleles) and is responsible for a severe clinical phenotype (Lerner-Ellis et al, 2006; 
Fowler et al, 2008).  
ATR belongs to the PduO family and, in the presence of an electron supplied by a 
reductase, catalyses the reduction of bound cob(II)alamin to cob(I)alamin, which then 
displaces tri-phosphate (PPPi) from ATP to generate AboCbl. This reaction is 
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thermodynamically unfavourable but it is favoured by the base-off conformation which 
increases the redox potential (Yamanishi et al, 2005; Padovani and Banerjee, 2009). 
ATR is a homotrimer where the monomer is a five-helix bundle. The α1 and α4 helices 
of each monomer associate to form the six-stranded coiled-coil core of the trimer, being the 
ATP-binding site at the interface between adjacent monomers. The active sites are located at 
the subunit interfaces and are distinctly different, since only two of them contain ATP and the 
other remains unlinked (Saridakis et al, 2004; Shubert et al, 2006; Fan et al, 2008). 
Studies have shown that the binding of ATP to the N-terminus initiates the reaction by 
triggering a significant local reordering of the ATR structure. This forms a deep pocket that is 
postulated to be the cobalamin binding site. Next, cob(II)alamin binds to the enzyme’s active 
site triggering the ordering of the C-terminus and the closure of a hinged lid, thus generating a 
four-coordinated cob(II)alamin intermediate. The final step is the electron transfer that 
generates the cob(I)alamin nucleophile, and AboCbl and PPi are formed in the active site 
(Maurice et al, 2008). The source of the electron used in the reduction reaction is still unknown 
(Mera et al, 2010). 
The observation that ATR only uses two of the three active sites suggests a sequential 
rotary mechanism for the synthesis and delivery of AdoCbl (Figure 3). ATP binds to ATR sites 1 
and 2 driving the catalysis of AdoCbl, while binding to site 3 provokes a conformational change 
in the adjacent subunit driving the cofactor transfer from site 1 to MUT, thus leaving one of 
the active sites empty in preparation for the next reaction (Padovani and Banerjee, 2009). 
Based on these observations, ATR seems to serve both as an enzyme to synthesize 
AdoCbl and as an escort to deliver the cofactor to MUT, which presents a DXHXXG motif for 
base-off/His-on binding of cobalamin. The MUT histidine residue (His627), which serves as 
ligand, plays an essential role in the transfer of the cofactor and its mutation to another amino 
acid impairs the cofactor transfer (Yamanishi et al, 2005). 
The assembly of AdoCbl to MUT is predicted to involve a GTP-dependent interaction 
with the MMAA protein. MMAA is coded by the MMAA gene (for MethylMalonic Aciduria type 
A) and, based on information from bacterial orthologs, belongs to the G3E family of P-loop 
GTPases. Mutations affecting the MMAA gene (MIM *607481) are responsible for the cblA 
complementation defect (MIM #251100) (Dobson et al, 2002b). 
MMAA function is not completely clear. The observation that fibroblasts from cblA 
patients exhibit low AdoCbl content indicates that MMAA plays a role in the transfer of the 
cofactor from ATR to MUT and also in the maintenance of MUT’s functional integrity, although 
the mechanism is not fully understood (Figure 3) (Banerjee et al, 2009; Froese et al, 2010). 
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Figure 3 – Schematic model for the function of ATR, MMAA and MUT enzymes. ATR (blue wheel) 
synthesizes AdoCbl that is transferred to the MUT (green circle) active site in a reaction gated by the 
MMAA protein (orange rectangle). MMAA gating and rescue functions are highlighted. The loss of 5’-
deoxyadenosine (Ado) from MUTs’ active site leads to its inactivation and MMAA promotes the 
dissociation of cob(II)alamin, allowing the reconstitution of the mutase with the active cofactor. 
Adapted from Gherasim et al, 2013b.  
 
 
The diagnostic approach to MMA involves metabolite analysis, genetic 
complementation and enzymatic studies and, finally, mutation analysis (Fowler et al, 2008). 
The first approach is the biochemical analysis of patients’ urine or plasma, and elevated levels 
of methylmalonic acid, 3-hydroxypropionate, 2-methylcitrate, lactate, propionylglycine and 
creatinine are found (Morel, 2005; Fowler et al, 2008). 
The treatment consists in dietary restriction, administration of vitamin B12, N-
carbamylglutamate, carnitine supplementation and, in the last years, liver or liver/kidney 
transplantation.  
Patients that belong to the cbl complementation groups often respond to 
pharmacological doses of B12 vitamin, for instance cblC, cblD and cblA defects are treated with 
hydroxocobalamin, but patients belonging to cblB group show lower levels of positive 
response, with about only 40% of the cblB patients improving with B12 supplementation 
(Fowler et al, 2008). 
Again, this treatment is not definite and it only ameliorates patient’s symptoms, raising 
the need to search for new therapies and therapeutic targets.  
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1.4. MITOCHONDRIAL DYSFUNCTION IN ORGANIC ACIDURIAS  
 
Mitochondria are essential organelles with a changing morphology and location in the 
cell. This phenomenon is dependent of fission and fusion processes that maintain structural 
integrity. Small spherical and oval mitochondria represent a fragmented or pro-fission state, 
whereas interconnected filamentous networks are a result of a pro-fusion phenotype 
(Galloway and Yoon, 2012; Shutt et al, 2012). They are involved in cellular bioenergetics and 
metabolic homeostasis, and the mitochondrial matrix contains a range of enzymes that play a 
role in the major metabolic pathways, like the tricarboxylic acid (TCA) cycle and the enzymatic 
machinery of oxidative phosphorylation (OXPHOS), responsible for adenosine triphosphate 
(ATP) production (Krauss, 2001; Kang and Pervaiz, 2012). Mitochondria are also involved in the 
regulation of redox and calcium (Ca2+) signalling, fatty acid oxidation and iron metabolism 
(Wajner and Goodman, 2011). 
OXPHOS relies on a series of respiratory complexes imbedded in the inner 
mitochondrial membrane: complex I (NADH-coenzyme Q reductase), complex III (coenzyme Q 
cytochrome c reductase), complex II (succinate-coenzyme Q reductase) and complex IV 
(cytochrome c oxidase) that catalyzes the last step of the electron transfer. Another 
component is ATP synthase (F1F0-ATPase) that uses the proton motive force to convert ADP 
and inorganic phosphate (Pi) to ATP which is then released into the matrix and can be 
transported to the cytosol by the adenine nucleotide translocase (ANT) (Figure 4).  
 
 
Figure 4– Mitochondrial respiratory chain. Q: oxidized ubiquinone, QH2: reduced ubiquinol, CoQ: 
coenzyme Q, Pi: phosphate, ∆Ψm: proton motive force. Adapted from Smith et al, 2012.  
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Side product of OXPHOS are reactive oxygen species (ROS), like hydroxyl radical (•OH), 
superoxide anion (O2-) and hydrogen peroxide (H2O2), that are generated especially by 
complexes I and III, but also by complex II (Ma, 2010; Circu and Aw, 2010; Cardoso et al, 2012). 
These species are essential for a number of cellular reactions like inflammatory response, 
vascular function and oxygen sensing (Alfadda and Sallam, 2012), but show a high chemical 
reactivity and thus can cause non-specific cellular damage (Brieger et al, 2012). Therefore, cells 
have developed mechanisms for their neutralization like antioxidant enzymes and scavengers. 
The cell homeostasis is kept by a tight balance between the generation of ROS and the ability 
of protection systems to remove them. When this balance is disturbed, either by the 
overproduction of ROS or by a defect in the action of the antioxidant defence systems, damage 
is observed at protein, lipid and DNA levels constituting an important disease mechanism. 
When damage surpasses a threshold, cell is programmed to death by apoptosis, a mechanism 
central to homeostasis.  
In an apoptotic event, and as a defence mechanism, mitochondria release apoptogenic 
signal molecules into the cytosol, a phenomenon called permeability transition (PT) that 
triggers the opening of a channel, the permeability transition pore (PTP), leading to loss of 
solutes with a molecular weight less than 1.5kDa (Wong et al, 2012; Brenner and Moulin, 
2012). 
Another trigger of PTP opening is the influx of Ca2+ into the cytosol, which leads to 
mitochondrial Ca2+ accumulation and consequent activation of respiratory dehydrogenases 
and oxidative phosphorylation (Kowaltowski et al, 2001). 
Mitochondrial PTP (mPTP) structure is not clear and there have been many candidates, 
among them, adenine nucleotide translocase (ANT) and cyclophilin D (CyP-D). CyP-D is a 
hydrophobic protein capable of binding strongly to the inner mitochondrial membrane 
component and its activity is enhanced by the presence of ADP and reduced in the presence of 
Ca2+ ions. Cyclosporine-A (CsA) is an inhibitor of CyP-D and it has been shown to block mPTP 
formation. A set of studies have demonstrated that ANT and Cyp-D seem to act mainly as 
regulators rather than an integrant part of mPTP. It has also been postulated that the voltage-
dependent anion channel (VDAC) plays an important role, but the observation that 
mitochondria from VDAC1 knockout mice possess a normal PTP has questioned this hypothesis 
(Javadov and Karmazyn, 2007; Arti et al, 2012).  
mPTP seems to have a multiple and dynamic identity dependent on the cellular model, 
status and treatment, playing a key role in Ca2+ homeostasis in a conductance-dependent 
manner (Brenner and Moulin, 2012). 
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Oxidative stress caused by ROS has been implicated in the physiopathology of a palette 
of disorders, like cancer, autoimmune, neurodegenerative, mitochondrial and also organic 
acidurias, especially methylmalonic aciduria (Pieczenik and Neustadt, 2007; Richard et al, 2007; 
Chandler et al, 2009; Wajner and Goodman, 2011; Schapira, 2012; Gallego-Villar et al, 2012). 
Mitochondrial dysfunction leading to high levels of ROS has been observed in liver, 
kidney and brain of MMA patients, and also in cultured skin tissues and mouse models, 
although the mechanism behind generation of ROS levels is not fully understood. The likeness 
of methylmalonic acid with the respiratory chain substrates lead to the hypothesis that 
methylmalonic acid was the main toxic metabolite in MMA, but it is now accepted that other 
metabolites, like 2-metylcitrate, may be involved (Richard et al, 2007; Mirandola et al, 2008; 
Chandler et al, 2009; Jafari et al, 2013). 
 
1.5. PYRUVOYLTETRAHYDROPTERIN SYNTHASE DEFICIENCY 
 
6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) is an essential cofactor for several 
enzymes central to metabolic function, including four aromatic amino acid hydroxylases 
(phenylalanine hydroxylase, tyrosine hydroxylase, tryptophan hydroxylase type 1 and 2), alkyl 
glycerol mono-oxygenase and three NO synthase isoenzymes. It is also crucial in a number of 
biological and pathological processes associated with monoamine neurotransmitter formation, 
endothelial and cardiovascular dysfunction, immune response and pain sensitivity. It belongs 
to the pteridine family, specifically to the unconjugated pterin group that is characterized by a 
2-amino-4-oxo structure. Biopterin is present in biological samples as biopterin, 7,8-
dihydrobiopterin (BH2) and BH4 (Blau et al, 2008). BH4 is synthesized de novo from GTP in a 
three steps, Mg2+, Zn2+ and NADPH-dependent reaction. The first step is catalysed by GTP 
cyclohydrolase I (GTPCH). The second reaction, converting 7,8-dihydroneopterin triphosphate 
to 6-pyruvoyltetrahydropterin, is catalysed by pyruvoyltetrahydropterin synthase (PTPS) in a 
Mg2+ and Zn2+ dependent reaction. The final reaction is NADPH-dependent and is catalyzed by 
sepiapterin reductase (SR) that transforms 6-pyruvoyltetrahydropterin into BH4 (Thöny and 
Blau, 2006).  
BH4 can also be obtained by two other pathways, the salvage and the alternative 
pathways that contribute to the BH4 synthesis in vivo when SR activity is insufficient (Figure 5). 
About 60% of all BH4 deficiencies are caused by defects in the PTPS enzyme (Liu et al, 
2008). PTPS is encoded by the PTS gene (MIM *612719) that maps to chromosome 11q22.3 – 
11q23.3 and encompasses 6 exons with variable lengths. The messenger has an ORF of 662 bp 
with an ATG at position 10, coding a 145 amino acid protein with a molecular weight of 16.5 
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kDa. The stop codon is followed by a 198 bp untranslated region and an adjacent stretch of 17 
adenines (Thöny et al, 1992; Nar et al, 1994). 
 
 
Figure 5 – Tetrahydrobiopterin synthesis, alternative and recycling pathways. nNOS, eNOS and iNOS: 
nitric oxide synthase enzymes, TyrOH: tyrosine hydroxylase, TrpOH: tryptophan hydroxylase, PheOH: 
phenylalanine hydroxylase, DAHP: 2,4-diamino-6-hydroxypyrimidine, MTX: methotrexate, GCH1: GTP 
cyclohydroxylase 1, PTS: 6-pyruvoyl tetrahydrobiopterin synthase, SPR: sepiapterin reductase, AR: 
aldose reductase, CR: carbonyl reductase, DHFR: dihydrofolate reductase, PCBD: pterin-4α-
carbinolamine dehydratase, QDPR: quinonoid-dihydrobiopterin reductase. Adapted from Costigan et al, 
2012.  
 
 
PTPS is a hexamer of identical subunits, formed by the association of two trimers in a 
head-to-head association, leading to the active enzyme complex. The substrate-binding sites, 
six per active hexamer, are located close to the trimer interface. Each catalytic site is formed 
by two subunits from one trimer and by one subunit from the adjacent trimer, and contains a 
metal-binding site formed by three histidine residues (Oppliger et al, 2009).  
PTPS deficiency presents an autosomic recessive mode of inheritance and is a 
phenotypically heterogeneous disorder. Patients with impaired PTPS activity can present three 
different clinical phenotypes, namely a central one presenting with a general lack of BH4 in all 
organs and monoamine neurotransmitter shortage in the central nervous system (CNS); a 
peripheral one, where patients do not synthesize BH4 in peripheral organs but have normal 
BH4 and neurotransmitter levels in the CNS and, finally, a transient form that may disappear 
during infant thriving. 
Until now, 52 different mutations have been identified, being missense the prevalent 
type. About 63% of all the mutant alleles identified so far are associated with the central 
phenotype (Thöny and Blau, 2006). 
The patient’s diagnosis consists in the measurement of phenylalanine and tyrosine 
levels in plasma or serum, before and after a BH4 challenge to discriminate between classic 
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phenylketonuria and biopterin variants, analysis of pterin levels in urine, measurement of 
DHPR activity in blood, analysis of pterins, folates and neurotransmitter metabolites in 
cerebral spine fluid (CSF) and measurement of enzymatic activity. The first two tests are 
essential because they enable the differentiation of all BH4 defects presenting with 
hyperphenylalaninemia (HPA) (Werner et al, 2011). 
The treatment depends on the enzyme-defect phenotype. In the case of PTPS 
deficiency with the central phenotype, BH4 supplementation and replacement therapy with 
neurotransmitter precursors such as levodopa, carbidopa and 5-hydroxytryptophan (5HT) are 
implemented. For the peripheral phenotype only BH4 is administered, and for the transient 
form BH4 is supplemented in the neonatal period (Laufs et al, 1998; Scheinfeld et al, 2010). 
Although the treatment is effective in most cases, a few patients do not respond to the 
combined treatment, resulting in severe progressive illness (Laufs et al, 1998). 
 
1.6. MUTATION SPECIFIC THERAPIES  
 
Genetic disorders displaying high penetrance genetic are normally caused by 
mutations that result in either loss-of-function (LOF), characterized by the reduction of the 
levels and/or activity of a protein, or in gain-of-function (GOF), characterized by the increase in 
protein levels and/or activity with the introduction of a pathological function (Beaulieu Let al, 
2012). 
The growing understanding of the pathogenesis in IMD allied to the information 
obtained from the human genome sequencing and the comprehension of genotype-phenotype 
relationships has lead to the development of strategies based in the mutations nature, such as 
metabolic manipulation, protein augmentation and, more recently, genetic medicine 
(O’Connor and Crystal, 2006; Dietz, 2010). 
 
1.6.1. Misfolding mutations and modulation of protein function 
 
A correct three-dimensional structure is essential to normal protein function and is 
acquired by a correct folding mechanism. The folding process occurs in the cytosol in a 
spontaneous manner for small proteins, but larger peptides have to be assisted by a battery of 
folding catalysts, like cofactors, and small molecules called chaperones. Chaperones protect 
the nascent protein from the cytosol’s crowded environment, shielding the proteins 
hydrophobic regions (Leandro and Gomes, 2008). 
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Although energetically favourable, the native state of a protein represents a very 
delicate equilibrium that can be disrupted by the presence of inherited or acquired mutations, 
various stress conditions, improper post-translation modifications and off-pathway folding, 
thus giving rise to misfolded proteins (Gregersen et al, 2006; Chen et al, 2011; Houck et al, 
2012). Misfolded proteins can affect cellular homeostasis by two major mechanisms. The first, 
where misfolded proteins are degraded, is marked by a loss of function, while the other, in 
which the misfolded proteins accumulate leading to oligomer and aggregate formation, 
represent a gain of function (Gregersen, 2006). 
To prevent protein unfolding, cells have an elaborate mechanism of defence called 
protein quality control (PQC) system (Figure 6). A system that seems to be spatially organized 
into compartments composed of molecular chaperones and proteases.  Although vital for the 
correct folding of nascent protein’s, PQC’s main function is to be the first line of defence 
against the damage caused by the accumulation of misfolded proteins, which are marked by 
chaperones to be degraded by the ubiquitine-proteasome pathway if they cannot be correctly 
folded (Gregersen and Bross, 2010). 
 
 
Figure 6 – Different protein quality control systems (PQC). Folding is promoted by folding chaperones, 
solubility is maintained by holding chaperones and unfolding chaperones dispose of disaggregate or 
misfolded proteins. Adapted from Gregersen N. et al, 2006.  
 
 
The involvement of misfolded proteins in pathophysiological manifestations of several 
disorders has been proved and the list of the so-called “conformational diseases” is 
continuously growing (Leandro and Gomes, 2008). 
Accordingly, misfolded proteins seem to be good candidates for therapies whose main 
goals are the rescue of the native conformation or the induction of stable intermediate protein 
states. In recent years, natural (cofactors), chemical and pharmacological chaperones have 
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been used as a possible therapeutic approach. Recently, the search for possible 
pharmacological chaperones in known compound libraries has proven to be successful (Pey et 
al, 2008). 
 
1.6.2. Mutations affecting splicing process and disease 
 
RNA plays a fundamental role in the transfer of information from DNA to proteins. 
When a protein-coding gene is transcribed, the pre-messenger RNA (pre-mRNA) must undergo 
a series of post-transcriptional processing events, mainly the removal of introns – pre-mRNA 
splicing – to obtain a mature mRNA that includes coding elements and appropriate signals for 
the translation of that information into functional proteins (Douglas and Wood, 2011). Pre-
mRNA splicing relies in a series of signals that define intron-exon boundaries, and allow correct 
mRNA processing. These signals include the 5’ and 3’ splice sites (ss) that define the exon-
intron and intron-exon junctions, respectively, the polypyrimidine (Py) tract and the branch-
point sequence which aid in the 3’ss recognition (Wood et al, 2010; Pandya-Jones, 2011). 
Splicing is carried out by the spliceosome, a large ribonucleoprotein (RNP) complex, 
consisting of five small nuclear RNPs (snRNPs) particles, U1, U2, U4, U5 and U6, that performs 
the two major functions of splicing: the recognition of the intron-exon boundaries and the 
catalysis of introns’ removal and subsequent exons’ union (Figure 7) (Faustino and Cooper, 
2003; Jensen et al, 2009). Splicing initiation involves the recognition of the transcript 5’ and 3’ 
intronic splice sites by U1 and U2 auxiliary factor (U2AF), and of the branch point by splicing 
factor 1 (SF1) and mammalian branch-point binding protein (mBBP). This structure is called the 
early complex (E complex). In the next step, E complex recruits U2 which binds to the branch-
point sequence and is converted to the A complex. The recruitment of U4, U5 and U6 snRNPs 
to complex A originates complex B, leading to a structural reordering to for the catalytic C 
complex (Jensen et al, 2009; Poulos et al, 2011). 
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Figure 7 – Pre-mRNA splicing by the spliceosome. Exons and introns sequences are shown as boxes and 
lines, respectively. Adapted from Will and Lührmann, 2011.  
 
 
The splicing process is also regulated by additional cis-acting sequences, located within 
both introns and exons, which recruit trans-acting splicing factors to ensure constitutive exons’ 
inclusion and modulate splice site recognition’s efficiency. These sequences have been 
classified in four functional categories: exonic splicing enhancers (ESEs), exonic splicing 
silencers (ESSs), intronic splicing enhancers (ISEs) and intronic splicing silencers (ISSs) (Garcia-
Blanco et al, 2004; Ward and Cooper, 2010). ESEs and ISEs promote exon inclusion in mature 
transcripts by recruiting members of the serine/arginine-rich (SR) family of splicing factors. 
ESSs and ISSs promote the binding of splicing suppressors that include the members of the 
heterogeneous nuclear RNP family (hnRNP). ESSs located within exons can inhibit their 
inclusion and when located within and intron can promote its excision. ISSs inhibit exon 
definition and may also prevent inclusion of “pseudo” exons into mature mRNAs (Garcia-
Blanco et al, 2004; Pozzoli and Sironi, 2005; Ward and Cooper, 2010). 
About 10 to 30% of mutations associated with genetic disorder affect splicing process 
(Garcia-Blanco et al, 2004; Rincón et al, 2007) (HGMD® Professional 2013.1). These mutations 
can disrupt single gene expression by disruption of a splicing cis-element, or affect multiple 
genes by disrupting a component of the splicing machinery or a splicing regulatory complex in 
a trans-effect (Faustino and Cooper, 2003).  
Most mutations that alter splicing pattern involve the invariant GT and AG 
dinucleotides at 5’ and 3’ splice sites, but can also affect other conserved sequences at the 
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intron-exon junction like the branch-point site and the Py tract, and also auxiliary splicing 
sequences. Splicing mutations can be considered gain-of-function or loss-of-function if a 
splicing element is enhanced or created or if a splicing element is weakened or destroyed, 
respectively, and they can lead to exon skipping, intron retention, introduction of new splice 
sites within exons or introns and cryptic splice sites activation (Garcia-Blanco et al, 2004). 
The creation of new donor or acceptor splice sites within an intronic sequence, the 
creation of de novo acceptor sites and the deletion or creation of splicing regulatory elements 
can lead to the introduction of intronic sequences, called pseudoexons, that are flanked by 
apparently good acceptor and donor splice sites, which however are not normally recognized 
by the spliceosome (Pérez et al, 2009; Dhir and Buratti, 2010). The majority of the activated 
pseudoexon sequences belong to transposable elements (TEs). TEs are very frequent repetitive 
sequences, displaying chromosomal mobility, and that often replicate themselves through RNA 
(retrotransposons). Retrotransposons can be divided in long terminal repeats (LTRs) and in 
long and short interspersed nuclear elements (LINEs and SINEs). SINEs are the most abundant 
and, within SINEs, the most common (10% of the human genome) are Alu elements (Sorek, 
2007; Vorechovsky, 2010). Alu are small primate-specific dimeric structures composed of left 
and right arms joined by an A-rich linker region that may serve as the Py tract required 
upstream the 3’ splice site (Sorek, 2007). 
With the increasing importance of splicing defects in human disorders came the 
realization that the splicing reactions and machinery are good targets for new therapeutic 
approaches (Garcia-Blanco et al, 2004). 
 
1.6.3. Antisense oligonucleotide therapy 
 
The first step in a therapeutic approach consists in the study of the molecular 
mechanism underlying the observed mutation’s effect. The in silico analysis of the affected 
region, using the several available bioinformatic programs, is a good starting point and allows 
the identification of the affected splicing factors.  
The subsequent study of the transcriptional profile of the patient’s cells allows the 
comprehension of mutations functional effects upon the splicing mechanism. A splicing model 
system using specific splice reporter vectors, called minigenes, can be used. Minigenes are also 
known as exon-trapping vectors and consist of exonic portions of a gene with functional 5’ and 
3’ splice sites separated by an intronic sequence that contains a polylinker. The exon and the 
respectively adjacent intronic regions of the mutant allele are cloned. The resulting construct is 
transfected into established cell lines and the splicing pattern is analysed. This system allows 
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the confirmation of the mutation’s effect upon the splicing process and is also important to 
analyse the effect of a sole mutation in the case of heterozygous patients. (Desviat et al, 2012)  
Upon the identification of the molecular mechanism of a given splicing mutation, the 
next step is to choose the therapeutic approach to modify the aberrant pattern and restore 
normal splicing. Agents designed to alter gene expression can act either at DNA level by 
inhibiting or activating transcription (antigene approach), or at RNA level to prevent translation 
(antisense approach) (Kaur et al, 2007). The last one can be achieved using various methods, 
like the over-expression of splicing factors, interference RNA (iRNA) or antisense 
oligonucleotides to selectively eliminate an aberrant mRNA. In this section, the focus will be 
centred on antisense oligonucleotides.  
Antisense oligonucleotides (AONs) have proven to be an effective therapy in the 
exclusion of pseudoexons, but have also been used in the blockage of sequences involved in 
the control of RNA processing, like ISSs, ESEs and ribozyme catalytic sites (Morcos, 2007; 
Rincón et al, 2007; Pérez et al, 2009; Wood et al, 2010; Saonere, 2011). 
AONs are simple oligonucleotides, oligonucleotide analogs or other polymers that bind 
to a sequence (sense strand) trough a Watson/Crick base-pairing mechanism and inhibit the 
transfer of genetic information from DNA to protein (Summerton and Weller, 1997; Dias and 
Stein, 2002; Summerton, 2007). 
Since their first use, many chemical modifications have been made in order to improve 
resistance to nucleases and, consequently, to improve their function and to limit their toxicity. 
One of the most successful modifications was the substitution of ribose moieties by 
morpholino moieties, linked by uncharged phosphorodiamidate groups instead of phosphates. 
For that reason, morpholinos are also known as phosphorodiamidate morpholino oligos 
(PMOs). Morpholinos normally consist of a 25 nucleotides chain with high specificity, water 
solubility and resistance to a wide range of nucleases, especially RNase H, that bind to the 
target mRNA and sterically-block the translation machinery (Summerton and Weller, 1997; 
Morcos, 2007). The entry in the cell is made by endocytosis and needs to be aided by a 
delivery mechanism, either electroporation, conjugation with weakly-basic polyamine, 
ethoxylated polyethylenimine (EPEI) or the commercially available delivery agent Endo-Porter® 
(Morcos, 2001). 
Because morpholinos do not freely cross the cells’ membrane, they cannot be used in 
in vivo experiments. In order to circumvent this problem, another modification was made 
through the attachment of a morpholino molecule to a transporter; this one consists in a 
dendritic structure, assembled around a triazine core that serves to position eight guanidinium 
head groups in a correct conformation, thus allowing an effective cell membrane penetration. 
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This structure is called vivo-morpholino. Intravenous (i.v) injections in mice have shown an 
efficient delivery of vivo-morpholinos in a variety of tissues with special relevance to brain, 
lung and heart (Li and Morcos, 2008; Morcos et al, 2008). 
Another type of oligonucleotides widely used is locked nucleic acids (LNAs). LNAs 
present a rigid structure due to a methylene bridge that connects the 2’-O atom and the 4’-C 
atom of the ribose ring, thus locking the nucleic acid in an ideal conformation for Watson-Crick 
binding (Campbell and Wengel, 2011). LNAs show structural resemblance with RNA, high 
affinity with complementary RNA, as well as with ssDNA, high specificity toward the target, 
high stability in vivo, lack of toxicity and good resistance to degradation by 3’-exonucleases. 
Another advantage is the possibility of synthesizing oligomers with lower sizes (6 to 20 
nucleotides) and with varied ratios of LNA, allowing different mixtures like LNA/LNA, LNA/DNA 
and LNA/RNA.  LNAs act mainly by recruiting RNase H to degrade the aberrant mRNA, although 
non-RNase H based mechanisms have also been reported (Veedu and Wengel, 2009). 
Currently, the antisense oligonucleotide Vitravene® (ISIS Pharmaceuticals) has been 
approved for the treatment of cytomegalovirus infection, and other AONs are already in phase 
1 and 2 of clinical trials (Kaur et al, 2007; Veedu and Wengel, 2009; Hua et al, 2011). These 
advances in antisense therapy are encouraging and open avenues to the use of antisense 
oligonucleotides in metabolic disorders.  
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1.7. OBJECTIVES 
 
Inherited metabolic disorders are considered rare disorder, although collectively they 
affect about 6 to 8% of the European population. The advances in technology, in recent years, 
have contributed to the uncovering of more disorders and also to the broadening of the 
knowledge about genetic and pathophysiological processes underlying IMDs. Despite these 
advances, until now, there are no definitive available therapies for patients affected by these 
disorders and, in the majority of cases, their quality of life is severely impaired.  
Recently, the concept of personalized therapy has emerged and the development of 
genome-based individualized medicine towards tailored treatments has become a goal in IMDs 
research field. In order to develop new therapeutic targets and treatment approaches, the 
structural and functional analysis of mutations and the physiopathological mechanisms 
underlying these disorders is crucial.  
 
In this work the following objectives were set: 
 
 Genetic analysis of isolated methylmalonic and propionic patients in Spanish 
and Portuguese populations.  
 
 Structural and functional analysis of mutations found in isolated 
methylmalonic patients belonging to cblB and mut type complementation 
groups.  
 
 Analysis of mitochondrial dysfunction in isolated methylmalonic patients 
belonging to cblB and mut type complementation groups.  
 
 Study of new therapeutic options in inherited metabolic disorders. Assessment 
of the effect of pharmacological chaperones in isolated methylmalonic aciduria 
cblB type and the effect of antisense therapy in 6-pytuvoyltetrahydrobiopterin 
synthase deficiency.  
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2.1. MATERIALS 
2.1.1. CHEMICAL REAGENTS  
Chemical reagents used in these studies were obtained from: Abnova (Heidelberg, 
Germany), Agilent Technologies Inc. (Santa Clara, CA, USA), American Radiolabeled Chemicals 
Inc. (St. Louis, MO, USA), Antibióticos SA (Alcobendas, Madrid, Spain), Bio-Rad Laboratories 
(München, Germany), Coriell Cell Repositories (Camden, NJ, USA), Difco Laboratories (Detroit. 
MI, USA), Exiqon (Vedbaek, Denmark), GE Healthcare Life Sciences – Amersham, Whatman 
(Township, NJ, USA), GeneTools (Philomath, OR, USA), Gentra Systems (Minneapolis, MN, 
USA), Life Technologies – Applied Biosystems, GibcoBRL, Invitrogen, Molecular Probes (Grand 
Island, NY, USA), Lonza Group (Basel, Switzerland), Mbiotech Inc. (Torrance, CA, USA), 
Polyplus-transfection SA (Illkirch, France), Promega (Madison, Wisconsin, USA), ProteinTech 
Group Inc. (Chicago, IL, USA), Qiagen (Düsseldorf, Germany), Roche Diagnostics (Basel, 
Switzerland), Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA), Seahorse Bioscience® (North 
Billerica, MA, USA), Serva Electrophoresis (Heidelberg, Germany), Sigma-Aldrich (St. Louis, MO, 
USA), Stratagene (Cedar Drive, TX, USA), Stressgen Bioreagents Inc. (Vitoria, British Columbia, 
Canada) and Thermo Fisher Scientific Inc. (Waltham, MA, USA).   
 
2.1.2. BIOLOGIC MATERIAL 
2.1.2.1. Patients’ samples 
In this work, three samples of pyruvoyltetrahydropterin synthase (PTPS) deficient 
patients, ten samples of isolated methylmalonic aciduria patients and two samples of patients 
with propionic aciduria were used.  
PTPS deficient patients presented elevated levels of phenylalanine and biopterin, no 
detectable biopterin levels and low PTPS enzymatic activity in primary dermal fibroblasts. Low 
levels of homovalinic and 5-hydroxyindolacetic acids were also detected.  
The biochemical parameters used for diagnosis of methylmalonic patients were the 
presence of elevated methylmalonic acid, 2-methylcitrate, low carnitine levels and absence of 
homocysteinuria in urine. Acylcarnitine levels in plasma were determined in some cases, 
confirming the presence of high levels of propionylcarnitine (C3) and methylmalonylcarnitine 
(C4DC). Propionic patients presented elevated levels of propionic acid and 2-methylcitrate. 
Genetic material (skin biopsies and blood samples) from patients and controls was 
collected with the consent of parents and the hospitals where collections were performed. The 
experiments performed using this genetic material were authorized by Comité de Ética de la 
Investigación from Universidad Autónoma de Madrid, and the Comité de Ética da Universidade 
PART 2 MATERIALS and METHODS 
 
 
28 
de Lisboa, according to the fundamental principles of the World Medical Association (WMA) 
Declaration of Helsinki, to the UNESCO Universal Declaration on the Human Genome and 
Human Rights and also by the European Convention on Human Rights and Biomedicine.   
 
2.1.2.2. Cell lines 
For these studies, fibroblasts from the following control cell lines were used: 
GM09503, GM08680, GM08333, GM05756 and CC2509, purchased to the Coriell Cell 
Repositories and also from Lonza (Table 1). The studies of splicing profile with minigenes were 
performed on immortalized cell lines, Hep3B proceeding from human hepatoma and COS-1 
proceeding from monkey kidney tissue.  
 
Table 1 – Characteristic of the control cell lines used in this work.  
Control Cell linea Ageb Sex Race Biopsy origin 
C1 GM09503 10 y M Caucasian Abdomen 
C2 GM08680 5 m M Caucasian Foreskin 
C3 GM08333 5 m M Black Foreskin 
C4 GM05756 2 m M Caucasian Inguinal region 
C5 CC02509 - M Caucasian Foreskin 
a Identification number of the Coriell Repositories and Lonza  
b Age of the individual at the moment of the sample collection.  
 
 
The immortalized cell lines derived from cblB patients’ fibroblasts, 19235-T 
(c.287T>C/c.584G>A – p.Ile96Thr/p.Ser174fs), 28040-T (p.Gly66fs/p.Ile117_Gln118del) and 
27764-T (c.568-570dup/c.548A>T – p.Arg190dup/p.His183Leu) were used to study the effect 
of compound V upon ATR protein analyzing 14C-propionate incorporation.  
 
2.1.2.3. Bacterial strains 
The following E.coli strains were used in this work:  
∗∗   XL1-Blue (Stratagene): supE44, hsdR17, recA1, endA1, gyrA46, thi, relA1, lac-, 
F’[proAB+lacIqlacZΔM15Tn10(tetr)] 
∗∗   TOPO One Shot Mach®1T1R (Invitrogen): lac ZΔM15, hsdR, lacX74, recA, endA, 
tonA 
∗∗   BL21 StarTM DE3 (Invitrogen): F- ompT hsdSB (rB-mB-)gal, dcm,rne131(DE) 
∗∗   BL21DE pLys (Promega): F-, ompT, hsdSb(rB-, mB-), dcm, gal, λ(DE3), pLysS, 
Cmr  
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2.1.2.4. Vectors 
The vectors used in this work were:  
∗∗   TOPO TA Cloning PCR 2.1-Topo Vector (Invitrogen) 
∗∗   pSPL3 (Life Technologies) gently given to our laboratory by Dr.Andersen 
(Buckler et al, 1991) 
∗∗   pIV1 obtained from the introduction of a fragment of gDNA from patient 
MD335 (P14) into pCR3.1 (Invitrogen), gently given to our laboratory by Prof. 
Beat Thöny 
∗∗   pET4.1 plasmid with MMAB wild-type cDNA, gently given to our laboratory by 
Dr. Ruma Banerjee (University of Michigan, Ann Arbor, USA) 
 
2.2. METHODS 
2.2.1. Isolation of genetic material  
Genomic DNA (gDNA) was obtained from patients’ or controls’ cultured dermal 
fibroblasts, using the MagNa Pure Compact Nucleic Acid Isolation kit and the MagNa Pure 
Compact automated apparatus from Roche. gDNA from blood soaked paper was obtained 
using the Generation DNA Purification Systems kit from Gentra Systems.  
Low amounts of plasmid DNA were obtained using Wizard* Plus SV Minipreps DNA 
Purification System from Promega and high amounts were obtained using the QIAGEN* 
Plasmid Maxi kit from Qiagen.  
Total RNA was obtained from patients or control cultured dermal fibroblasts using 
Tripure Isolation Reagent from Invitrogen, RNeasy Mini kit from Qiagen or the MagNa Pure 
Compact RNA isolation kit from Roche.  
 
2.2.2. DNA amplification  
2.2.2.1. gDNA amplification 
Specific primers for the different DNA fragments (Table 2) were designed using the 
reference sequences available at the Ensembl public data base (www.emsenbl.org/index.html) 
using the Primer3 software (frodo.wi.mit.edu/primer3). The DNA fragments were amplified 
using Fast Star (Roche) or Platinum (Invitrogen) polymerases and the corresponding buffers.  
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Table 2 – Primers used for gDNA amplification.  
Gene Oligonucleotide name  Sequence (5' - 3') 
MUT 6 S GCT ATT CTG AAG CTT AAT ATG G 
MUT 6 AS CTG AAT TTT TTT TGC AAA CAT CG 
MMADHC 2 S ACC TTC GAA GAG TGG ACG TT 
MMADHC 2AS ATA CCA CCC AAT GCC ATC AT 
MMADHC 3 AS CCA AAA GGA GAT TTG TTT CAG G 
MMADHC 4 S AAC GGA CTT GCC TGT GAT CT 
MMADHC 4 AS GGA CAA TGC CAA GTT TTC CA 
PCCB ex1a CGT ACC CAC GCT TTA GCA CAT 
PCCB ex1b GGG CAC GCA GTG ATA GGT C 
PCCB 184A CTT CAA GCC CTC CCA TGA ACA GC 
PCCB 184B GGT AGG CCA GCT GAG CCA CAC CT 
PCCB 304A GGC ATA GTG GCC AAA CTC ATT AG 
PCCB 304B       AGT TTT CAT TCC CCA AGA TTG GC 
PCCB 373A         CAC TGG GTT TTC ATC TCT AGC 
PCCB 373B        GTA CCT AGC TCA GTG TCT TGT 
PCCB 5An TGT GGT ATT TTG TGA ATG TCG TT 
PCCB 5BN AGG CCA TGG CTT AGA GAA CTT A 
PCCB 6A       TAT CTT TCC ACA GAT AAT GCC TC 
PCCB 6B GGT AAC AAC CTA GAT CTG GGT CAG  
PCCB 764A          GAA GCA GCA ACT TTG GGC TGG C 
PCCB 764B       CCT GTC AGG GCA GAG AAA GGC AA 
PCCB 885A          AAG CCC AGC AGG GAC AGA ACT GG 
PCCB 885B       CAA GTG GTC CAG TGC TTC CTC AC 
PCCB 965A          GAA ATG TCA TTC TGT AGT GTC AT 
PCCB 965B     GAC AGA AAG GAT ACC ATG GAC C 
PCCB 1091A          GGA TGG CTG CTG AGG ACA AA 
PCCB 1199B     TCC CAC CAC GGC TAT GCT GTA G 
PCCB AvaII       GCC AAG CTT CTC TAC GCA TTT G  
PCCB 1300B     AGC TAT GCC TTG AGC TCT CGC 
PCCB 1398A CAG TTC CTC CCT CTA TGC TAT G 
PCCB 1399B     CAC TAG TCA ACA GAT TAG ACT GC 
PCCB 14Anew GCA CCC ACA CAC AGT GAT AAT G 
PCCB 1399B     CAC TAG TCA ACA GAT TAG ACT GC 
PCCB 1499 CTA CCA TCT CTG TAT CAG GTT G 
PCCB cDNA2 GCT CTA GAC TTG GTT TCT TTT CCT TTG ATT T 
 
  
PART 2 MATERIALS and METHODS 
 
 
31 
 
 
2.2.2.2. cDNA amplification 
cDNA was obtained by retrotranscription of total RNA from controls’ and patients’ skin 
fibroblasts using the SuperScript III First-Stand Synthesis System from Invitrogen, or the AMV 
Reverse Transcription System kit from Promega. Full-length cDNA was amplified using specific 
primers (Table 3) designed as described for gDNA.  
 
Table 3 – Primers used for cDNA amplification 
Gene Oligonucleotide Name Sequence (5' - 3') 
PTS PTPS-53 TTT CAA TAA ATA GGC ACT CC 
PTS PTPS-54 ATG AGC ACG GAA GGT GGT 
MMADHC cblD cDNA S GTT CTG GGA CAG CTG GAG AC 
MMADHC cblD cDNA AS CAA TGT GGA TGT GTT CAA CG 
 
 
2.2.3. PCR products purification 
Single fragments obtained by PCR amplification were directly purified using SpinClean 
PCR Purification kit from MBiotech. PCR products containing more than one transcript were 
loaded into an agarose gel (GibcoBRL), separated and purified using QIAEX® II Gel Extraction kit 
(Qiagen). 
 
2.2.4. DNA sequencing 
Direct sequencing analysis was performed by the termination chain reaction with 2’,3’-
dideoxynucleotides (ddNTPs) incorporation (Sanger et al, 1977). The reactions were performed 
with BigDye Termination v3.1 Cycle Sequencing kit on an ABI Prism 3730 automated 
sequencer, both from Applied Biosystems. The sequence analyses were performed at the 
genomic department of Parque Científico de Madrid.  
Mutations found were designated according to the official mutation nomenclature 
(Human Genome Variation Society at www.hgvs.org). 
 
2.2.5. Cloning and bacterial transformation 
MUT patient – Exon 6 and the corresponding flanking intronic regions of patient (P5) 
with isolated methylmalonic aciduria were amplified using the primers MUT 6 S and MUT 6 AS 
described in table 2. After sequence confirmation, the purified PCR product was cloned into 
TOPO TA vector according to manufacture instructions. The inserted sequence was excised, 
using restriction enzyme EcoRI, and the insert was subcloned into pSPL3 vector (Figure 8A) 
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after prior vector linearization with EcoRI. The resulting construct was transformed into XL1-
Blue or TOPO One Shot® supercompetent bacteria by thermal shock (30 minutes at 4°C, 45 
seconds at 42°C and 2 minutes at 4°C) and platted on LB-agar plates supplemented with 
ampicillin. The resulting colonies were isolated and grown in LB medium supplemented with 
ampicillin and plasmidic DNA was isolated as described in section 2.2.1. 
PTPS patient – A DNA fragment encompassing PTS exons 2 to 4 from a control 
individual was amplified using a mixture of Taq and Pfu polymerases (Promega), cloned into 
pCR3.1 vector (Invitrogen) (Figure 8B) and used as a template (pIV1). The mutation c.164-
712A>T from patient P14 was introduced using the QuikChange II XL kit (Agilent Technologies) 
and the primer 5’ – CCT CCC AGG TTC TGT CGA TTC TCC AGC – 3’ and its reverse complement 
(pDM2).  
Using the vector pIV1 as template, variant minigenes containing the mutations c.164-
714C>A and c.164-715T>A were generated by site-directed mutagenesis using the primers 5’ – 
CTC CAC CTC CCA GGT ACG AGC GAT TCT CC – 3’ and 5’ – CTC CAC CTC CCA GGT ACG TAG AGC 
GAT TCT CC – 3’, respectively, and their reverse complement. The resulting constructs were 
transformed into XL1-Blue supercompetent bacteria, as described for MUT patient, and the 
positive clones were selected by direct sequencing.  
 
 
 
Figure 8 – Vectors used in cloning and bacterial transformation. A) pSPL3 structure representation. 5’ 
and 3’ splice sites are indicated in orange. Ampr is the ampicilin resistance gene. B) pCR3.1 structure 
adapted from Invitrogen Technologies. 
(http://tools.invitrogen.com/content/sfs/manuals/pcdna3_1_man.pdf) 
 
 
 
A) B) 
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2.2.6. Site directed mutagenesis  
Site directed mutagenesis was performed by PCR using the QuickchangeTM Site 
Directed Mutagenesis kit from Stratagene. Primers were designed using Primer3 and Agilent 
Primer designer software and are listed in (Table 4).  
To obtain the different allelic variants of the MMAB gene, the prokaryote pET4.1 
plasmid containing the MMAB wild-type cDNA (without the mitochondrial leader sequence) 
was used as template. The presence of the desired mutation was assessed by direct 
sequencing of the clone’s DNA.  
 
Table 4 – Sequence of the different primers used for site directed mutagenesis. The underlined 
nucleotide represents the location of the mutation and [] defines the sequence deleted by the 
p.Ile117_Gln118del mutation. 
Gene Protein change Oligonucleotide name Sequence (5' - 3') 
MMAB ATR p.His183Leu MMAB H183L S AGC TCG GCG CTG CTT TTC TGC CGG 
MMAB ATR p.His183Leu MMAB H183L AS CCG GCA GAA AAG CAG CGC CGA GCT 
MMAB ATR p.Arg186Trp MMAB R186W S CAT TTC TGC TGG GCC GTG TGC 
MMAB ATR p.Arg186Trp MMAB R186W AS GCA CAC GGC CCA GCA GAA ATG 
MMAB ATR p.Glu193Lys MMAB E193K S CCG GGC CAA GAG ACG TGT GGT G 
MMAB ATR p.Glu193Lys MMAB E193K AS CAC CAC ACG TCT CTT GGC CCG G 
MMAB ATR p.Arg190dup MMAB R190dup S CGG GCC GTG TGC CGC CGC CGG GCC GAG AGA CG 
MMAB ATR p.Arg190dup MMAB R190dup AS ACG TCT CTC GGC CCG GCG GCG GCA CAC GGC CCG 
MMAB ATR p.Ile117-Gln118del MMAB c.349-1G>A S 
GAG CTT CAG AAA [ATC CAG] TGC ACA 
TTG CAG 
MMAB ATR p.Ile117-Gln118del MMAB c.349-1G>A AS 
CTG CAA TGT GCA [CTG GAT ] TTT CTG 
AAG CTC 
 
 
2.2.7.  Mitochondrial isolation 
For mitochondrial isolation, Anti-TOM22 MicroBeads (Mitochondrial isolation kit, 
Miltenyi Biotec, Bergisch Gladbach, Germany) were used.  
8.0x105 cells of control and patients’ immortalized fibroblasts were seeded in T75 
flasks and incubated overnight at 37˚C. The cells were treated with 80µM of compound V, 1µM 
of OHCbl, or with the combination of compound V and OHCbl, and incubated for 72 hours. 
Two flasks were used for each treatment.   
The cells were harvested by trypsinization and the pellets were re-suspended in 1mL of 
lysis buffer (Miltenyi Biotec) and homogenized with a 25g needle using 15 stokes. The resulting 
solution was transferred to a 15 mL conical tube and 9 mL of ice-cold 1x separation buffer and 
50 µL of anti-TOM22 MicroBeads were added. This solution was incubated for 1 hour at 4˚C 
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with gentle shaking. Subsequently, the suspension was loaded onto a pre-equilibrated MACS 
Column (Miltenyi Biotec), which was placed in the magnetic field of a MACS Separator 
(Miltenyi Biotec). Columns were washed three times with 3 mL of separation buffer and, after 
removing the column from the magnetic field, retained mitochondria were eluted with 1.5 mL 
of separation buffer (Miltenyi Biotec). Following centrifugation at 13,000 rpm for 1 min, 
mitochondrial pellet was washed with 300 µL of storage buffer (Miltenyi Biotec) and was 
finally resuspended in 50 µL of storage buffer.  
 
2.2.8. Protein quantification 
Total amount of protein obtained from skin fibroblast cell pellets, Hep3B cell or 
bacterial cell pellets were quantified using the Bradford reagent (BioRad) according to the 
manufacturer’s instructions or the method described by Lowry (Lowry et al, 1951), using 
bovine serum albumin (BSA) as calibration standard.  
 
2.2.9. SDS-PAGE and Western Blot analysis 
Total protein extracts, obtained from skin fibroblasts and Hep3B pellets, were re-
suspended in PBS and a protease inhibitor cocktail (Complete mini EDTA free – Roche) and 
ruptured by three 5 minutes cycles of freezing and thawing and centrifuged for 5 minutes at 
13,000 rpm. 
Total amount of protein was assessed as described in section 2.2.8. and aliquots 
containing equal amount of protein were prepared in a buffer containing β-mercaptoethanol, 
glycerol and bromophenol blue, or DTT 1mM and NuPAGE LDS sample buffer 4x (Invitrogen).  
Samples were separated by SDS-PAGE in 10, 12 or 15% acrylamide/bis-acrylamide gels 
(Serva). 10% or 4-12% NuPAGE Bis-Tris gels and 4-morpholineethanesulfonic acid (MES) 
electrophoresis buffer from Invitrogen were also used.  
After SDS-PAGE, samples were transferred to Whatman nitrocellulose membranes 
using Mini Protean III (BioRad) at 100 V for 1 hour or the iBlot gel TransferStacks Nitrocellulose 
Regular and the iBlot system from Invitrogen (Life Technologies) at 20V for 7 minutes. Protein 
equal loading was accessed using Ponseau S staining. Nitrocellulose membranes were 
incubated with 5% skinny milk in PBS with 0.1% Tween for 1 to 2 hours. The following step was 
the incubation with primary antibodies according to assay:  
• Wild-type ATR and mutant proteins: rabbit anti-human ATR polyclonal 
antibody (1:1,000 – ProteinTech); 
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• PTPS protein: rabbit anti-human polyclonal antibody SZ28 (1:500), gently 
provided by Prof. Beat Thöny; 
• Lon protease: anti-LONP1 polyclonal antibody (1:1,000 – Abnova); 
• Mitochondrial chaperones Hsp-60 and Hsp-70: anti-hsp60 and anti-hsp70 
monoclonal antibodies (1:1,000 – Stressgen and Thermo Fisher Scientific 
respectively); 
• Tubulin: anti-αtubulin monoclonal antibody (1:5,000 – Santa Cruz) 
• Citrate synthase: anti-citrate synthase polyclonal antibody (1:5,000 – Sigma 
Aldrich) 
 
After incubation with primary antibodies, membranes were washed with PBS Tween 
0.1 % for 10 minutes for three times, and then incubated with the following secondary 
antibodies: conjugated goat-anti rabbit IgG-horseradish peroxidase (1:5,000 – Santa Cruz) and 
conjugated goat-anti mouse IgG-horseradish peroxidase (1:10,000 – Santa Cruz). Protein was 
detected using Enhanced Chemiluminescense System (ECL) (Amersham) and the relative 
amount of protein was determined using a calibrated densitometer GS-800 from BioRad. 
 
2.2.10. Cell culture, transfection and treatments 
Primary fibroblast cultures were grown in MEM medium supplemented with 1 % 
glutamine 200 mM, 10 % foetal calf serum (FCS) and antibiotics (penicillin 100 U/mL and 
streptomycin 100 µg/mL) in a humidified atmosphere containing 5 % CO2 at 37 ⁰C, in T25, T75 
flasks or in six-wells (p6) and p100 plates, according to the experiment. 
Cultures of immortalized primary fibroblast and of Hep3B and COS-1 were grown in 
MEM medium supplemented with 1 % glutamine 200 mM, 5 % foetal calf serum (FCS) and 
antibiotics (penicillin 100 U/mL and streptomycin 100 µg/mL) and puromycin (0.5 µg/mL) in a 
humidified atmosphere containing 5 % CO2 at 37 ⁰C, in T25 flasks or in p6 and p100 plates 
according to the experiment. 
 
2.2.10.1. MUT minigene 
For these experiments, 4x105 COS-1 cells were plated on a six well plate – p6. The 
experiments were performed in MEM complete medium using 8 µL of JetPei (Polyplus 
Transfection) and 2 µg of plasmid DNA from the empty pSPL3 vector and the minigene bearing 
the wild-type or the mutant sequences of MUT’s exon 6. The cells were incubated at 37 °C for 
48 hours. After this period, cells were harvested by trypsinization and RNA was extracted as 
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previously described. The transcriptional profile was studied by PCR amplification of the cDNA 
using the pSPL3 vector specific primers (Table 5):  
 
Table 5 – pSPL3 vector specific primers. 
Oligonucleotide name Sequence (5' - 3') 
SD6 (sense) TCT GAG TCA CCT GGA CAA CC 
SA2 (antisense) ATC TCA GTG GTA TTT GTG AGC 
 
 
2.2.10.2. Antisense oligonucleotide treatment  
For these experiments, 5x105 dermal fibroblasts of patients and controls were cultured 
as described. Cells were passaged by trypsinization and studied at a passage number ranging 
from 6-23.  
The 25-mer AMO were designed, synthesized and purified by Gene Tools and were 
targeted to donor or acceptor cryptic splice sites in the pre-mRNA. The sequences of the three 
AMOs PTS-AMO1, PTS-AMO2, and PTS-AMO3 used are shown in Table 6. 
As a negative control, a standard 25-mer Morpholino control oligonucleotide provided 
by Gene Tools was used. As a delivery reagent, Endo-Porter® was used following the 
manufacturer’s recommendations. 
 
Table 6 – Sequence of the AMOs used for the treatment of PTPS patients’ cells. 
Oligonucleotide name Sequence (5' - 3') 
PTPS AMO1 AGT GCC TAC AAT GTA ACA GGC AAG T 
PTPS AMO2 AGG CTG GAG AAT CGC TCG AAC CTG G 
PTPS AMO3 AGG CTG GAG AAT CGC TCG CAC CTG G 
Negative control CCT CTT ACC TCA GTT ACA ATT TAT A 
 
 
After transfection with 0, 20 and 30 µM of the corresponding AMO, cells were 
harvested at 24 hours and mRNA was isolated using the MagnaPure system following the 
manufacturer’s protocol. The cell lines were incubated with cycloheximide 0.75-1 mg/mL, 4 to 
6 hours prior to cell harvest. PCR amplification of transcripts derived from patient P12 and 
patient P13 cell lines was performed using 5´-TAT GGA GGA GGC GAT TAT GC-3´ and 5’-TTT 
CAA TAA ATA GGC ACT CC-3´ as forward and reverse primer, respectively. To exclude 
amplification from the allele bearing the c.163+2T>G mutation in patient P14 sample, a specific 
forward primer located in the exon 1 and exon 2 junction was used (5´-CCG ATT GTA CAG TAA 
ATT TCT AA-3´). 
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Antisense Vivo-Morpholinos (AMOs) that were covalently linked to Vivo-Porter (also 
supplied by Gene Tools) were added directly to the primary dermal fibroblast cell cultures. 
After 24 hour incubation, cells were harvested and conventional RT-PCR for splice analysis was 
performed as described in section 2.2.2.2. 
LNAs were designed, synthesized and purified by Exiqon against the target sequence 
for patients patient P12 and patient P14, as shown in Table 7. For this experiment, 2x105 cells 
were plated on p6 plates and were treated with different doses of LNA (1, 5, 25, 50 nM and 5 
µM) and 10 µL of Lipofectamin 2000, for 24 hours.  
The cells were collected by trypsinization and the pellet was stored at -70°C prior to 
use. Total RNA was extracted using the Tripure Isolation Reagent (Invitrogen).  
 
Table 7 – LNA sequences used in PTPS patients. 
Name 5' - 3' Sequence Target mutation 
PTS-LNA1 CAAACAAACCTTAACT c.84-322A>T 
PTS-LNA2 TCGCTCGAACCTGGGA c.164-712A>T 
 
 
2.2.11. PTPS enzymatic activity assay 
For these experiments, 1x106 non-stimulated patients’ skin fibroblast cells were grown 
in 75-cm2 plates in MEM, treated with 30 μM of AMO and incubated for 48 or 72 hours. The 
cells were harvested by trypzinization and the pellets were stored at -70°C until analyzed. The 
pellets were re-suspended in 150 µL of lysis buffer (10 nmol/L Tris-HCl, pH 7.4, containing 10 
mL/L Triton X-100) and lysed by freezing and thawing six times. After centrifugation at 15,000g 
for 5 minutes, 50 µL of the supernatant was added to 60 µL of reaction mixture containing 100 
mmol/L Tris-HCl, pH 7.4, 10 mmol/L MgCl2, 1mmol/L NADPH, 1 mmol/L NADH, 3 mU of SR, 220 
mU of DHPR and 60 µmol/L of dihydroneopterin triphosphate, in a final volume of 110 µL. A 50 
µL aliquot was incubated at 37 °C for 120 minutes and another aliquot was used as blank. The 
reaction was stopped by cooling the samples on ice and adding 15 µL of 300 g/L trichloroacetic 
acid (TCA) for protein precipitation. The samples were centrifuged at 15,000 g for 5 minutes 
and oxidized by incubating 50 µL of the supernatant with 10 µL of 10 g/L iodine for 60 minutes, 
at room temperature, in the dark. The oxidation reaction was stopped by adding 15 µL of 10 
g/L of ascorbic acid. The samples were then diluted (1:4 by volume) with water and heated at 
60 °C for 2 hours before being deproteinized using an Ultrafree-MC filter and analysed by 
HPLC. One unit of PTPS produces 1 µmol of biopterin per minute at 37 °C. (Bonafé et al, 2001) 
 
PART 2 MATERIALS and METHODS 
 
 
38 
2.2.12. Pterin quantification  
For pterin quantification, 1x106 patients’ skin fibroblasts and Hep3B immortalized cells 
were grown in 75-cm2 plates in MEM. When the patients cells reached a confluent monolayer, 
the expression of the GTPCH enzyme was stimulated with a cytokine cocktail containing 1250 
U of recombinant human interferon-γ (IFN-γ) and 500 U of tumour necrosis factor α (TNF-α), 
and incubated for 24 to 96 hours. At the same time, the cells were treated with 30 μM of the 
corresponding AMO and harvested at 48, 72 or 96 hours after transfection. Cells grown for 96 
hours were transfected twice with the AMOs. After incubation, cells were washed with PBS, 
harvested by trypsinization, counted to determine the cell number, washed again with PBS, 
and kept at -70 °C until analyzed for neopterin and biopterin. All the harvesting procedure was 
done in low light conditions.  
Cytokine-stimulated patients’ cells and non-stimulated Hep3B cell pellets were lysed in 
150 μL of lysis buffer (100 mM Tris-HCl, pH 8.0, 2.5 mM EDTA, 300 mM KCl and 10 % glycerin) 
by freezing and thawing six times. Lysate was centrifuged at 15,000 g for 15 min at 4 °C. A 
volume of 100 μL of supernatant was oxidized with 6 μL of 1 M HCl and 20 μL of a 10 g/L iodine 
solution for 30 minutes, at room temperature, in the dark. The remaining supernatant was 
used for determination of protein concentration using the Bradford reagent (Bio-Rad). The 
oxidation reaction was stopped by the addition of 20 μL of 10 g/L ascorbic acid (freshly 
prepared). To adjust the pH to 8.0-9.0, 10 μL of dephosphorylation buffer (1 M Tris-HCl pH 9.6 
containing 80 mM MgCl2) was added to the sample with alkaline phosphatase (20 U) to 
dephosphorylate the neopterin triphosphate. The sample was incubated at 37 °C for 60 min. 
The reaction was stopped by acidification to pH 2.0 with 7 μL of 2 M HCl. The sample was 
deproteinized using a low protein binding centrifugal filter (Whatman) and analyzed by HPLC. 
The intracellular concentrations of neopterin and biopterin after cytokine stimulation are 
expressed as pmol per mg of total protein ( Werner et al., 1996; Bonafé et al, 2001). 
 
2.2.13. Prokaryotic expression and purification of wild-type and mutant ATR proteins  
Human ATR gene mutations, p.Ile117-Gln118 p.His183Leu p.Arg186Trp, p.Arg190dup, 
and p. Glu193Lys were introduced by site directed mutagenesis as previously described. Wild-
type and mutant ATR proteins were expressed in BL21StarTMDE3 One Shot cells and incubated 
at 37 °C until optimum optical density (about 0.6-0.8 absorbance units) was reached and 
protein expression was induced with 1mM IPTG. The bacterial cultures were re-incubated at 
37°C for five hours and pellets were collected by centrifugation at 6,000 rpm for 10 minutes at 
4 °C and frozen at -70°C until further use. Cell pellets were re-suspended at 4 °C in 50 mM 
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potassium phosphate buffer pH 8, 100 mM NaCl, 1 mM DTT, 1 mM EDTA, 0.05 mg/mL DNase I, 
0.03 mg/mL lysozyme and a protease inhibitor cocktail (Complete Mini, EDTA-free Protease 
Inhibitor Cocktail Tablets®, Roche) and incubated for 1 hour with agitation at 4 °C. After, the 
cell suspension was sonicated and centrifuged to obtain the crude soluble cell extract. At this 
point, total protein concentration was assessed using the Bradford reagent (Bio-Rad) and 
samples containing 1 mg/mL were prepared to perform protein stability assays. The remaining 
protein extract was precipitated with ammonium sulphate, dialysed and separated by anion-
exchange chromatography using a HiTrap Sepharose Q column (GE Healthcare), as previously 
described (Leal et al, 2004; Jorge-Finnigan et al, 2010). Fractions eluted from the HiTrap 
Sepharose Q column were subjected to SDS-PAGE to identify those enriched in ATR protein 
and, before the ATR enzymatic assay, wild-type and mutant ATR proteins were further purified 
by molecular exclusion chromatography in Tris-HCl pH 8 buffer using a HiLoad Superdex 200 
60/10 column (GE Healthcare) at 4 °C, as described. (Jorge-Finnigan et al, 2010). 
 
2.2.14. ATR protein stability studies 
The stability of the wild-type and mutant ATR proteins (p.Ile117-Gln118del, 
p.His183Leu, p.Arg190dup, p.Arg186Trp and p.Glu193Lys), expressed in a prokaryotic system, 
was measured by incubation at 37 °C following IPTG induction. The wild-type and mutant 
p.His183Leu were also incubated at 27 °C. Soluble supernatant was incubated at 37 or 27 °C 
and aliquots were removed at different time points. The cell extracts were subjected to SDS-
PAGE. Western blot analysis was performed as described above. Following densitometric 
analysis, relative protein levels were expressed as percentage referred to time zero.  
 
2.2.15. Effect of ligands upon mutant and wild-type ATR proteins 
2.2.15.1. Stabilization of wild-type and mutant ATR proteins in a prokaryotic system 
As described in section 2.2.13., the prokaryotic expression of wild-type and mutant 
forms of ATR protein were induced over night in LB medium in the presence of 80 µM of 
compound V for the wild-type and p.His183Leu, p.Arg186Trp and p.Glu193Lys mutant forms. 
Since compound V is suspended in DMSO, bacteria were also incubated with the 
corresponding DMSO concentration (0.1 % or 0.2 %) as control. 
The wild-type ATR and mutant p.Ile96Thr proteins, previously used for compound V 
studies, were also incubated in the presence of 1 µg/mL of hydroxocobalamin and the 
combination of the two compounds, compound V and hydroxocobalamin. 
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The bacterial extracts were obtained as described in section 2.2.13 and analysed by 
SDS-PAGE and Western-Blot as described in section 2.2.9.  
 
2.2.15.2. Analysis of in vivo effect of ligands upon wild-type ATR protein 
Seventeen 12 weeks old wild-type (wt) female mice (C57BL/6J) were bought from 
Harlan Laboratories (Harlan Laboratories Inc., Indianapolis, IN, USA). The animals were housed 
at Centro de Biología Molecular Severo Ochoa at 22 ± 1°C on a 12/12h light/dark cycle with ad 
libitum access to food and water. Mice were kept under standard laboratory conditions in 
accordance with European Community Guidelines (directive 86/609/EEC). All animals were 
handled in strict accordance with good animal practice as defined by the national animal 
welfare bodies and institutional guidelines. The mice (23-25g) were treated with 25 µL 
suspension containing (a) 0.25 mg/mL (about 0.7 mM and (b) 5mg/mL (about 14 mM) of 
compound V in 10 %DMSO and 9 % glucose for 12 days. The loading was made using a pipette 
and letting the animals drink the solution. Each treatment group was composed by 6 animals. 
The control group was loaded with DMSO and glucose and was composed by 5 animals due to 
the death of one of them before the beginning of treatment.  
Approximately 30 minutes after the last dose, the animals were sacrificed with CO2 and 
liver and brain were removed. The brain and liver samples were divided in three equal parts 
and one was frozen in liquid nitrogen for further studies. Liver extracts were prepared  in 
phosphate saline buffer (PBS) with a protease inhibitors cocktail (Roche), and brain extracts 
were prepared in modified RIPPA buffer (50 mM Tris-HCl pH 7.4, 1 %Triton, 150 mM NaCl, 1 
mM EDTA, 1 mM NaF, 1 mM Na3VO4, 1 µg/mL protease inhibitor cocktail and 0,25 % Na-
deoxycholate). Liver samples were homogenized using a TissueLyser II (Qiagen) and brain 
samples were prepared using a glass tissue grind tube SZ 20 (Kimble Chase, Vineland, NJ, USA). 
Extracts were clarified by centrifugation at 13,000 rpm for 30 minutes at 4°C and the 
supernatants were stored at -70 °C prior to use.  
 
2.2.15.3. Analysis of the effect of ligands in vivo by MS/MS 
The control and treated mouse livers were divided in three equal parts. Two parts 
were homogenized using a glass tissue grind tube SZ 20 (Kimble Chase) in 1 mL of methanol 
(MeOH) or DMSO, respectively. The homogenate was centrifuged at 4 °C at 13,000 rpm for 10 
minutes, and the liquid phase was collected. Samples in MeOH and DMSO were completely 
dried under a stream of nitrogen at 40 °C and re-suspended in 150 µL of the mixture, DMSO, 
H2O and formic acid (100:50:0.2 %). An external calibration was made using different 
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concentrations of compound V (0 to 75 µmol/L). No internal calibration was used. The samples 
were analyzed by HPLC-MS/MS.  
Analyses were performed in a HPLC 1100 series (Agilent Technologies) coupled to a 
MS/MS QTrap (Applied Biosystems) using a mobile phase consisting in a solution of H2O, 
MeOH and formic acid (25:75:0.1) in an isocratic mode, running for 16 minutes.  The flow rate 
was established at 150 µL/min and 10 µL of each sample were loaded into a Symmetry® C18 
column (2.1x100 mm, 3.5 µm particle size, Waters Corp, Milford, MA, USA). 
The MS/MS acquisition consisted of a multiple reaction monitoring from the ion par 
m/z 320≥91, after the method’s optimization, where molecular ion 320 corresponds to [M+H+] 
(the molecular weight of the compound V plus one proton) and 91 corresponds to the ion 
weight of an abundant fragment of the compound. 
 
2.2.16. Propionate Incorporation 
4x105 skin fibroblasts of cblB patients and controls, both normal or immortalized, were 
plated on p6 plates and incubated in 1 mL of Puck’s saline solution containing glucose (0,5 
mM), fetal calf serum (15 %), propionate (1 mM) and 1 µCi/mL of 14C Propionate for 18 hours. 
Then, cells were washed with PBS, harvested by trypsinization and centrifuged at maximum 
speed for 10 minutes. The pellet was re-suspended and allowed to stand in a 5 % TCA solution 
at 4 °C. After centrifugation, TCA-precipitated material was re-suspended in NaOH 0.5 N, as 
described (Perez-Cerdá et al, 1989). Incorporation of 14C into TCA precipitate was estimated by 
re-suspending the samples in scintillation liquid and radioactivity quantification was performed 
in a Wallac RackBeta 1219 liquid scintillation counter (PerkinElmer, Waltham, MA, USA). The 
obtained data was divided by the corresponding amount of protein that was assessed using 
the Lowry method. This experiment was performed at 37 °C or 42 °C for some assays. 
 
2.2.17. Analysis of mitochondrial profile  
2.2.17.1. ROS analysis 
For analysis of reactive oxygen species (ROS), 3x105 skin fibroblasts from three control 
and the patients’ cell lines were cultured in a p6 plate, as previously described in section 
2.2.10. One auto-fluorescence, one negative and one positive control were included in each 
assay. The cells were washed with PBS and detached by trypsinization for 1 minute; the 
reaction was immediately stopped by adding 1 mL of complete culture medium. 500 µL of a 
mixture of H2DCFDA fluorescence probe (2,7-dichlorodihydrofluorecence diacetate; Molecular 
Probes) at a final concentration of 5 µM and PBS was added to the controls and patients’ cells. 
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The auto-fluorescence control was treated only with PBS, a mixture of PBS and 4 M NaCl was 
added to the negative control, and the positive control was treated with a mixture of PBS with 
fluorescent probe and 4 M NaCl. The cells were incubated at 37 °C in the dark for 30 min. After 
centrifugation, cells were re-suspended in 0.001 % propidium iodide (Sigma-Aldrich) and PBS 
mixture to detect cell death. ROS levels (H202) were monitored by flow cytometry and samples 
were analysed using a FACSCalibur apparatus with two solid-state lasers (λ 488 and λ 633 nm) 
(Becton Dickinson & Comp., Franklin Lakes, NJ, USA). A minimum of 10,000 individual events 
were recorded and the data was acquired using Cell Quest-Pro (Becton Dickinson, New Jersey, 
USA) and analysed using FlowJo software. 
 
2.2.17.2. Bioenergetic Profile 
An XF24 Analyser (Seahorse Biosciences) was used to measure bioenergetic function. 
Control and patients skin fibroblasts were seeded to a density of 50,000 cells in 24-well tissue 
culture microplates and incubated with 100 µL of DMEM or DMEM lacking D-glucose and 
supplemented with galactose respectively, and incubated at 37 °C for 3 to 5 hours. After the 
incubation period, another 250 µL of the corresponding medium was added and incubated 
overnight at 37 °C. The next day the medium was removed and the cells were washed with PBS 
and 700µL of the corresponding medium (DMEM or DMEM lacking D-glucose and 
supplemented with galactose) lacking sodium bicarbonate was added. Then the plates were 
incubated at 37 °C in a non-CO2 incubator for 1 hour. To assess the bioenergetic profile, we 
used modulating compounds, like oligomycin (6 µM), carbonyl cyanide p-(trifluoromethoxy)-
phenylhydrazone (FCCP) (50 µM), rotenone (1 µM) and actinomycin A (1µM). The calibration 
plate, containing these compounds, was prepared according to manufacture’s protocol. The 
oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) were monitored 
in real time.  After the completion of the assay, the number of viable cells was assessed and 
the results were normalized using those values (Dranka et al, 2011). 
 
2.2.17.3. Mitochondrial morphology analysis 
The mitochondrial morphology of patients’ and controls’ derived-fibroblast was 
observed using the Mitotracker® Red CM-H2Ros probe (Molecular Probes). Fibroblasts were 
seeded at a density of 1x105 cells over a 10 mm glass coverslip placed inside a 24-well tissue 
culture plate and incubated with 1mL of MEM at 37 °C overnight. Afterwards, cells were 
incubated at 37 °C for 40 minutes with 500nM Mitotracker® in MEM media, and then fixed in 
0.5 mL 10 % formalin at room temperature for 20 minutes. Cells were washed with PBS for 
three times and mounted with the cells facing down in a microscope slide in mounting media. 
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Images were taken one day after fixation, using an Axiovert200 inverted microscope (Zeiss, 
Jena, Germany) with a DsRED filter and 63x magnification.  
 
2.2.17.4. Mitochondrial Ca2+ uptake in permeabilized cells  
Mitochondrial Ca2+ uptake from patients and control fibroblast cell lines was measured 
in the presence of the Ca2+ - sensitive fluorescent probe Calcium-Green 5N (Invitrogen) at a 
final concentration of 0.1 µM (excitation λ 506 nm, emission λ 532 nm) using digitonin 
permeabilized cells. A minimum of 2x106 cells were harvested by trypsinization, followed by 
centrifugation on MEM medium. Cells were washed and re-suspended in MSK buffer (125 mM 
KCl, 2 mM potassium phosphate, 3 mM MgCl2, 20 mM Hepes, pH 7.4) and kept on ice for 18 
hours. An AMINCO-Bowman (series 2) spectrofluorometer (Thermo Fisher Scientific), provided 
with temperature control and continuous stirring was used to perform the experiments carried 
out at 30 °C in the presence of the respiratory substrates succinate (5mM) and rotenone (1 
µM), and also in the presence of ATP and cyclosporine A (5 µM). Digitonin (80 µM) was added 
to permeabilize the cells and, after 3 to 5 min of incubation, CaCl2 was added repeatedly to the 
cuvette until mPTP opening.  
 
2.2.18. In silico analysis  
All cDNA and gDNA sequences of genes studied in this work were obtained using the 
public databases Ensembl (http://www.ensembl.org/index.html) and GenBank from NCBI 
(http://www.ncbi.nih.gov/). For mutation nomenclature the Human Genome Variation Society 
(HGVS, http://www.hgvs.org/) guide lines were followed, and all the mutations found were 
consulted on the Human Gene Mutation Database Professional release (HGMD Professional 
2013.1, http://www.hgmd.cf.ac.uk). 
The program BLAST (http://ncbi.nlm.nih.gov/BLAST/) was used to search public 
databases for sequence homology. 
Analysis of DNA sequences was performed using the Chromas 1.45 software (Griffith 
University, Australia).  
As previously described, the oligonucleotides used for DNA amplification were 
designed using the Primer3 (v. 0.4.0) program (Rozen and Skaletsky, 2000). 
The location of possible exonic splicing enhancers (ESEs) was assessed using the 
programs for prediction of splicing factors recognition sequences, ESE Finder (v 3.0, 
http://rulai.cshl.edu/tools/ESE) (Cartegni et al, 2003) and HSFinder (v 2.4, 
http://www.umd.be/HSF/) (Desmet et al, 2009). The Berkeley Drosophila Genome Project 
(BGDP, http://www.fruitfly.org/seq.tools/splice) server and the Alternative Splice Site 
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Predictor (ASSP, http://wangcomputing.com/assp/index.html) were used to predict the effect 
of mutation upon splicing sites.  
The pathogenesis and possible functional effect of missense mutations was evaluated 
using the Polymorphism Phenotyping (PolyPhen-2) software 
(http://genetics.bwh.harvard.edu/pph2/) and also the SIFT software (http://sift.jcvi.org/).  
Protein sequences were obtained from the Protein Data Bank (PDB, 
http://www.rcsb.org/pdb/home/) and from SWISS-PROT (http://www.expasy.org/sprot/).  
The entropy levels from wild-type and mutant hATR proteins were calculated using the 
CAFFE bioinformatic program which calculates the entropy levels necessary to form the 
correctly folded protein (Bastolla et al, 2001; Bastolla et al, 2004). 
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3.1. MOLECULAR CHARACTERIZATION OF PATIENTS WITH ORGANIC ACIDEMIAS 
In this section, seven patients were studied, five of them presenting biochemical and 
clinical symptoms of isolated methylmalonic aciduria, while the remaining two presented 
symptoms of propionic academia. The results revealed that four patients (P1, P2, P3 and P4) 
carried mutations in the gene MMADHC, one patient (P5) presented a mutation in the MUT 
gene and two patients (P6 and P7) presented mutations in the PCCB gene.  
In Table 8 are depicted the biochemical and enzymatic data, as well as the clinical 
phenotype and the clinical outcome of the four cblD patients analyzed. The biochemical 
analysis of these four patients suggested they presented isolated methylmalonic aciduria 
(Table 8). However, analysis of MUT enzymatic activity of patients P1, P2 and P3 showed levels 
in the control range, discarding the possibility of mutations affecting the MUT gene. For P4 
only gDNA was available hence, the enzymatic and response to hydroxycobalamin data were 
not available. 
Patients P1, P2 and P3 presented a clear response to treatment with 
hydroxycobalamin, which could indicate a defect in MMAA or MMAB genes. Both were 
analyzed by direct sequencing, but no mutations were found. The identification of the 
MMADHC gene as responsible for the cblD complementation defect (Coelho et al, 2008) during 
the time of this work, led to the search of mutations in this gene for these four methylmalonic 
patients, whose genotypes remained unidentified. Direct sequence analysis of cDNA and/or 
gDNA from these four patients allowed their full molecular characterization. Three new 
mutations, c.165_166del2, c.170G>A, c.10-1G>C, as well as one already described mutation, 
c.57_64del8, were identified in homozygosity (Figure 9).  
Patient P1 revealed to be homozygous for the previously described mutation c. 
57_64del8 (p.Cys19fs) (Coelho et al, 2008). This mutation leads to the deletion of 8 nucleotides 
in exon 2, causing an out-of frame deletion of the protein C-terminal end. 
Patient P2 was homozygous for the novel mutation c.165_166del2 (p.Thr55fs). This 
mutation leads to the exclusion of two nucleotides in exon 3 and, just like the previous 
mutation, to the production of an out-frame mutation. 
In Patient P3 a novel point mutation, c.170G>A (p.Trp57X) in exon 3, was identified. 
This is, probably, a severe pathogenic mutation, since it leads to the introduction of a 
premature stop codon (PTC), putatively leading to a truncated protein. 
Patient P4 presented also a novel point mutation, c.10-1G>C. This mutation affects the 
guanosine residue of the original 3’ splice site of intron 1. In silico analysis revealed that the 
deletion of the original acceptor splice site results in the increase of the score of an AG 
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dinucleotide located inside exon 2, which probably leads to the activation of this new splice 
site (Figure 10). Hence, 14 exonic nucleotides are, probably, eliminated, resulting in a 
disruption of the ORF. This mutation is also responsible for the creation of a new binding site 
for the serine/arginine-rich splicing factor 6 (SRSF6), which plays an important role in 
determination of alternative splicing events. 
All the novel mutations are likely pathogenic since all produce, most probably, a 
truncated protein. 
 
 
Figure 9 – Mutations identified by direct Sanger sequencing of the MMADHC gene. A) P1 presented a 
deletion of 8 nucleotides in exon 2. B) P2 presented a small deletion of 2 nucleotides in exon 3. C) P3 
presented a C>T change in exon 3 and D) P4 presented a G>C change in the first nucleotide upstream 
exon 2. Mutations according to NM_000532.3. 
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Table 8 – Genetic, biochemical and clinical parameters of the methylmalonic cblD type patients studied.  
Patiente Mutation (cDNA/gDNA/protein)* 
MUT 
Enzimatic 
Activity** 
[14C]-Propionate 
Incorporation ex vivo Clinical 
Onset Treatment Outcome -OHCbl / +OHCbl 
(Fold change) 
P1 
c.57_64del8/c.57_64del8    
Chr2(hg19):g.150438731_1504387
38del8  
p.Cys19fs/p.Cys19fs 
0.96 0.13 / 2.30  (17.7) 
Severe onset on 4th day of live with 
hypotonia and a severe metabolic 
acidosis. At 6th day clinical worsening 
with coma and elevated 
hyperammonemia (>400µmol/L) 
Hypoproteic 
diet, vitamin B12 
(1mg/day) and 
L-carnitine 
Mild delay in motor 
performances and normal mental 
development with very mild 
cerebral MRI abnormalities. Very 
good clinical evolution. 
P2 
c.165_166del2/c.165_166del2 
p.Thr55fs/p.Thr55fs 
Chr2(hg19):g.150436151_1504361
52del2 
3.03 0.15 / 4.97  (33.1) 
Elevated levels of cystein, methylmalonic 
and butyric acid. Vitamin B12 Good evolution. 
P3 
c.170G>A/c.170G>A 
p.Trp57*/p.Trp57* 
Chr2(hg19):g.150436147C>T 
2.86 0.17 / 8.2  (48.2) 
Convulsions in 1st year of life, no fever, 
severe muscular hypotonia and 
psychomotor delay. At age of two 
presented polyuria, polydipsia and 
progressive degeneration of height and 
height growth. Renal failure and elevated 
ammonia levels in plasma Positive 
screening for creatinine and 
methylmalonic acid 
Injections of 
vitamin B12 
(1mg) twice a 
week and L-
carnitine  
Good evolution. 
P4 c.10-1G>C/c.10-1G>C Ch2(hg19):g.150438786C>G ND ND 
Vomiting and anorexia since 15 months 
old. Metabolic decompensations 
associated with neurological signs.  
Severe high anion gap metabolic acidosis, 
ketosis and ketonuria, hyperammonemia 
and hyperglycinemia. Also presented 
thrombocytopenia and neutropenia. 
1st treatment: 
Carbalu and 
dialysis for 
hyper 
ammonemia 
2nd treatment: 
vitamin B12 and  
L-carnitine 
Good evolution. 
Normal aminoacid levels in urine, 
elevated glycine, lysine and 
metylmalonic acid levels in 
plasma. 
C — 0.89±0.43 
1.94±1.2/ 
2.29±1.5 (1.18) — — — 
ND: Non determined.   *Mutations according to NM_015702.2 and NC_000002.11 (MMADHC) obtained using the Mutalyzer 2.0 beta 26 version software according to hg19 
(https://mutalyzer.nl/positionConverter). **Mutase activity (nmol/min per mg protein) measured with 36 µM AdoCbl.  ***[14C]-Propionate incorporation (nmol/10h/mg 
protein) in the absence or presence of 1µg/mL of hydroxocobalamin. 
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Table 9 – Genetic and biochemical data from propionic and methylmalonic mut type patients.  
Patient Gene Mutation*(cDNA/gDNA/protein) 
Propionic acid at 
diagnostics 
(mmol/mol creatinine) 
Methylmalonic acid at 
diagnostics 
(mmol/mol creatinine) 
Outcome 
P5 MUT 
c.1408-10A>G/ c.244dupA 
Chr6(hg19):g.49416575T>C/g.49426936dup 
p.?/p.Leu81fs 
– 378 Good evolution with no developmental delays. 
P6 PCCB 
c.1218del14ins12/ c.183+3G>C 
Chr3(hg19):g.136045712delins12/g.135969403G>C 
p.Gly405fs/p.Arg61fs 
3795 – NA 
P7 PCCB 
c.1218del14ins12/ c.1218del14ins12 
Chr3(hg19):g.136045712delins12  
p.Gly405fs 
2185,2 – NA 
NA: Non available 
*Mutations according to NM_000532.3 and NC_000003.11 (PCCB) and NM_000255.3 and NC_000006.11 (MUT). The genomic coordinates were obtained from the 
Mutalyzer 2.0 beta 26 software according to hg19 (https://mutalyzer.nl/positionConverter).  
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Figure 10 – Prediction of the effect of mutation c-10-1G>C (bold letters) in P4 splicing profile from in 
silico data. The upper part represents the normal splicing profile while the lower part represents the 
possible mutation effect. Splicing scores were calculated with the BDGP software (www.fruitfly.org) and 
the underlined sequence represents a new binding site for the SRSF6 protein. 
 
 
Patient P5 is a female born of non consanguineous parents who presents a mild 
methylmalonic phenotype. Only gDNA was available from this patient, hence, no enzymatic 
analysis was performed. Since the presence of mutations in MUT gene is responsible for the 
majority of the isolated methylmalonic deficits described until now, the analysis started with 
the amplification and sequencing of the 13 exons of this gene, which lead to the identification 
of two novel mutations, c.244dupA and c.1408-10A>G. None of the mutations was described 
in the Exome Variant Server (http://evs.gs.washington.edu/EVS). For further characterization, 
exon 1, bearing mutation c.244dupA, and its intronic flanking regions were cloned into the 
TOPO® TA vector and sequenced.  
The c.244dupA is a frameshift mutation that leads to the insertion of an adenosine 
nucleotide in exon 1. This mutation is predicted to be pathogenic since it probably originates a 
truncated protein, p.Leu81fs (Figure 11).  
The mutation c.1408-10A>G is responsible for the substitution of an adenosine 
nucleotide for a guanosine in the position -10 of intron 5 (Figure 11). The functional analysis of 
this mutation is presented in the next section.  
 
 
Figure 11 – Mutational profile of patient P5. A) Mutation c.244dupA in exon 1 was cloned into the 
TOPO® TA vector and analyzed. B) Splicing mutation, c.1408-10A>G in intron 5.  
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Regarding the propionic patients, P6 and P7, and since the mutations incidence is 
higher in the PCCB gene, their molecular characterization started with the amplification and 
direct sequencing of this gene. This strategy revealed to be appropriate, because it allowed the 
full characterization of the two patients and revealed the presence of two known mutations, 
c.1218del14ins12 and c.183+3G>C. 
Patient P6 revealed to be a compound heterozygote for the two known mutations, 
c.1812del14ins12 and c.183+3G>C (Figure 12). Mutation c.183+3G>C affects the guanosine 
residue in position +3 in the 5’ donor site of exon 1. This transversion weakens the wild-type 
donor splice site and may induce the selection of another GT in position +21 which presents a 
naturally elevated splice score (0,96). Segregation analysis was performed and it was possible 
to establish the parental origin of both mutations.  
 
 
Figure 12 – Mutational profile of patient P6. This patient is a compound heterozygous for the mutations 
c.1218del14ins12 and c.183+3G>C (down panel). In the upper panel are the mutations found in the 
parental study.  
 
 
Patient P7 was homozygous for the mutation c.1218del14ins12 (Figure 13). This 
mutation affects codon 406 in exon 12 of PCCB gene and consists in the deletion of 14 
nucleotides and the simultaneous insertion of 12 nucleotides in the place occupied by the 
deleted nucleotides. This mutation is fairly common and is associated with a premature stop 
codon and, consequently, a truncated protein.  
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Figure 13 – Sequence profile of patient P7 genomic DNA. A) Wild-type sequence where the deleted 
nucleotides are highlighted. B) Sequence bearing the mutation found in P5. The inserted sequence is 
highlighted in red. 
 
 
3.2. FUNCTIONAL ANALYSIS OF MUTATIONS IN ORGANIC ACIDURIAS 
In this section we analyzed the functional effect of the splicing mutation found in MUT 
gene and of missense mutations found in MMAB gene.  
Mutations are important genetic factors of human diseases and their role is 
determined by the diversity of their impact on molecular function. The analysis of mutations 
effect upon protein structure and function allows the elucidation of the effect of the allelic 
variants upon the MUT and ATR proteins, respectively, in order to find the best therapeutic 
option based on mutations specific mechanism of action. 
 
3.2.1. Characterization of a splicing mutation in methylmalonic aciduria mut type  
Since mutation c.1408-10A>G has not been previously described in the literature, we 
proceeded to analyze its possible effect upon the splicing profile and the resulting protein, in 
order to elucidate if this is a disease causing mutation and the pathogenic mechanism to 
address therapeutic strategies.  
The in silico analysis of the sequence encompassing the mutation, using the human 
splicing finder software (www.umd.be/HSF/), indicated that this mutation might create a new 
acceptor splice site with a higher score (87.81), upstream the natural acceptor splice site. This 
analysis showed also that the natural splice site presents a low score (75.58), which might 
favor the possibility of activation of another splice site.  
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In order to study the effects of this new mutation, and since it was not possible to 
obtain patients’ cells, an ex vivo minigene assay was performed to analyze the transcriptional 
profile. In this assay, exon 6 of MUT gene and the respective intronic flanking regions were 
amplified from P5 and from a control sample, and cloned into the pSPL3 vector. After the 
transfection of a COS cell line and a 24 hour incubation period, total RNA was extracted and 
analyzed by RT-PCR (Figure 14).  
Direct sequencing analysis showed that the mutation creates a new splicing site 
upstream the original splice site for exon 6, which presents a low splicing score, as previously 
predicted by in silico analysis, leading to the introduction of nine additional nucleotides. The 
final result should be the introduction of three additional amino acids into the protein 
sequence. The corresponding band (band number 4, Figure 14) was a heteroduplex of the 
sequence containing nine additional nucleotides and also the normal sequence.  
We also observed the presence of a lower molecular weight band, resulting from the 
elimination of 135 nucleotides from exon 6, which might translate into the elimination of 45 
amino acid residues from the protein. The in silico analysis of the sequence corresponding to 
the wild-type exon 6, using the Alternative Splice Site Predictor (ASSP - 
http://wangcomputing.com) software, revealed the presence of a cryptic acceptor site 
(gaattgccagGAACACACAA), located inside exon 6, with a higher score (3.505) when compared 
with the one observed for the constitutive acceptor site (2.278).  
We observed the presence of the same band in the control profile, and also a band 
corresponding to the heteroduplex formed between the normal sequence and the sequence 
lacking the 135 nucleotides, what suggests that this may be a normal event in control 
individuals.   
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Figure 14 – Transcriptional profile obtained with the minigene ex vivo assay for the c.1408-10A>G 
mutation. A) RT-PCR profile, B) schematic representation of the different fragments obtained, C) 
Sequences of each fragment obtained. Splicing scores were calculated using the Human Splicing Finder 
software (http://www.umd.be/HSF). 
 
 
3.2.2. Structural and functional analysis of allelic variants identified in methylmalonic 
cblB type patients 
Five mutations were studied, two new mutations (p.His183Leu and p.Arg190dup), and 
three previously described mutations (p.Ile117_Gln118del, p.Arg186Trp and p.Glu193Lys). 
(HGMD® Professional 2013.1)  
The new mutations (p.His183Leu and p.Arg190dup) were previously identified in two 
siblings with isolated methylmalonic cblB type phenotype (P8 and P9 – Table 10). Patient P8 
was detected by expanded newborn screening and the phenotype of isolated methylmalonic 
aciduria was confirmed by the analysis of metabolites in urine by GS/MS, which showed 
elevated methylmalonic acid levels. Family genetic studies were performed and his sibling, P9 
was later characterized and presented a small increase in methylmalonic acid levels. Both 
patients present a positive response to hydroxocobalamin treatment.  
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Table 10 – Biochemical, clinical and genetic data from isolated methylmalonic cblB type patients. 
Patient Gene 
MMA levels at 
diagnosis 
(mmol/molcreat) 
[14C]-Propionate 
incorporation 
-OHCbl/+OHCbl* 
(Fold change) 
Genotype**(cDNA/gDNA/protein) Clinical Outcome 
P8 MMAB 830 0.63/1.19 (2X) 
c.548A>T/c.568_570dup 
Chr12(hg19):g.109998881T>A/g.109998859_109998861dup 
p.His183Leu/p.Arg190dup 
One month. 
Asymptomatic 
P9 MMAB 58 1.06/2.59 (3X) 
c.548A>T/c.568_570dup 
Chr12(hg19):g.109998881T>A/g.109998859_109998861dup 
p.His183Leu/p.Arg190dup 
9y. Asymptomatic. 
Studied due to previous 
affected sibling 
Control - 1 – 13 1.90±1.18/2.34±1.61 - - 
NS: Not studied.  
* [14C]-Propionate incorporation (nmol/10h/mg protein) in the absence or presence of 1µg/mL of hydroxocobalamin. 
**Mutations according to NM_052845.3 (MMAB) and the genomic coordinates were obtained using the Mutalyzer 2.0 beta-26 software according to hg19 
(https://mutalyzer.nl/positionConverter).  
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Further analysis revealed that p.His183Leu and p.Arg190dup variants were not 
described in the exome variant database (evs.gs.washington.edu). To identify genetic 
background variances that could explain the biochemical differences between the siblings, the 
promoter was sequenced and analysis of genomic rearrangements was performed. The 
genomic rearrangements were studied using a customized high-resolution comparative 
genomic hybridization assay (Metaboloarray°) and no changes or copy number variations were 
found.  
The levels of immunoreactive ATR protein were analyzed by western blot in control 
and patients’ derived fibroblasts and, as shown in Figure 15, both patients presented lower 
protein levels than the control, although P8 presents decreased levels when compared with his 
sibling P9.  
 
 
Figure 15 – Analysis of the immunoreactive ATR protein. ATR protein levels were assessed in control 
and methylmalonic cblB type patients, P8 and P9, by western blot. 
 
 
To further assess the effect of these mutations upon the protein function of the cblB 
type patients, the metabolic pathway function was assessed by an indirect measure of [14C]-
propionate incorporation levels at physiological conditions (37 °C) and also under stress 
conditions (42 °C) (Figure 16). 
The results of the [14C]-propionate incorporation show a significant decreased rate at 
physiological conditions for patient P8, when compared with the control and with his sibling, 
patient P9 who, in the same conditions, presented levels comparable to the control. When the 
cells were incubated at 42 °C, the incorporation rate for P9 was decreased, indicating that, in a 
stress situation, the fibroblasts derived from this patient have the same behaviour as those of 
his affected sibling.  
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Figure 16 – Effect of stress conditions upon the ATR protein function. [14C]-propionate incorporation of 
control and patients’ dermal fibroblasts at 37 °C or 42 °C in the absence of hydroxocobalamin (OHCbl) to 
provide an indirect quantification of ATR activity. Results are the means ± SD for three independent 
experiments. (*P<0.05, **P<0.01) 
 
 
3.2.3. Stability analysis of the p.His183Leu and p.Arg190dup allelic variants using a 
prokaryotic expression system 
To further assess the effect of p.His183Leu and p.Arg190dup mutants found in patients 
P8 and P9, both were studied using a prokaryotic expression system. The human wild-type and 
the different mutant ATR proteins were expressed in an E.coli strain at physiological 
temperature (37 °C), and crude protein extracts were loaded into a SDS-PAGE gel. The results 
are shown in Figure 17 and, as can be observed, no soluble protein was obtained for the 
p.R190dup mutation, even when high amounts of crude extract were loaded.  
 
 
Figure 17 – Western blot of wild-type and mutant ATR proteins. A) Wild-type and p.His183Leu crude 
protein extracts obtained from an E.coli strain. B) Lanes 1 to 7 – different amounts of crude soluble 
bacteria extract of wild-type ATR, lanes 8 to 14 – different amounts of crude soluble bacteria extract of 
p.Arg190dup mutant.  
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Since it was not possible to obtain enough amount of protein for the p.Arg190dup 
mutant, no stability studies could be performed. 
The mutation p.His183Leu was further studied in order to assess its impact upon the 
ATR protein folding stability. The wild-type and the mutant were expressed using the same 
prokaryotic system, both at physiological temperature (37 °C) and permissive folding 
conditions (27 °C) and samples were collected at different times. The crude extracts were 
analyzed by SDS-PAGE followed by immunodetection, and the amount of reactive protein was 
quantified by laser densitometry (Figure 18). 
The results obtained at physiological temperature showed that the mutant 
p.His183Leu is more unstable than the wild-type protein, presenting about 58 % decrease in 
stability when compared with the wild-type, which indicates that this could be a destabilizing 
mutation (Table 11).  
When p.His183Leu and wild-type proteins were incubated in permissive folding 
conditions (27 °C), in vitro stability was increased for both proteins, but especially for the 
p.His183Leu mutant that presented a 3.3 fold increase reaching the wild-type levels. This 
indicates that most probably p.His183Leu is a folding mutant (Figure 18).  
 
Table 11 – Relative protein stability for wild-type and p.His183Leu mutant at physiological and folding 
permissive temperatures.  
 
Relative protein stability (hours) 
Fold change 
37°C 27°C 
Wild-type ATR 5.4 6.1 1.13 
p.His183Leu ATR 2.28 7.6 3.3 
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A) 
 
B) 
 
Figure 18– Degradation profile of the wild-type and mutant p.His183Leu at A) physiological (37 °C) and 
B) permissive conditions (27 °C). The crude extracts were incubated over time at 37 °C and aliquots 
were collected and analyzed by western-blot. The data show the mean value ± SD (n=6) and represent 
the percentage of the density of each protein compared to time zero. 
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3.2.4. Chaperone and protease profile in cblB type patients bearing p.His183Leu and 
p.Arg190dup mutations 
Since patients P8 and P9 have the same genotype but different phenotypes, and both 
mutations (p.His183Leu and p.Arg190dup) are responsible for a decrease in protein stability, 
the mitochondrial protein quality control system (mtPQC) was studied. The levels of 
mitochondrial chaperones, Hsp60 and Hsp70, and the protease Lon protein, were analyzed by 
western blot in fibroblasts derived from control and cblB patients, P8 and P9. 
Figure 19 shows an increase on the immunoreactive protein levels of the 
mitochondrial protein Hsp70 in both patients when compared to control, although patient P8 
presents higher levels than his sibling P9. Mitochondrial chaperone Hsp60 levels seem normal 
in patient P8 cells, while a slight decrease was observed in patient P9.  
 
 
 
 
 
Figure 19 – Mitochondrial protein quality control analysis. Western blotting of soluble crude extract 
from patients´ fibroblasts using anti mtHsp70, mtHsp60 and Lon antibodies is shown. The α -tubulin 
protein was used as control loading protein. Protein amount was quantified by laser densitometry and 
data represent the mean quantification values ± SD of three independent experiments (*P<0.05). 
Re
la
tiv
e 
am
ou
nt
 o
f p
ro
te
in
 
* 
* 
* 
PART 3 RESULTS 
 
 
62 
The analysis of immunoreactive levels of Lon protease (Figure 19) showed an increase 
in protein levels for patient P8, while his sibling P9 showed a markedly decrease in the amount 
of reactive protein.  
 
3.2.5. Stability analysis of allelic variants affecting the ATR protein using a prokaryotic 
expression system 
The effect of other allelic variants affecting ATR protein was also analyzed. The 
previously described mutations, p.Ile117_Gln118del, p.Arg186Trp and p.Glu193Lys were 
studied. The p.Ile117_Gln118del was identified in a cblB type patient diagnosed in the 
laboratory, and the p.Arg186Trp and p.Glu193Lys variants were analyzed due not only to their 
high incidence in the cblB type patients population (p.Arg186Trp) and also due to their 
characterization as folding mutants, and hence, as interesting targets for therapeutic approach 
using chaperones (Fan and Bobik, 2008). 
As described before, human wild-type ATR and the different mutants were expressed 
in an E.coli strain at physiologic temperature (37 °C), and crude protein extracts were loaded 
into a SDS-PAGE gel. The results are shown in Figure 20 and, as can be observed, no soluble 
protein was obtained for p.Ile117_Gln118del mutation.  
 
 
Figure 20 – Western blot of wild-type ATR and p.Ile117_Gln118del mutant. Crude protein extracts 
obtained from an E.coli strain were analyzed at physiological temperature (37 °C).  
 
 
The p Ile117_Gln118del was also expressed at permissive folding conditions (27 °C), 
but no differences in the expression of the mutant were observed. 
Stability studies were performed at 37 °C for both p.Arg186Trp and p.Glu193Lys 
mutants, as described before and a decrease in stability was observed for the two mutant 
proteins, especially for p.Glu193Lys mutant (Figure 21). 
The p.Arg186Trp mutant present a reduction in stability of about 37 % when compared 
to the wild-type, while the p.Glu193Lys mutant presents a 93 % reduction of stability in the 
same conditions (Table 12).  
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Figure 21– Degradation profile of the wild-type and the p.Arg186Trp and p.Glu193Lys mutant ATR 
proteins at physiological conditions (37 °C). The crude extracts were incubated over time at 37 °C and 
aliquots were collected and analyzed by western-blot. The data show the mean value ± SD (n=3) and 
represent the percentage of the density of each protein compared to time zero. 
 
 
Table 12 – Relative protein stability for wild-type ATR and p.Arg186Trp and p.Glu193Lys mutants at 
physiological temperature. 
 Relative protein stability at 37 °C (hours) 
Relative protein 
stability reduction (%) 
Wild-type ATR 5.4 100 
p.Arg186Trp ATR 3.4 37 
p.Glu193Lys ATR 0.38 93 
 
 
3.2.6. Structural analysis of missense changes affecting ATR protein 
The ATR protein is a homotrimer, being each subunit composed of five α-helices with 
the active site located at the monomers interface, and mutations affecting protein residues are 
responsible for structural and functional defects. In order to analyze the effect of the 
p.Ile117_Gln118del, p.His183Leu, p.Arg186Trp, p. Arg190dup and p.Glu193Lys mutations upon 
the trimeric ATR protein structure, the crystallographic structure (2IDX) available at the public 
database Protein Data Bank (PDB – www.pdb.org) was used.  
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Figure 22 – Tridimensional trimeric ATR structure and localization of the mutated residues. All three 
monomers are represented in blue and the residuesIle117 in green, Gln118 in red, His183 in yellow, the 
Arg186 in orange, Arg190dup in pink and the Glu193 in purple. This image was obtained using the SPDB 
software and the protein structure available at PDB database (2IDX). 
 
 
The residues Ile117 and Gln118 are located on the 2α-helix of the ATR protein. The 
Gln118 is an invariant residue that establishes hydrogen bonds with the 3α – 4α helices loop 
(Schubert and Hill, 2006), hence its elimination probably disrupts the protein structure leading 
to a severe effect.  
The Arg190 residue is located in the 4α-helix of the ATR protein and establishes 
hydrogen bonds with ATP (Schubert and Hill, 2006). The duplication of this residue probably 
has a severe impact on the protein structure, leading to its complete loss-of-function.  
The effect of the missense mutations, p.His183Leu, p.Arg186Trp and p.Glu193Lys, was 
also analyzed in silico using the bioinformatic program CAFFE. This computational method is 
based on a fold recognition algorithm that uses an effective free energy function, instead of 
relying on sequence similarity and derived energy parameters for simplified models of protein 
folding. This program analyzes the entropy energy lost to form the protein complex. It sets a 
minimum threshold of 2.3 for the inter-chain energy and if all the three ATR chains (A, B and C) 
present a value above 2.3, the complex is formed (Bastolla et al, 2001; Bastolla et al, 2004). 
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The three missense mutations were analyzed and the values obtained were compared 
to the wild-type protein and are depicted in Table 13. The p.Glu193Lys mutation is the most 
unstable and none of the values obtained for the three chains was above 2.3, indicating that 
this mutant does not assembles correctly. The complex assembly is also compromised for 
mutation p.His183Leu although two of the chains (A and C) may interact. Mutation 
p.Arg186Trp presents the same inter-chain values as the wild-type but a slightly higher total 
energy value. This suggests the change of an arginine residue for a tryptophan makes the 
molecular structure more rigid, thus affecting the protein mobility and stability.  
 
Table 13 – Amount of entropy necessary to form the three stable chains (A, B and C) observed in the 
wild-type ATR protein and mutants, p.His183Leu, p.Arg168Trp and p.Glu193Lys. The values showed 
were obtained using the CAFFE program which uses a minimum of 2.3 (3RT) threshold for a stable 
formation.  
 
Inter-chain energy Total chain energy 
Wild-type ATR 
-2.43 A 
-2.36 B 
-2.56 C 
-24.0 (ABC) 
p. His183Leu ATR 
-2.32 A 
-2.25 B 
-2.45 C 
-16.2 (AC) 
-6.5 (B) 
p. Arg186Trp ATR 
-2.43 A 
-2.36 B 
-2.56 C 
-24.7 (ABC) 
p. Glu193Lys ATR 
-2.26 A 
-2.19 B 
-2.22 C 
-8.2 (A) 
-6.1 (B) 
-6.3 (C) 
 
 
The results obtained with the in silico analysis corroborate the data obtained with the 
stability assays performed, and are also in accordance with the data available in the literature 
for the p.Arg186Trp and p.Glu193Lys mutants.  
 
3.3. MITOCHONDRIAL DYSFUNCTION IN ISOLATED METHYLMALONIC ACIDURIA  
Organic acidurias have been related with mitochondrial dysfunction, which can be 
translated in high reactive oxygen species (ROS) levels, impaired bioenergetic function, 
defective mitochondrial morphology and, ultimately, apoptosis. In order to assess if the 
phenotypic differences observed in the previously described cblB type patients could be 
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related to defects in mitochondrial function, ROS levels, mitochondrial morphology and 
bioenergetics function was assessed in patients P8 and P9. Mitochondrial dysfunction was also 
analyzed in two methylmalonic mut type patients, patients P10 and P11 (Table 14).  
 
Table 14 – Biochemical, clinical and genetic data from isolated methylmalonic mut type patients. 
Patient Gene MMA levels (mmol/molcreat) Genotype (cDNA/gDNA/protein)* Outcome 
P10 MUT 3032 
c.1808G>A/c.1957-892C>A 
Chr6(hg19)g.49409553C>T/g.49404227G>T 
p.Val583fs/p.Gln652fs 
Deceased 
P11 MUT 4159 
c.1850T>G+c.205A>G/c.1957-898A>G 
Chr6(hg19):g.49408025A>C+g.49426975T>C
/g.49404234T>C 
p.Leu617Arg+p.Ile69Val/p.Gln652fs 
Deceased 
Control - 1 – 13 - - 
NS: Not studied.  
ND: Non determined. 
* Mutations according to NM_052845.3 (MMAB) and NM_000255.3 (MUT) and the genomic 
coordinates were obtained using the Mutalyzer 2.0 beta-26 software 
(https://mutalyzer.nl/positionConverter). 
 
 
 
Figure 23 – Methylmalonic acid levels of cblB and mut type patients. 
 
 
These patients were included in this study for comparison with cblB type patients, 
since they present higher methylmalonic acid levels (Figure 23), which have been related to 
mitochondrial dysfunction. 
 
 
3.3.1. Analysis of ROS and mitochondrial morphology in isolated methylmalonic patients 
Total ROS levels were analyzed by flow cytometry in cblB type patients (P8 and P9) and 
control samples, using a H2DCFDA fluorescence probe to measure hydrogen peroxide (H2O2) 
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levels and propidium iodide to quantify the number of death cells. The ROS levels of patient 
P10 were previously measured (Richard et al, 2007) and were also included in the graph for 
comparison.  
As shown in Figure 24, both cblB type patients present significant elevated ROS levels 
when compared with control, and patient P8 present higher ROS levels than his sibling, P9. 
Patient P10 also present significantly high ROS levels when compared with control. 
 
 
Figure 24 – Analysis of intracellular ROS content in isolated methylmalonic patients. Control and cblB 
patients´ fibroblasts were analyzed. Cells were incubated with the H2DCFDA fluorescence probe and 
propidium iodide. ROS levels were accessed by flow cytometry. The X axis represents patients´ cell lines 
and the Y axis represents the fluorescence levels. Data represent the mean ± SD levels of five 
independent experiments each performed in triplicate. (*P<0.05, ***P<0.001). 
 
 
Elevated ROS levels have been related to altered mitochondrial morphology, hence, a 
specific mitochondrial probe, MitoTracker® Red CM-H2Ros, was used to stain control, cblB 
type (P8 and P9) and mut (P10 and P11) patients’ mitochondria and the cells were analyzed by 
confocal microscopy (Figure 25).  
The thread-like mitochondria morphology is associated with mitochondrial fusion, 
while the dotted or grain-like morphology is associated with mitochondrial fission and 
mitochondrial dysfunction. 
As can be observed in Figure 25, the mitochondria in control-derived fibroblasts 
present a low percentage of grain-like morphology, while both cblB and mut type patients 
present a higher percentage. Although the levels of grain-like mitochondria are also elevated 
in patient P9 when compared with control, they are lower than the ones displayed by his 
sibling, P8, and the mut type patients, P10 and P11. 
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Figure 25 – Mitochondrial morphology in control, cblB type (P8, P9) and mut type patients (P10 and 
P11). Cells labeled with MitoTracker®Red CM-H2Ros lead to two distinct phenotypes: thread (Control, 
P9) and grain (P8, P10 and P11), being the last associated with mitochondria fission. The results are 
shown as means ± SD of three independent experiments. 
 
 
The bioenergetic function was analyzed in cblB and mut type patients and also in 
controls. The cells were incubated in culture medium supplemented with glucose or galactose 
and the mitochondrial function was assessed in adherent cells using a SeaHorse® extracellular 
flux analyzer. 
A series of respiratory chain inhibitors and uncouplers [oligomycin, carbonyl cyanide 4-
(trifluoromethoxy) phenyl-hydrazone – FCCP, antimycin and rotenone] were added throughout 
the experiment and the oxygen consumption rate (OCR) levels were assessed.  
The profile obtained for this assay is represented in Figure 26. The first three values 
represent the cells basal respiration rate. When the ATP synthase inhibitor, oligomycin, is 
added, the OCR rate decreases representing the ATP-linked respiration. The addition of the 
uncoupler, FCCP, leads to an increase in OCR due to the cells intent to produce ATP and 
represents the maximal respiration rate. Finally, the addition of antimycin, a cytochrome c 
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reductase inhibitor, and rotenone, a complex I inhibitor, leads to the complete inhibition of 
oxidative phosphorylation.  
 
 
Figure 26 – Representation of the fundamental parameters of mitochondrial respiration obtained with 
this experiment. Basal respiration, ATP-linked respiration, proton leak, maximal respiration, reserve 
capacity (spare respiratory capacity) and non-mitochondrial respiration. (www.seahorsebio.com). 
 
 
The results obtained for the patients and control cells incubated in a glucose rich 
medium are shown in Figure 27. A decrease in the general OCR levels is observed for all the 
patients when compared with the control. Regarding the cblB type patients, the OCR levels of 
patient P8 are lower than the ones of the sibling, P9. Comparing the OCR levels among the mut 
type patients, the general OCR levels of patient P10 are much lower when compared with 
those of patient P11. 
When the control and patients’ cells were incubated in a galactose rich medium, an 
increase in general OCR levels was observed for control and patients (Figure 27). The 
respiration levels were also decreased for all patients when compared with the control levels. 
The maximum OCR levels (the OCR value obtained after the addition of FCCP), the 
reserve capacity (maximum OCR minus basal OCR value), ATP-linked respiration (OCR after the 
addition of oligomycin minus the basal OCR), and non-mitochondrial respiration (OCR obtained 
after the addition of rotenone and antimycin) were calculated using the data obtained and the 
results are shown in Figure 28.  
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A) 
 
B) 
 
Figure 27 – Bioenergetic profile of control and cblB and mut type patient fibroblasts. Cells were 
treated with DMEM supplemented with glucose A) or galactose B) and the OCR profile for each was 
measured. Data are means ± SD for one independent experiment, performed in triplicate. 
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Figure 28 – Bioenergetic profile of 
control and cblB and mut type 
patient fibroblasts. Cells were 
treated with DMEM supplemented 
with glucose A) or galactose B) and 
the OCR profile for each was 
measured. Maximum OCR (the OCR 
value obtained after the addition of 
FCCP), reserve capacity (maximum 
OCR minus basal OCR value), ATP-
linked respiration (OCR after the 
addition of oligomycin minus the 
basal OCR), and non-mitochondrial 
respiration (OCR obtained after the 
addition of rotenone and antimycin) 
were calculated using the data 
obtained.  Data are means ± SD for 
three independent experiments, 
each performed in triplicate.  
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Isolated methylmalonic patients, cblB and mut type, derived fibroblasts incubated in 
glucose rich medium (Figure 28) presented markedly lower basal respiration levels, ATP-linked 
respiration and reserve capacity when compared with the control levels. Patient P9 presents 
higher maximal respiration and reserve capacity levels, but also proton leak levels, when 
compared with patients P8, P10 and P11. All patients’ cells present slightly higher non-
mitochondrial respiration levels than the control.  
When the cells were incubated in a galactose rich medium, patients P8, P9 and P11 
derived fibroblasts presented lower basal respiration levels when compared with control and 
also with patient P10. All the patients present decreased maximal respiration and ATP-linked 
respiration levels when compared to the control, although patients P9 and P10 present higher 
OCR levels than patients P8 and P11, respectively. Patients P9 and P10 showed reserve 
capacity levels in the control range, while P8 and P11 showed decreased levels. It is to note 
that in galactose rich medium, patient P8 displayed increased non-mitochondrial respiration 
levels.  
Finally, the velocity of formation/opening of the mitochondrial permeability transition 
pore (mPTP) was also determined in fibroblasts derived from cblB and mut type patients and 
control. Velocity of mPTP formation/opening can be measured by following the ability of 
mitochondria to take up and retain Ca2+.  
The control and patients-derived fibroblasts were incubated in the reaction medium 
for 18 hours and the formation/opening of the pore was assessed by a fluorimetry assay. A 
Ca2+ specific fluorescent probe was used, the cells were permeabilized and Ca2+ insults were 
performed over time. Fluorescence increases from baseline value with each Ca2+ addition and, 
as the mitochondria takes up the Ca2+, a decrease in fluorescence is observed until 
mitochondria takes up enough Ca2+ for the mPTP formation/opening occur and an increase of 
fluorescence is observed due to the intramitochondrial Ca2+ release. The experiment was 
performed in the presence of adenine nucleotide, ADP, and the results are shown in Figure 29.  
The formation/opening of the mPTP is premature for cblB type patients, P8 and P9, 
when compared with control and especially for patient P8 who presented a higher 
formation/opening rate than his sibling P9. The mut type patients presented an mPTP 
formation/opening rate similar to the control, although in patient P10 the mPTP 
formation/opening rate was slightly premature when compared with control and patient P11.  
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Figure 29 – Mitochondrial permeability transition pore formation/opening profile for cblB A) and mut 
B) type patients. The data are representative of the profile obtained in one experiment although at least 
three independent experiments were performed. The maintenance of the same profile for each patient 
and control was taken into account.  
 
 
3.4. SPECIFIC THERAPY STRATEGIES IN INHERITED METABOLIC DISORDERS 
3.4.1. Effect of pharmacological chaperones on ATR protein 
Some patients respond to treatment with hydroxocobalamin, but the majority does 
not present biochemical and/or clinical improvements. Most of the mutations affecting cblB 
type patients are of missense type and hence, chaperone therapy is a good therapeutic option.  
 In order to find new pharmacological chaperones, a set of 2,000 compounds, from a 
commercially available library (MyriaScreen Diversity Collection) bearing a total of 10,000 
compounds, has been previously analyzed in the laboratory by differential scanning 
fluorimetry (DSF) and circular dichroism (CD), and a total of six compounds were selected.  
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The effect of these six compounds was also previously analyzed in the laboratory using 
a prokaryotic expression system and a cellular line bearing the missense mutation p.Ile96Thr. 
Two different concentrations of the compounds, 40 µM and 80 µM, and also the 
corresponding amount of DMSO, since the compounds are suspended in that solvent, were 
used. Of these six compounds, one was selected as the most efficient at the highest 
concentration (80 µM): compound V (N-{[(4-chlorophenyl)carbamothioyl]amino}-2-
phenylacetamid) (Figure 30).  
 
 
Figure 30 – Compound V structure (A) and DSF profile (B). The DSF profile was obtained using the 
purified ATR protein and a shift to the right (red line), indicating a stabilizing effect was observed. In the 
left lower part of the figure, a representation of the crude results is also showen.  
 
 
3.4.2. Evaluation of the pharmacological effect of compound V upon missense mutations 
affecting MMAB gene using a prokaryotic expression system 
The effect of compound V upon the p.Ile96Thr mutant was previously study in the 
laboratory and, to widen the study of this pharmacological compound upon other missense 
mutations found in cblB patients, the mutant variants p.His183Leu, p.Arg186Trp and 
p.Glu193Lys were also studied. The mutant and wild-type ATR proteins were expressed in a 
prokaryotic expression system and incubated with 80 µM of compound V and the results are 
depicted in Figure 31.  
An increase in the in vitro stability of all proteins, both wild-type and mutants, was 
observed and is presented in Table 15. The stability of the wild-type ATR protein was slightly 
increased (about 1.1 fold) while the highest increase (about 15 fold) was observed for the 
p.Glu193Lys mutant. The incubation with compound V had the same stabilizing effect on 
p.His183Leu and p.Arg186Trp mutants. The p.His183Leu showed an increase of 2.8 fold and 
the p.Arg186Trp mutant revealed an increase of about 2.5 fold when compared with the 
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respective mutants without treatment. The increase in the stability observed for mutants 
p.His183Leu and p.Arg186Trp is in the same range of the increase in stability previously 
observed for the p.Ile96Thr mutant (3.24 fold). 
 
 
A) Wild-type ATR 
 
 
 
 
 
B) p.His183Leu ATR 
 
 
 
 
C) p.Arg186Trp ATR 
 
 
 
 
D) p.Glu193Lys ATR 
 
 
 
Figure 31 – Degradation profile of the A) wild-type ATR and B) p.His183Leu, C) p.Arg186Trp and D) 
p.Glu193Lys mutant ATR proteins at physiological conditions (37 °C) treated with 80 µM of compound 
V. The crude extracts were incubated over time at 37 °C and aliquots were collected and analyzed by 
western-blot. The data show the mean value ± SD (n=3) and represent the percentage of the density of 
each protein compared to time zero. 
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Table 15 – Relative protein stability for wild-type ATR and p.His183Leu, p.Arg186Trp and p.Glu193Lys 
mutants at physiological temperature before and after compound V treatment. 
 
Relative protein stability at 37°C (hours) 
Fold change 
Non-treated 80 µM compound V 
Wild-type ATR 5.4 6.1 1.1 
p.His183Leu ATR 2.28 6.4 2.8 
p.Arg186Trp ATR 3.4 8.6 2.6 
p.Glu193Lys ATR 0.38 5.8 15.2 
 
 
These results indicate that compound V is a promising pharmacological chaperone for 
treating cblB patients carrying diverse missense mutations.  
 
3.4.3. Study of the stabilizing effect of compound V upon p.His183Leu mutant using a 
cellular model 
In order to assess the effect of compound V upon the p.His183Leu mutant, an 
immortalized fibroblast-derived cell line harboring this mutation was used. Since the effect of 
compound V upon p.Ile96Thr mutant had been previously characterized, an immortalized cell 
line harboring this mutation was used as positive control. An immortalized cell line harboring 
the mutation p.Ile117_Gln118del was used as a negative control.  
The cells were incubated with 80 µM of compound V, or the corresponding amount of 
DMSO for 72 hours and the ATR activity was indirectly assessed by measuring the propionate 
incorporation into acid-precipitable material (Figure 32).  
 
 
Figure 32 – Effect of compound V upon p.His183Leu mutant studied in a cellular disease model. 
Immortalized patient-derived fibroblasts harboring the missense mutations p.Ile117_Gln118del, 
p.Ile96Thr and p.His183Leu were incubated with 80 µM of compound V for 72 hours. The ATR activity 
was indirectly measured via [14C]-propionate incorporation into acid-precipitable material in intact cells.  
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Nevertheless, as observed in Figure 32, the treatment with compound V was not 
effective since the propionate incorporation levels were not increased.  
 
3.4.4. Comparison of OHCbl and compound V stabilizing effect upon p.Ile96Thr mutant 
Hydroxocobalamin (OHCbl) is administered to cblB patients as therapy, with positive 
results in some cases. In this context, the stabilizing effect of compound V was compared with 
the effect obtained with OHCbl administration. In these experiments, cultures of cblB patients’ 
fibroblasts were supplemented with 1 µg/mL of OHCbl, corresponding to the amount normally 
administered to patients. 
The p.Ile96Thr mutant, previously used for compound V analysis, and the wild-type 
protein were expressed in a prokaryotic expression system and incubated overnight at 37 °C 
with 80 µM of compound V, 1 µg/mL of OHCbl or the combination of the two compounds. The 
soluble protein extract was obtained and incubated again at 37 °C. Aliquots were removed at 
different times, loaded onto SDS-PAGE gels and ATR protein was detected by western 
immunobloting.  
As shown in Figure 33, the stabilizing effect afforded by compound V is markedly 
higher when compared with OHCbl, while the combination of the two compounds seems to 
have an even higher stabilizing effect, which could indicate a synergistic effect. This implies 
that, in vitro, compound V is a more efficient pharmacological chaperone than OHCbl. 
Moreover, the combination of both compounds may be profitably used in mutants that do not 
respond to OHCbl administration.  
 
 
Figure 33 – Effect of compound V and OHCbl on wild-type and p.Ile96Thr ATR proteins. Cells were 
treated over time with 80 µM of compound V, 1 µg/mL OHCbl and compound V with OHCbl at 
physiological conditions (37 °C). The crude extracts were incubated over time at 37 °C and aliquots were 
collected and analyzed by western-blot. The data show the mean value ± SD (n=3) and represent the 
percentage of the density of each protein compared to time zero. 
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To assess if the stabilizing effect observed over bacteria extracts was reproducible in a 
eukaryotic cell system, immortalized fibroblast-cell lines, derived from a control and from a 
patient bearing the p.Ile96Thr/p.Ser174fs mutations, were incubated for 72 hours with the 
same amounts of compound V (80 µM) or OHCbl (1 µg/mL) and also with the combination of 
the two compounds. The restoration of the metabolic pathway was indirectly evaluated by 
measuring the incorporation of radiolabeled propionate into acid-precipitable material of 
intact cells. The reactive ATR protein levels, in control and patients’ cell lines, were also 
measured by western blot. So, immortalized fibroblasts were treated as previously described, 
mitochondria were extracted and loaded into a SDS-PAGE gel.  
As observed in Figure 34, the propionate incorporation levels in the control cell line 
were not altered by the treatment with either compound V, OHCbl or the combination of both 
compounds. In the cell line harboring the missense p.Ile96Thr mutation, an increase in the 
propionate incorporation was observed when the cells were treated with OHCbl, as expected. 
Moreover, the cells treated with 80 µM of compound V showed an even higher incorporation 
level, which rose again upon treatment with compound V and OHCbl. This observation 
indicates that compound V, and especially its combination with OHCbl, displays ex vivo a high 
stabilizing effect upon this missense mutation.  
 
 
Figure 34 – Effect of compound V and OHCbl in a cellular disease model. Immortalized cell lines, 
derived either from control or a patient harboring the mutations p.Ile96Thr/Ser174fs were incubated 
with 80 µM of compound V, 1 µg/mL of OHCbl and the combination of the two compounds, for 72 
hours. A) The ATR activity was indirectly measured via [14C]-propionate incorporation into acid-
precipitable material in intact cells and B) the amount of immunoreactive ATR protein from isolated 
mitochondria was analyzed by western blot. Mitochondrial Hsp60 was used as loading control. The data 
show the mean value ± SD (n=3) (*P<0.05). 
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When the ATR protein levels were analyzed by western blot, the obtained results for 
the patients’ cell line harboring the p.Ile96Thr mutation also indicate that the highest 
stabilizing effect is obtained under the combined effect of compound V and OHCbl.  
Concerning the control cell line, the incubation with compound V and the combination 
of compound V and OHCbl showed a less stabilizing effect when compared with the incubation 
with OHCbl alone.  
 
3.4.5. Analysis of the in vivo pharmacological effect and toxicity of compound V  
In order to establish the chaperone effect of compound V upon the stability of 
endogenous ATR protein, and also to assess its pharmacokinetics, toxicity and absorption, 
distribution and excretion levels,  an in vivo system was used. Since a cblB mouse model is not 
available, a wild-type C57BL/6 mouse strain was used.  
Two doses (0.25 mg/kg/d and 5 mg/kg/d) of compound V were orally administered 
every day for a 12 day period. No secondary effects of compound exposure (weight loss, 
automutilation, tumors, abnormal movements, etc.) were observed in any of the animals 
tested. One mouse, belonging to the control group, was deceased previously to treatment 
administration. After treatment, the animals were sacrificed and brains and livers were divided 
into three sections. One was used for analyzing the amount of ATR protein by immunoblotting 
and the other two were frozen in liquid nitrogen for further experiments.  
Brain and liver extracts were prepared and the soluble protein was loaded into a SDS-
PAGE gel and analyzed by western blot. The results are shown in Figure 35, where an increase 
in the amount of ATR protein can be observed, both in liver and brain extracts of mice treated 
with the highest compound V concentration (5 mg/kg/d). These two organs are disease-
relevant in cblB patients and, accordingly, these results indicate that compound V has an ATR 
stabilizing effect in vivo.  
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Figure 35 – Effect of compound V in wild-type mice. Two groups of six wild-type C57BL/6 mice were 
orally treated for 12 days with 0.25 mg/kg/d or 5 mg/kg/d of compound V. The control animals (5 mice) 
were treated with 10 % DMSO in a 9 % glucose solution used for vehicle for compound V administration. 
After treatment, whole liver and brain extracts were prepared and ATR protein levels were detected by 
immunoblotting. The results represent the mean ± SD for each group (n=3). 
 
 
Since ATR protein is responsible for the synthesis of AdoCbl, the cofactor of the MUT 
enzyme, western blot analyses were performed to assess if compound V also had an effect 
upon MUT protein. Experiments were performed as described for ATR protein, only differing in 
sample number: five liver samples treated with 5mg/kg/d and three and five samples of 
control and brain extracts treated with 0.25mg/kg/d, respectively. The results are shown in 
Figure 36 and a slight increase in the amount of immunoreactive MUT protein was observed, 
both in liver and brain extracts treated with 0.25 mg/kg/d. No increase in the amount of MUT 
protein was observed in the samples treated with the higher concentration of compound V.  
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Figure 36 – Effect of compound V in wild-type mice. Two groups of six wild-type C57BL/6 mice were 
orally treated for 12 days with 0.25 mg/kg/d or 5 mg/kg/d of compound V. The control animals (5 mice) 
were treated with 10 % DMSO in a 9 % glucose solution used for vehicle for compound V administration. 
After treatment, whole liver and brain extracts were prepared and MUT protein levels were detected by 
immunoblotting. The results represent the mean ± SD for each group (n=3). 
 
 
To assess the metabolization rate of compound V by the wild-type mice, liver extracts 
from the control and treated mice groups were suspended in DMSO or methanol to dissolve 
compound V, and analyzed by HPLC-MS/MS Figure 37). The best results were obtained when 
DMSO was used, since the compound is more soluble in such solvent.  
Figure 37 shows an example of the external calibration using 40 µmol/L of compound 
V, which has a retention time of about 11.5/11.6 minutes. As can be observed, the liver 
extracts belonging to the control group did not reveal any amount of compound V, while the 
samples corresponding to the two treated groups showed the presence of the drug. 
The liver extracts of mice treated with 5 mg/kg/d of compound V presented the 
highest amount of compound V but also other chromatographic peaks, not observed in the 
liver extracts of mice treated with 0.25 mg/kd/d. These peaks may probably correspond to 
metabolization and/or degradation products of compound V, when present in higher amounts. 
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Figure 37 – Quantification of the amount of compound V detected in the liver of treated mice. 
A) Profile of the pike corresponding to compound V at a concentration of 40 µmol/L. B) Profile of liver 
extracts obtained from mice treated with the mixture of glucose 9 % and DMSO 10 %. C) Profile of liver 
extracts obtained from the mice treated with 0.25 mg/Kg/d. D) Profile of liver extracts obtained from 
mice treated with the higher concentration, 5 mg/Kg/d. The peak corresponding to compound V has a 
retention time of 11.5 minutes and in the profile obtained for the higher concentration we can also 
observe other peaks that may correspond to metabolization and/or degradation products. 
 
 
3.5. ANTISENSE THERAPY IN TETRAHYDROBIOPTERIN DEFICIENCY 
3.5.1.  Biochemical and genetic analysis of PTPS deficient patients 
Three tetrahydrobiopterin deficient patients (P12, P13 and P14) identified by Prof. 
Beat Thöny group (Meili et al, 2009), following newborn screening for hyperphenylalaninemia, 
were studied. Patient P12 presented a severe form of PTPS, P13 was born from first cousins of 
Moroccan origin and presented a mild form of PTPS and P14 also presented a severe form of 
PTPS deficiency.  
Mutation analysis was carried out in the laboratory of Prof. Beat Thöny, using gDNA 
and cDNA samples prepared from primary dermal fibroblasts and/or whole blood samples, and 
the results revealed that P12 was homozygous for the nucleotide transversion c.84-322A>T, 
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P13 was compound heterozygous for the changes c.163+695_163+751del57 and c.393delA 
and P14 was also compound heterozygous for the transversions c.163+2T>G and c.164-712A>T 
(Table 17). 
Analysis of the primary dermal fibroblast from P12 revealed an insertion of a LINE2 
sequence of 79 bp between exon 1 and 2 (r.83_84ins79), while in primary cells of P13 the 
maternal deletion of 57 nucleotides, located 20 nucleotides upstream an antisense Alu 
sequence, originated the introduction of 45 intronic nucleotides. In P14, the intronic mutation 
c.163+2T>G is located in the 5’splice site of intron 2 and generates three distinct shorter cDNA 
fragments  corresponding to the skipping of exon 2, of exons 2-3 and of exons 2-4. The intronic 
mutation c.164-712A>T is located in the “putative exonic splicing silencer” site (PESS), 5’ from 
the antisense Alu sequence in intron 2 of the PTS gene, and leads to the inclusion of a similar 
antisense Alu exon found in P13. P14 also presents a 70 nucleotide longer fragment that 
corresponds to the 45 nucleotide fragment found in P9 extended by 25 nucleotides at the 5’ 
side (Figure 38).  
 
 
 
Figure 38 – Deep intronic mutations found in PTPS deficient patients. Splicing patterns showing the 
regions of the PTS gene where the splicing mutations were found. The numbers indicate the splicing 
scores calculated using the BDGP software available at fruitfly site (http://www.fruitfly.org/).  
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Table 16 – Biochemical and phenotypical data from PTPS deficient patients. 
Patient Phe (µM) 
Neop. 
(U)* 
Biop. 
(U)* 
Neop. 
(CSF) nM 
Biop. 
(CSF) nM 
5-HIAA 
(CSF) nM 
HVA (CSF) 
nM 
PTPS (RBC) 
µU/g Hb 
PTPS (FB) µU/mg 
protein 
P12** 1694 38.0 <0.01 69.0 8.05 31 81 0.34 0.21 
P13** 1100 5.04 <0.01 10.1 34.7 527 1023 0.41 0.05 
P14 668 50 <0.01 N.A. N.A. 85.1 56 N.A. 0.22 
Reference*** <120 1.40-18.71 0.89-7.60 15-35 20-70 150-800 300-1100 11-29 0.4-1.6 
*mmol/mol creatinine 
**Described in Meili et al, 2009.  
***Reference values in unaffected controls (BIODEF). Phe: phenylalanine levels in blood, Neop.: neopterin, Biop.: biopterin, 5-HIAA: 5-hydroxyindoleactic acid, HVA: 
homovanillic acid, CFS: cerebrospinal fluid, RBC: red blood cells, FB: skin fibroblasts.  
 
Table 17 – Genetical and treatment data for the PTPS deficient patients analyzed. 
Patient Gene Mutation*(cDNA/gDNA/RNA) Treatment 
P12 PTS 
c.84-322A>T/c.84-322A>T 
Chr11(hg19):g.112098995A>T/g.112098995A>T 
r.83_84ins79/r.83_84ins79 
BH4 (5 mg/kg/d) followed by treatment with L-Dopa/Carbidopa, 5-
OH-tryptophan and folinic acid. The dosage of BH4, L-
Dopa/Carbidopa and 5-OH-tryptophan was increased to 6 
mg/kg/d, 10 mg/kg/d and 6 mg/kg/d, respectively due to the 
development of tremor and mild hypertonia of the limbs. 
P13 PTS 
c.163+695_163+751del57/c.393delA 
Chr11(hg19):g.112100091_112100147del57/g.112104233delA 
r.163_164ins45/ –  
Treated with BH4 (1 mg/kg/d), L-Dopa/Carbidopa (10 mg/kg/d) 
and 5-OH-tryptophan (10 mg/kg/d). 
P14 PTS 
c.163+2T>G/c.164-712A>T 
Chr11(hg19): g.112099398T>G/g.112100219A>T 
 – /r.164_165ins45/70 
NA 
NA: Non available.  
* Mutations according to NM_000317.2 and NC_000011.8 and the genomic coordinates were obtained using the Mutalyzer 2.0 beta-26 software according to hg19. 
(https://mutalyzer.nl/positionConverter).  
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The region of the Alu sequence is located between exons 2 and 3 and contains a 
putative 5’ splice site and at least two 3’ splice acceptor sites, being the most upstream 
predicted to define the “natural” Alu exon, which is located 70 nucleotides downstream the 
corresponding 5’GT splice site, identical to the pseudoexon 5’ site of P13.  
It has been reported that complementarity to U1 snRNA exerts, to some extent, a 
dominant effect on 5’ splice site selection (Roca et al, 2005). Mutation c.164-712A>T, found in 
patient P14, is located near the exon-intron boundary and might affect the complementarity to 
U1 snRNA. In order to analyze more extensively this 5’GT splice site and the effect of c.164-
712A>T mutation, an ex vivo minigene assay was used (Figure 39).  
The 5’ splice site motif consists of nine partially conserved nucleotides at the exon-
intron boundary, corresponding to the last 3 nucleotides of the upstream exon and the first 6 
intronic nucleotides. The effect of the original mutation c.164-712A>T found in P14, as well as 
two additional changes (c.164-714C>A and c.164-715T>A) upon U1 snRNA complementarity 
was also tested. As shown in Figure 39, both these last changes, c.164-714C>A and c.164-
715T>A, activate pseudoexon splicing insertion, although c.164-714C>A shows a profile more 
similar to the wild-type construct, activating the pseudoexon to a much lesser extent.  
 
 
Figure 39 – Ex vivo splicing assay for patient P14 using a minigene bearing the wild-type sequence, the 
mutation c.164-712A>T found in P14 and the two additional changes c.164-714C>A and c.164-715T >A. 
A) Schematic representation of the base pairing between the 5’ splice site of the pseudoexon and the 
U1 snRNA sequence, plus the different minigene constructs. The 5’ splice sequence consists of nine 
partially conserved nucleotides at the exon-intron boundary and the differences between the PTS gene 
sequence and the perfect match to the U1 sequence are underlined. The changes to the perfect match 
sequence are in red and also underlined. B) RT-PCR profile of the ex vivo splicing assay obtained for the 
different minigene constructs.  
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Mutation c.164-715T>A appears to be more efficient in the 70 nucleotide pseudoexon 
activation when compared with mutation c.164-712A>T, found in P14. This mutation also 
activates the insertion of the 45 nucleotide pseudoexon, although to a minor extent.  
These results show that, by changing the nucleotides found in positions +3 (-715T>A) 
or +6 (-712A>T) downstream the pseudoexon, the complementary to U1 snRNA was improved 
and the 5’ splice site was strengthened, unequivocally proving that the c.164-712A>T is located 
in the site of U1 snRNA union.  
 
3.5.2. Antisense therapy in PTPS patients   
Since antisense therapy has been successfully used in other disorders to rescue 
aberrant splicing, antisense oligonucleotides (AONs), particularly antisense morpholino 
oligonucleotides (AMOs) were used in order to investigate if the pathological insertions, 
activated by the mutations found in patients P12, P13 and P14, could be suppressed.  
Cell cultures of patient-derived fibroblast were treated with specific AMO targeted to 
the 3’ (PTS-AMO1) and 5’ cryptic splice sites (PTS-AMO2 and PTS-AMO3), aiming to block the 
access of the splicing machinery to the pseudoexonic regions in the pre-mRNA (Table 18). 
Although patients P13 and P14 show the activation of the same pseudoexon, the AMO 
sequences used are different according to the patient’s mutation. The PTPS AMO2 sequence 
hybridizes with the normal sequence of the exon-intron junction sequence, while the PTPS 
AMO3 sequence hybridizes with the sequence of the exon-intron junction sequence of patient 
P14 that bears an A>T transversion at position +6.  
 
Table 18 – AMO sequence and target used for antisense therapy on PTPS deficient patients. 
Name 5' - 3' Sequence Target mutation 
PTPS AMO1 AGT GCC TAC AAT GTA ACA GGC AAG T r.83_84ins79 
PTPS AMO2 AGG CTG GAG AAT CGC TCG AAC CTG G r.163_164ins45 
PTPS AMO3 AGG CTG GAG AAT CGC ACG AAC CTG G r.164_165ins45/70 
 
 
Patients’ fibroblasts were transfected with two different concentrations of the 
corresponding AMO, 20 µM and 30 µM, for a 24 hour period, followed by transcriptional 
profiling analysis. The results depicted in Figure 40 show that the splicing profile was restored 
in all three cases and in a dose dependent manner. For all patients, the upper band 
corresponding to the intronic insertion disappeared, even though cells were cultured in the 
presence of cycloheximide to avoid mRNA degradation. The obtained cDNA fragments were 
subjected to direct sequence analysis, and in patient P13 the presence of the c.393delA 
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mutation was confirmed in heterozygous state after AMO treatment as can be seen in Figure 
41.  
Furthermore, and to demonstrate AMO specificity, the three patients’ fibroblasts were 
treated with a scrambled AMO and, as shown in the right panel of Figure 40, the correct 
splicing profile was not restored.  
 
 
Figure 40 – Splicing therapy using antisense AMO to avoid pseudoexon inclusion in primary dermal 
fibroblasts from PTPS-deficient patients. A) Transcriptional analysis by conventional RT-PCR of 
fibroblasts derived from patients P12, P13 and P14 untreated (0 µM) or treated (20 µM and 30 µM) with 
the corresponding AMO.  B) Transcriptional analysis by conventional RT-PCR of fibroblasts derived from 
patients P12, P13 and P14 untreated (0 µM) or treated (30 µM) with scrambled AMO sequence. 
 
 
 
Figure 41 – Patient P13 cDNA analysis by direct sequence. The cDNA obtained after AMO treatment 
was sequenced and the presence of the mutation c.393delA can be observed in heterozygosis.  
 
 
VIVO-morpholino complexes have a new transporter structure that provides effective 
in vivo delivery of morpholino antisense oligomers into a variety of tissues. VIVO-morpholinos 
are conjugates resulting from the covalently linkage between an octa-guanidine dendrimer 
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and the morpholino oligo. Moreover, a new class of shorter and more stable oligonucleotides 
called LNA (locked nucleic acid) was proven to be effective in the prevention of pseudoexon 
inclusion. Taken these two facts into account, both these approaches were tested to 
averiguate if the splicing correction was comparable to AMO treatment under cell culture 
conditions. Due to poor growth behavior of the primary dermal fibroblasts from patient P13, 
only P12 and P14 were used in this analysis.  
The VIVO-morpholino sequence was similar to the already used AMO sequence and 
the sequence of the LNAs is shown in Table 19.  
 
Table 19 – LNA sequence used for antisense therapy. 
Name 5' - 3' Sequence Target mutation 
PTS-LNA1 CAAACAAACCTTAACT r.83_84ins79 
PTS-LNA2 TCGCTCGAACCTGGGA r.164_165ins45/70 
 
 
The LNAs were designed to target the 5’ splice donor site of both pseudoexon 
sequences. Figure 42 shows the results obtained with both treatments. For the LNA treatment, 
the oligonucleotide delivery is performed using a powerful transfection agent and, 
consequently, lower oligonucleotide doses were used (1nM, 5nM, 25nM, 50nM and 5µM). 
These doses were obtained from positive results described in the literature (Beane et al, 2007; 
Gupta et al, 2010). The treatment with VIVO-morpholino was performed using the same 
concentrations used for AMO treatment and showed that the aberrant splicing profile was 
reversed using both concentrations.  
The treatment using LNA was more efficient for patient P14 than for patient P12. In 
P12 the treatment was dose dependent and a higher dose (5 µM) was used for this patient in 
comparison with P14.  
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Figure 42 – Treatment with VIVO-morpholino and LNA oligonucleotides. Transcriptional profile analysis 
by RT-PCR of patients P12 and P14 derived fibroblast upon the treatment with different concentrations 
of A) VIVO-morpholino and B) LNA. 
 
 
3.5.3. Effect of AMO antisense therapy upon protein and metabolites  
After the successful recovery of the normal splicing pattern with AMO, we investigated 
the effect of treatment upon the amount of PTPS reactive protein and also upon enzymatic 
activity. Primary dermal fibroblasts were treated with the higher dose of AMO, 30 µM, during 
48 hours to assess the amount of protein, and during 48 and 72 hours for evaluation of 
enzymatic activity 
As shown in Figure 43, after treatment all patients’ cells showed a recovery in protein 
production, almost reaching control levels in patient P14. In P13, the recovery level was much 
lower, but still a band corresponding to the PTPS protein was observed.  
The recovered protein, observed in the western blot, was shown to be functional. In 
Figure 43, an increase in activity in the range of normal levels was observed in all patients’ cells 
after treatment. The highest activity levels were obtained after a 48 hours treatment, being 
the levels slightly lowered after 72 hours of treatment. Primary dermal fibroblasts of patients 
P12 and P13 reached normal activity levels, which are between 0.4 and 1.6 µU/mg (Bonafé et 
al, 2001). It is interesting to notice that, although the level of reactive protein was lower in 
patient P13, the enzymatic activity levels were higher than the observed in patients P12 and 
P14, who showed the highest levels of reactive protein.   
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Figure 43 – Protein expression and PTPS enzymatic activity analysis in primary patients’ fibroblasts 
after AMO treatment. A) PTPS protein expression in control and patients’ derived fibroblast untreated 
or treated with 30 µM of the corresponding AMO. B) Functional correction of PTPS enzymatic activity 
after treatment. The activity was assayed in a control cell line and in primary dermal fibroblasts derived 
from the patients treated at different times with 30 µM of the corresponding AMO. 
 
 
PTPS patients always present an altered pterin profile, showing an increase in 
neopterin and a decrease in biopterin levels. Since GTPCH is not expressed in dermal 
fibroblasts, the metabolic pathway must be induced upon co-treatment with TNFα and INFγ 
(Ionova et al, 2008). Pterin levels were quantified in patients’ fibroblasts after treatment with 
30 µM of the corresponding AMO and simultaneous cytokine stimulation.  
The cells were treated for 48, 72 and 96 hours and, as shown in Table 20, the 
neopterin levels were decreased and the biopterin levels increased to variable degrees, 
depending on the cell line. Nevertheless, and in general, the neopterin-biopterin ratio was 
decreased in all patients’ cells in a time dependent manner. During the 96 hour treatment, 
cells were transfected twice, the first at time 0 and the second after 48 hours.  
For both patients, P12 and P14, the best results were obtained after 96 hours of 
treatment, although patient P12 presented the best recovery, once a decrease of more than 
1,000 fold in the neopterin/biopterin ration was observed. This must probably be due to the 
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fact that P12 is homozygous for the splicing allele, while the other two patients carry a second 
mutation that cannot be corrected by the pseudoexon exclusion therapy.  
Due to the poor growth rate of P13 fibroblasts, positive results were only obtained 
after 48 hours of treatment, though a significant decreased was also observed.  
 
Table 20 – Neopterin and biopterin levels in PTPS patients P12, P13 and P14 before and after 
treatment with 30 µM AMO for 48, 72 and 96 hours.  
Patient 
Time of 
treatment 
(h) 
Neopterin 
(pmol/mg) 
Biopterin 
(pmol/mg) 
Neopterin 
Fold 
Activation 
Biopterin 
Fold 
Activation 
N/B 
ratio 
P12 
0 281.16 0.40 - - 703 
48 75.88 14.17 3.71 35.05 5.35 
72 57.84 32.91 1.31 2.32 1.76 
96 15.61 26.86 3.71 0.82 0.58 
P13 ** 
0 378.23 0.51 - - 741.60 
48 243.32 5.53 1.55 10.84 44.00 
P14 
0 235.37 1.48 - - 159.49 
48 123.23 8.98 1.91 6.09 13.72 
72 38.46 9.52 3.20 1.06 4.04 
96 6.50 2.09 5.92 0.22 3.12 
Control * 48 - 72 11.42 45.85 - - 0.25 
Patient 
(U) *** 
Untreated 45 nmol/L 0 nmol/L - - - 
Treated 34 nmol/L 25 nmol/L - - 1.36 
* Neopterin and biopterin in control fibroblasts. 
**The assay was performed only at 48 hours post-transfection due to the poor growth behavior of the 
primary fibroblasts. 
***Neopterin and biopterin in patient’s urine before and 24 hours after an oral loading test with 20 
mg/Kg synthetic BH4. Neopterin and biopterin in control urine are 5-22 nmol/L and 4-10 nmol/L, 
respectively; ratio: 1.25-2.2 (Blau et al, 2003). 
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In this work we performed the description and characterization of mutations found in 
isolated methylmalonic and propionic patients, we have elucidated the pathophysiological 
mechanism of mitochondrial dysfunction in cblB type patients and, finally, we have 
demonstrated the application of two different therapeutical approaches, chaperone and 
antisense therapy, in isolated methylmalonic aciduria and 6-pyruvoyl-tetrahydropterin 
synthase deficiency, respectively. 
4.1. MOLECULAR CHARACTERIZATION OF PATIENTS WITH ORGANIC ACIDEMIAS 
In this section, isolated methylmalonic and propionic patients from Spanish and 
Portuguese origin were characterized allowing the identification of the mutations causing 
these disorders and, consequently, familiar genetic counseling of the patients’ families, 
prenatal diagnosis and also genotype-phenotype correlation.  
Patients with isolated methylmalonic aciduria belong to the cblD variant 2 and mut 
complementation groups, while the propionic patients belonged to the pccB complementation 
group.  
The characterization of the cblD variant 2 type patients, the first done in our 
laboratory, allowed the expansion of the known MMADHC gene mutational spectrum, since 
three new mutations (c.165_166del2, c.170G>A and c.10-1G>C) were identified. Moreover, 
one already described mutation, c.57_64del8, was also identified (Coelho et al, 2008; Stucki et 
al, 2011).  
Until now, only three mutations responsible for a cblD variant 2 type had been 
described in the literature, representing 25 % of the mutations found in the MMADHC gene, 
and the mutational spectrum is heterogeneous with no prevalent mutation type (Coelho et al, 
2008; HGMD® Professional 2013.1). This mutational heterogeneity has also been described for 
other genes such as MMAA and MUT, also responsible for an isolated methylmalonic 
phenotype, although ethnic-specific mutations have been described (Acquaviva et al, 2005; 
Martinez et al, 2005; Worgan et al, 2006; Merinero et al, 2008).  
The novel mutation c.10-1G>C affects the original acceptor splice site of intron 1. In 
silico analysis revealed that this mutation is responsible for the inactivation of the constitutive 
acceptor splice site and for the increase of the splicing score of an AG dinucleotide located 
inside the exon, creating a new acceptor splice site and consequently, the deletion of the first 
five amino acids of the protein. Exon 2 starts at the Val4 residue, located in the proposed 
mitochondrial leader sequence (residues 1-11) (Coelho et al, 2008; Plesa et al, 2011). This is a 
conserved residue among several species and the disruption of this sequence impairs the 
transfer of cobalamin to its mitochondrial metabolization pathway. 
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The novel mutations c.165_166del2 and c.170G>A also affect conserved protein 
residues, Thr55 and Trp57, respectively. Mutation c.165_166del2 eliminates 2 nucleotides, 
disrupting the ORF and may lead to the introduction of a premature stop codon, while 
mutation c.170G>A introduces a premature stop codon, putatively leading to a truncated 
protein.  
The cblD complementation group is the most heterogeneous within the cobalamin 
complementation defects, since the affected patients can present three different phenotypes; 
isolated methylmalonic aciduria (cblD variant 2), isolated homocystinuria (cblD variant 1) and 
the combination of methylmalonic aciduria and homocystinuria (cblD) (Suormala et al, 2004). 
The MMADHC protein function is not fully understood, but it seems to interact with the 
MMACHC protein in order to direct cobalamin to the cytosol or to the mitochondrion (Coelho 
et al, 2008; Stucki et al, 2011). A study revealed that MMADHC protein has several interaction 
domains with MMACHC protein, all of them located towards the C-terminal end (Plesa et al, 
2011).  
All the four mutations identified in our patients are located in the N-terminal end of 
the protein and, most importantly, before the Met62 residue. It has been described that 
residues Met62 and Met116 are located within a sequence compatible with the Kozak 
consensus one, and that they might be used as second initiation codons. This fact could explain 
why cblD variant 2 patients have a normal MeCbl synthesis in spite of an AdoCbl impaired 
synthesis (Coelho et al, 2008; Stucki et al, 2011). 
The characterization of mutations within a population allows genetic counseling and 
also the possibility to establish genotype-phenotype correlations. All the studied cblD variant 2 
type patients presented severe clinical symptoms within the first two years of life, and carry 
mutations that are normally associated with a severe effect upon the protein. Nevertheless, all 
the patients show a positive response to B12 treatment and a good clinical evolution. This 
positive response is not fully understood since the AdoCbl synthesis requires an intact 
mitochondrial leader sequence and also the sequence downstream Met62 (Stucki et al, 2011). 
The observation that the interaction between MMADHC and MMACHC proteins increased the 
levels of AdoCbl synthesis with low effect on MeCbl synthesis (Stucki et al, 2011), and the fact 
that none of the mutations described in this work affects the weakly conserved putative B12-
binding motif, GXXXHXD, located between residues 81 and 86, could indicate that the complex 
formed by these two proteins is stabilized by the excess of vitamin B12, shifting the balance 
towards AdoCbl synthesis. Another hypothesis is the stabilization of the truncated protein by 
cobalamin that could act as a natural chaperone, as described for other disorders (Rodrigues et 
al, 2012). 
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The characterization of the propionic patients allowed the identification of two 
previously described mutations in PCCB gene, a small indel mutation (c.1218del14ins12) and a 
splicing mutation (c.183+3G>C) (Gravel el al, 1994; Rodrígues-Pombo et al, 1998). The 
c.1218del14ins12 is the most common mutation among Caucasians, being present in 32 % of 
white origin alleles. A study involving 29 patients of Spanish and Latin American heritage led to 
a similar result. This is a complex mutation, resulting from a deletion of 14 nucleotides and 
their replacement by 12 nucleotides that are unrelated to the deleted nucleotides. This leads 
to the generation of a frameshift, arising in a stop codon about 100 amino acids proximal to 
the normal protein C-terminal, thus possibly originating a truncated and unstable protein. The 
origin of this indel is not clear, but it might derive from the duplication of nine nucleotides 
upstream the mutation site, with random filling of three more nucleotides. Hybridization 
studies, using mutant allele-specific oligonucleotides, showed that the inserted 12 nucleotides 
did not originate in a 1Kb region around the mutation (Tahara et al, 1990; Rodríguez-Pombo et 
al, 1998; Fenton et al, 2001). The identification in unrelated patients of another in-frame 
deletion in the same region suggests that this region of PCCB gene may be prone to undergo 
this type of mutation (Tahara et al, 1990). 
The c.183+3G>C mutation affects intron 1 donor splice site, disrupting the normal 
splicing profile. The in silico analysis using the Human Slicing Finder software shows that the 
substitution of a guanosine residue by a cytidine at position +3, leads to the decrease of the 5’ 
donor splice site score from 83.41 to 79.54 and, possibly, the activation of a cryptic donor 
splice site located downstream which presents a higher splice site score, 86.28. The 
c.183+2T>C mutation was described in propionic patients and already characterized (Desviat et 
al, 2006). This mutation also affects the 5’ donor splice site of intron 1 and activates a cryptic 
donor splice site located downstream, which leads to the insertion of 20 nucleotides of intron 
1 between exons 1 and 2 and probably originate a frameshift and, consequently an aberrant 
protein. Since these two mutations are located in the same region, their effect could be similar 
and the insertion of the additional 20 nucleotides from intron 1 observed for c.183+2T>C 
mutation could also occur in the patient affected by the c.183+3G>C mutation. Functional 
analysis should be performed in order to confirm this hypothesis.  
Due to the lack of patient cells, the effect of this mutation could not be fully 
elucidated, although a good approach could be the use of an ex vivo minigene assay to confirm 
the effect of this mutation (Desviat et al, 2012; Morse et al, 2012). The recognition of the exon-
intron junction by the spliceosome is essential for the splicing process and the spliceosome 
assembly is initiated by the binding of U1snRNP to the donor splice site. It is postulated that, in 
a functional donor site, there is a minimal number of 5 or 6 base pairing to U1 snRNA and that 
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the disruption of any of these bases could affect normal splicing (De Conti et al, 2012). 
Overexpression of a mutant U1snRNA, engineered to bind specifically to the mutant donor 
splice site, has been used successfully to correct the aberrant splicing profile and thus, by 
analogy, could be a good therapeutical approach for this type of mutations (Zhuang et al, 
1986; Sanchez-Alcudia et al, 2011; Glaus et al, 2011). 
 
4.2.  FUNCTIONAL ANALYSIS OF MUTATIONS IN ORGANIC ACIDURIAS 
Mutations are responsible for diverse effects upon the protein function, leading to 
either a loss or a gain of function. The majority of IMD is caused by loss of function of a 
particular protein, which can be complete, originating a protein with null function, or a 
reduction of the protein’s ability to work. The analysis of the mutation effects upon protein 
function allows the identification of the molecular mechanisms responsible for these 
disorders. In this section, the functional effect of six allelic variants, one identified in MUT gene 
and five identified in MMAB gene, was assessed using appropriate models. The knowledge of 
the molecular mechanism underlying the pathogenic effect of these mutations allows the 
identification of new therapeutic targets and the development of alternative treatments based 
in individual genotypes.  
The results indicate that the identified allelic variants are pathogenic; one mutation 
affects the correct mRNA processing (c.1480-10A>G in the MUT gene), while two in frame 
mutations (p.I117_Q118del and p.R190dup in MMAB gene) and three missense mutations 
(p.H183L, p.R186W, and p.E193K in MMAB gene) are responsible for the destabilization of the 
ATR protein residual activity.  
Transcriptional analysis of the patient bearing the c.1480-10A>G mutation in the MUT 
gene confirmed the results anticipated by the ex vivo minigene splicing assay.  
Direct transcriptional analysis of the MUT gene patient bearing the c.1480-10A>G 
mutation was not possible because DNA was the only biological material available from the 
patient. This problem was circumvented by using an ex vivo minigene splicing assay which 
revealed that this mutation is responsible for the creation of a new acceptor 3’ splice site with 
a higher splice score that the original site, which leads to the insertion of 9 additional 
nucleotides in the beginning of exon 6. This mutation also leads to the activation of a cryptic 
acceptor splice site within exon 6 and the consequent elimination of its first 135 nucleotides. 
The presence in the control individuals’ profile of the smaller transcript, lacking the 135 
nucleotides, indicates that this splicing event may also occur in physiological conditions and 
that it may be due to the fact that the constitutive acceptor splice site of exon 6 has a low 
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splice score. Furthermore, the minigene profile analysis also revealed the simultaneous 
presence of the normal MUT transcript.  
The patient’s phenotype is mild, even though a small duplication, c.244dupA, 
responsible for the disruption of the normal ORF, was also found in the other allele. The 
presence of these two mutations should be associated with a severe effect, but the presence 
of the normal transcript, even in small amounts, may be responsible for the amelioration of 
the phenotype. An RT-PCR should be performed using the patient’s derived fibroblasts or 
linfoblasts in order to demonstrate the presence of the normal transcript. Although the 9 
nucleotides inserted do not disrupt the ORF, one of the triplets encodes a stop codon, which 
could lead to a truncated protein. In this case, in which the original splice site is not altered, 
one therapeutical option could be the use of AONs specifically designed to block the 
recognition of the mutant transcript by the splicing machinery. Since this mutation is located in 
close proximity to the constitutive acceptor splice site, small and highly specific 
oligonucleotides, like locked nucleic acids (LNAs), might ensure better results.  
The analysis of the variants identified in MMAB gene, p.Ile117_Gln118del, 
p.His183Leu, p.Arg186Trp, p.Arg190dup and p.Glu193Lys, indicates they affect the stability 
and function of the ATR protein.  
The novel variants, p.His183Leu and p.Arg190dup were found in two siblings (P8 and 
P9) who presented different phenotypic manifestations while bearing the same genotype. 
Both changes were absent from the Exome Variant data base (evs.gs.washington.edu) and 
were classified as probably damaging by PolyPhen2 (genetics.bwh.harvard.edu/pph2). No 
other variants were found in the promoter sequence of these patients and no exonic copy 
number variations were detected by genomic rearrangements (Metaboloarray®). The analysis 
of the immunoreactive ATR protein, in patients’ derived-fibroblasts, revealed low protein 
levels when compared to controls. The comparison of the ATR protein levels between siblings 
revealed that patient P8 present lower levels than P9. When compared to controls, the 
analysis of the protein function at physiological temperature revealed lower propionate 
incorporation levels for P8 fibroblasts and normal levels for P9 fibroblasts, when compared to 
controls, but when the cells were incubated at 42 ˚C, the propionate incorporation levels of P9 
fibroblasts were impaired and reached patient P8 levels. This indicates that, in a stress 
situation such as a fever episode, patient P9, normally asymptomatic, could present the same 
phenotype as his sibling P8.  
A prokaryotic system was used to perform in vitro expression analysis of the mutants 
p.His183Leu and p.Arg190dup, and for the last mutation, no detectable amount of protein was 
produced. The Arg190 residue is located in the protein α4-helix, which is involved in the 
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formation of the active site cleft. The main carboxyl chain of Arg190 establishes hydrogen 
bonds with the five-member ring of ATP and also with the ribose oxygen molecule (Schubert 
and Hill, 2006). The p.Arg190His mutant has been reported in methylmalonic cblB type 
patients and although the study of this mutant revealed a similar affinity for cobalamin when 
compared to the wild-type protein, it also revealed a decreased affinity for the ATP molecule, 
confirming the role of this residue in ATP binding (Zhang et al, 2009). These data indicate that 
the in-frame deletion affecting this residue probably has a severe impact on the protein 
structure and, consequently, a complete loss-of-function as shown by the functional analysis.   
The new p.His183Leu mutant was studied more thoroughly. The expression of the 
mutant variant, using a prokaryotic system at physiological temperature, showed a reduced 
stability of about 58 % when compared with the wild-type protein, while the expression of the 
mutant in permissive folding conditions (27 °C) increased the mutant stability to wild-type 
levels. The stabilization of missense mutations by permissive folding conditions is a trait of 
folding mutants and has been described for other disorders, like phenylketonuria (Gámez et al, 
2000). Residue His183 is located inside the ATR α4-helix, distant from the active site, but 
nevertheless it is postulated that the local conformation of single amino acid residues at one 
site of the protein can control the structure of more distant regions (Muntau and Gersting, 
2010). The proximity to a hydrophobic loop between α3 and α4, that may be involved in 
dimethylbenzimidizole (DMB) binding, suggests that mutations in this residue may affect DMB-
off transition in vivo (Fan and Bobik, 2008). In silico analysis was performed, revealing that the 
substitution of an aromatic histidine residue by a branched-chain leucine residue was 
responsible for the destabilization of the protein structure with the impairment of the trimer 
functionality.  
A mutation in the same residue, p.His183Tyr, has been described and western blot 
analysis revealed protein levels near wild-type in vivo and a positive response to vitamin B12 
treatment. The authors postulated that this mutation could interfere with the in vivo reduction 
of cob(II)alamin to cob(I)alamin, thus impairing ATR activity (Fan and Bobik, 2008). These 
results are similar to the ones obtained in the present work, what indicates that the p.H183L 
mutant could exert a similar effect.  
Since this mutation is responsible for a folding defect, the levels of mitochondrial 
Hsp60 and Hsp70 chaperones, and also Lon protease, were analysed by western blot in 
patients P8 and P9 derived-fibroblasts and high levels of Hsp70 chaperone were detected. 
Although normal mtHsp60 levels were obtained for patient P8, patient P9 presented slightly 
impaired mtHsp60 levels when compared to controls and also low levels of Lon protease.  
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Hsp70 family of chaperones is highly conserved in evolution and mitochondrial Hsp70 
(mtHsp70) is essential for de novo protein folding and suppression of protein aggregation 
under stress conditions (Richter et al, 2010; Hageman et al, 2011). mtHsp70 is also involved in 
the translocation of mitochondrial precursor proteins across the mitochondrial membrane, 
and maintains the proteins in an unfolded state until they are assembled in their tertiary 
structures. It is also implicated in the efficient degradation of damaged proteins by proteases 
(Luce et al, 2010; Gregersen and Bross, 2010; Baker et al, 2011). Mitochondrial Hsp60 
(mtHsp60) is also involved in the proper folding of proteins after their import into the 
mitochondrion, in an ATP-dependent process (Stuart et al, 1994). mtHsp70 levels are induced 
under stress conditions, such as high temperatures or unfolded proteins, and hence the high 
levels observed in patients P8 and P9 can be related to the folding defect of ATR protein 
caused by the p.His183Leu mutation (Stuart et al, 1994; Callahan et al, 2002). The low stability 
levels of this variant could induce the expression of mtHsp70 in an attempt to refold the 
mutant protein and establish normal cellular homeostasis.  
The interaction between mtHsp70 and matrix proteases has been described (Luce et 
al, 2010). One of the most important mitochondrial matrix soluble proteases is the Lon 
protein, an ATP-dependent serine/lysine protease of the AAA+ family (Luce et al, 2010). Apart 
from its proteolytic role, Lon is also important for protein complex assembly and maintenance 
of mitochondrial DNA integrity (Gottesman et al, 1997; Lu et al, 2007). Lon is up-regulated 
under stress conditions and low levels of this protease have been described in patients with 
hereditary spastic paraplegia (Hansen et al, 2008). The slightly high levels of Lon protease 
observed in P8 may indicate that this protein is activated by the stress conditions induced by 
the folding mutant p.His183Leu and also by the high levels of mtHsp70. Interestingly, patient 
P9 presented low Lon immunoreactive protein levels, which could indicate that, in this patient, 
the protease system is less activated when compared to control and to his sibling P8, allowing 
the misfolded ATR protein to undergo more folding attempts, instead of being prematurely 
degraded. This has been observed for patients with reduced mtHsp60 levels, a situation also 
observed in patient P9 (Hansen et al, 2008). 
Regarding the other ATR mutant proteins (p.Ile117_Gln118del, p.Arg186Trp and 
p.Glu193Lys), in vitro expression analysis was also performed using a prokaryotic system and, 
as for mutant p.Arg190dup, no detectable amount of protein was found for 
p.Ile117_Gln118del mutation at physiological conditions. The Ile117 and Gln118 residues are 
located on the α2-helix and the Gln118 residue establishes hydrogen bonds with the α3-α4 
loop and with the α1-helix. The α3-α4 loop is involved in the active site cleft formation and the 
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elimination of these two residues may impair the formation of the active site and, 
consequently, impair the protein function (Schubert and Hill, 2006).  
The prokaryotic expression of missense p.Arg186Trp and p.Glu193Lys mutants, at 
physiological temperature, revealed a decreased stability of 36 % and 93 %, respectively, when 
compared to the wild-type. These results confirm the in silico analysis of these mutants, using 
the CAFFE bioinformatic software, that showed that the p.Glu193Lys mutant was more 
unstable than the wild-type, with a total inability to form the active trimer, while the 
p.Arg186Trp mutant presented a higher degree of stability. These two variants have already 
been described and studied in the literature. The Arg186 residue is located in the α4 helix and 
forms, along with the Arg90, Phe170 and Phe221 residues, the surface of the active site cleft. 
The invariant side chain of Arg186 residue projects below the ATP molecule, although not 
directly interacting with it; instead, it could interact with the cobalamin molecule. Studies 
performed with the bacterial LrPduO revealed that Arg186 (Arg128 in LrPduO) forms a salt 
bridge with a conserved aspartate residue (Asp35) from the adjacent unit, being this salt 
bridge essential for the formation of the enzyme/ATP complex. The Arg186 is highly conserved 
and its substitution for a tryptophan residue is the most common missense mutation affecting 
MMAB gene. The expression of this mutant rendered low amount of soluble protein indicating 
an impairment of protein folding and rapid degradation, while enzymatic studies revealed that 
this mutant present a null activity, even in the presence of high amounts of ATP and cobalamin 
(Schubert and Hill, 2006; Maurice et al, 2008; Mera and Escalante-Semerana, 2010). 
The Glu193 residue is located on the ATR α4-helix and establishes hydrogen bonds 
with the Mg2+ and the Lys78 residue, which is important for the in vivo binding of 
MgATP/cobalamin to the ATR protein. This mutant is enzymatically inactive and probably 
affects cobalamin binding, since it is unable to mediate the base-off transition of AdoCbl 
(Schubert and Hill, 2006; Fan and Bobik, 2008). These results support our findings of an 
impaired protein function in these mutants.  
Taken together, our data and the data available in the literature indicate that the 
MMAB missense mutants, p.His183Leu, p.Arg186Trp and p.Glu193Lys, are responsible for 
folding defects and, consequently, a decreased stability of the ATR protein. Hence, these 
mutants could be good candidates for treatment with pharmacological chaperones.  
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4.3. MITOCHONDRIAL DYSFUNCTION IN ISOLATED METHYLMALONIC ACIDURIA 
Mitochondrial dysfunction has been described to be involved directly or indirectly in 
the pathogenesis of inherited metabolic disorders and also in organic acidurias (Wajner and 
Goodman, 2011). It is postulated that the impairment of OXPHOS and other pathways involved 
in energy production is due to the accumulation of toxic intermediates in the mitochondrion 
(secondary mitochondrial dysfunction). The accumulation of these intermediates affects 
organs such as liver, heart, skeletal muscle, kidney, pancreas and brain (Wajner and Goodman, 
2011). The impairment of mitochondrial function has been described in methylmalonic 
aciduria and is translated into decreased levels of NADH-cytochrome c reductase (complex 
I+III), succinate cytochrome c reductase (complex II+III) and COX (complex IV). Lower GSH and 
GSSG levels were also observed in liver extracts. These findings were described in patients’ 
cells, liver extracts and also in a Mut-/- mouse model (Cosson et al, 2008; Keyzer et al, 2009; 
Chandler et al, 2009). Since high ROS and apoptosis levels, as well as MnSOD levels, were 
described in cblB type methylmalonic patients (Richard et al, 2005; Richard et al, 2007; Jorge-
Finnigan et al, 2010), and a correlation between protein aggregation and mitochondrial 
dysfunction has been demonstrated, mitochondrial function was assessed in patients P8 and 
P9 bearing the destabilizing mutants, p.H183L and p.R190dup. In this section, two 
methylmalonic mut type patients (P10 and P11) were also analyzed.  
Analysis of total ROS levels revealed an increase for both patients, when compared to 
controls, although P9 presented lower levels than his sibling P8. ROS levels are influenced by 
diverse factors, including perturbations in the respiratory chain, lipid oxidation and toxic 
accumulation of metabolites, related to loss of enzyme function due to misfolding mutations 
(Gregersen and Bross, 2010).  
All patients also presented an altered mitochondrial physiology, characterized by an 
increase in mitochondria presenting a grain-like structure, although exhibiting differences 
among them. Patients P8 (cblB type), P10 and P11 (mut type) presented similar values while P9 
(cblB type) presented lower levels of altered mitochondria. Mitochondria are dynamic 
organelles which constantly change shape and location inside the cell (Galloway and Yoon, 
2012). Mitochondrial morphology is dependent on two processes, fusion and fission, that are 
in equilibrium in normal conditions. Fusion is activated for mitochondrial rescue, since the 
affected mitochondria can exchange damaged proteins and lipids with other mitochondria 
and, although it is not essential for cell maintenance in vitro, it is required for embryogenesis 
development. Fission is essential for maintenance of normal mitochondria number in growing 
and dividing cells and has been related to quality control, since it segregates damaged 
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mitochondria parts, targeting them to mitophagy (Youle and van der Bliek, 2012). In 
fibroblasts, mitochondria are usually long filaments and this morphology is associated with 
fusion events, while a grain-like morphology is associated with fission events (Youle and van 
der Bliek, 2012). A grain-like morphology has also been associated with elevated ROS levels 
due to accumulation of a misfolded protein in short-chain acyl-CoA dehydrogenase deficiency 
(SCAD) (Schmidt et al, 2010; Schmidt et al, 2011). These results are similar to the ones 
observed in the patients analyzed in this work, since high grain-like structure levels are 
observed in patients who also present elevated total ROS levels.  
The analysis of the oxygen consumption rates (OCR) in the four patients revealed 
differences between cblB and mut type patients. The patients’ cells were incubated in glucose 
or galactose rich medium and, in both environments, cblB and mut patients derived fibroblasts 
presented lower oxygen consumption rates when compared to controls. In glucose rich 
medium, all patients presented lower basal and ATP-linked respiration rates, but also an 
impaired reserve capacity, which indicates that in a stress or high ATP demand situation, 
patients’ cells have a poor response. Regarding maximal respiration, all patients but P9 
presented lower levels than the controls. When the cells were incubated in a galactose rich 
medium, an increase in the oxygen consumption rate was observed for all cell lines because 
cells are forced to rely on OXPHOS instead of glycolysis (Marroquin et al, 2007). In this 
situation, the differences in OCR levels were emphasized between patients, as well as the 
underlying OXPHOS defects (Aguer et al, 2011). In this case, all patients, but P10, presented 
lower basal respiration levels, while all four patients showed low maximal and ATP-linked 
respiration levels. Differences in the reserve capacity were also observed, since both P9 (cblB) 
and P10 (mut) patients presented levels similar to the controls. An increase in non-
mitochondrial respiration was observed in patient P8, indicating that the fibroblasts derived 
from this patient are not able to completely rely on OXPHOS, even when its use is forced upon 
the cells. Comparing the data among the four patients, P8 (cblB) and P10 (mut), seem to have a 
decreased bioenergetic function when compared to P9 (cblB) and P11 (mut). The differences 
observed between the two siblings, P8 and P9, can be related to the differences also observed 
in ROS levels and mitochondrial morphology.  
Another mitochondrial structure influenced by elevated ROS levels is the permeability 
transition pore. Mitochondrial permeability transition pore (mPTP) is responsible for 
mitochondrial permeability transition, a phenomenon that results in the modification of the 
permeability properties of the mitochondrial inner membrane (Brenner and Moulin, 2012). 
mPTP is a structure formed in the mitochondria, due to an increase in Ca2+ levels, which 
enhances the permeability across the mitochondrial membrane of solutes with molecular mass 
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under 1.5 kDa. This drives to loss of proton-motive force, mitochondrial swelling and reduced 
Ca2+ retention ability (Siemen and Ziemer, 2013). mPTP can also be triggered by oxidative 
damage and adenine nucleotides depletion (Brookes et al, 2004). The mPTP opening 
represents a point of no return and is associated with apoptosis, although some studies 
suggest that this event may be reversible (Rasola and Bernardi, 2011; Siemen and Ziemer, 
2013). The analysis of the cblB type patients, P8 and P9, revealed that both patients’ derived 
fibroblasts presented a high velocity of formation/opening of the mPTP when compared to 
controls’ derived fibroblasts, especially in P8, whose fibroblasts showed the fastest velocity of 
mPTP formation. The same was not observed in fibroblasts of mut type patients, P10 and P11, 
which presented a velocity of formation/opening of the mPTP similar to controls’ derived 
fibroblasts. The profile of mPTP opening observed in cblB patients can be related to the 
oxidative damage observed in these two patients but, since mut type patients also presented 
oxidative damage, this parameter alone is not enough to justify the differences observed in 
mPTP opening/formation. The mPTP components have not been fully characterized and there 
are conflicting data in the literature about mPTP structure (Elrod et al, 2013; Siemen and 
Ziemer, 2013). Nevertheless, it has been postulated that mPTP formation can be influenced by 
other factors, such as cyclophilin D (CypD), inorganic phosphate (Pi), Complement Component 
1, q Subcomponent Binding Protein (C1QBP) and p53 protein levels. ADP, adenine nucleotides 
and divalent cations such as Mg2+, Sr2+, Ba2+ and Mn2+ have been shown to inhibit mPTP 
formation (Vaseva et al, 2012; Elrod et al, 2013). Differences in any of these parameters, 
observed between the cblB and mut type patients’ cells, could account for the differences 
observed in the opening/formation of the mPTP.  
The analysis of all the mitochondrial parameters (ROS levels, mitochondrial 
morphology, bioenergetic function and mPTP formation/opening) in cblB and mut type 
patients indicates the existence of mitochondrial dysfunction in fibroblasts derived from these 
methylmalonic patients. The phenotypic variation between the two cblB type siblings could be 
explained by the differences observed in the mitochondrial function, since patient P8, also 
presented a higher mitochondrial impairment when compared with his sibling, P9.  
Mitochondrial impairment has been related to high levels of methylmalonic acid due 
to the similarity of this metabolite to complex II inhibitors, such as malonate (Ballhausen et al, 
2009). The mitochondrial dysfunction observed in these patients does not correlate with 
methylmalonic acid levels, since mut type patients (P10 and P11) presented significantly higher 
levels than cblB type patients (P8 and P9). Patients P8 and P11 showed similar bioenergetic 
function, and no premature opening/formation of mPTP was observed for mut type patients. 
These results are in accordance with data obtained from the analysis of the effect of 
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methylmalonic acid in brain, which indicate that other metabolites derived from the 
alternative oxidation of propionyl-CoA, such as 2-methylcytrate and malonate, are also 
involved in mitochondrial dysfunction of methylmalonic patients (Kölker et al, 2003; Kölker and 
Okun, 2005). Further studies involving tissues of peripheral organs, such as liver and kidney, 
could shed light on the metabolites involved in mitochondrial dysfunction and the mechanism 
underlying that effect.  
Ultimately, these results indicate that methylmalonic acid alone is not responsible for 
the mitochondrial impairment observed in these patients, and that mitochondrial dysfunction 
can be considered, not only a phenotypic modifier for these methylmalonic cblB type patients, 
but also a therapeutic target. Further studies with a wide range of patients with the same 
genotype and phenotype inconsistencies should be performed in order to confirm these 
results in other mutants.  
 
4.4. SPECIFIC THERAPEUTIC STRATEGIES IN INHERITED METABOLIC DISORDERS 
In this work two different therapeutical approaches have been tested: the effect of 
pharmacological chaperones upon missense mutations affecting ATR protein, and also, 
antisense therapy targeted to pseudoexon exclusion in 6-pyruvoyltetrahidropterin synthase 
deficiency.  
The first therapeutical approach in this work was the use of a pharmacological 
chaperone, named as compound V (N-{[(4-chlorophenyl)carbamothioyl]amino}-2-
phenylacetamid), which had been previously selected from a commercially library 
(MyriaScreen Diversity Collection) of 2,000 compounds. Its effect was tested, in our laboratory, 
in the wild-type ATR protein and in the missense mutant p.Ile96Thr, using both prokaryotic 
and eukaryotic expression systems, and a stabilizing effect was observed for wild-type and 
mutant proteins in either systems.  
Missense mutations represent 58 % of the mutations identified in the MMAB gene 
(HGMD® Professional 2013.1) and, hence, the pharmacological effect of compound V was 
further assessed upon other missense mutations described in patients diagnosed in the 
laboratory, and also upon variants described in the literature as folding mutants, p.His183Leu, 
p.Arg186Trp and p.Glu193Lys (Schubert and Hill, 2006; Fan and Bobik, 2008). The production 
of these mutants in a prokaryotic expression system supplemented with 80 µM of compound 
V, at physiological conditions, revealed a significant stabilizing effect upon all mutant proteins.  
In order to compare the chaperone effect of compound V with the one exerted by 
hydroxocobalamin, one of the current treatments for responsive patients, a prokaryotic 
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system was used to test the effect of compound V, OHCbl or the combination of both upon the 
wild-type protein and the p.Ile96Thr mutant. A slight stabilizing effect was observed when 
both wild-type and p.I96T mutant were expressed in the presence of OHCbl, although the 
stabilizing effect was much higher when compound V was used. The combination of the two 
compounds was responsible for a higher stabilizing effect when compared with the effect of 
isolated compound V or OHCbl.  
These experiments were also performed ex vivo, using a control cell line and an ATR -/- 
cellular model derived from fibroblasts bearing the p.Ile96Thr/p.Ser174fs genotype. 
Propionate incorporation levels were measured upon cell treatment and the incorporation 
rates observed in the wild-type cell line were not influenced by compound V, OHCbl or the 
combination of both; however, in the cell line bearing the missense p.Ile96Thr mutation, 
propionate incorporation rate was higher when the cells were incubated in the presence of 
compound V when compared with OHCbl treatment, but the higher incorporation rate was 
reached when the cells were incubated in the presence of both, compound V and OHCbl. This 
synergistic effect between compound V and OHCbl was also observed upon production of 
immunoreactive protein, suggesting that both compounds probably bind to different sites in 
the protein, but also that both sites must be in close proximity, since the union of one of the 
compounds could stabilize the binding site of the other compound.   
It has been described that, for mice bearing defects in PCCA gene, enzymatic activities 
around 10-15% of the wild-type are responsible for a significant improvement on the 
biochemical parameters (Miyazaki et al, 2001). Accordingly, the high stabilizing effect 
displayed by compound V alone is very significant. Moreover, the pharmacological effect of 
compound V seems to be mutation dependent, once p.Glu193Lys is more stabilized in the 
prokaryotic system than p.His183Leu and p.Arg186Trp mutants. Accordingly, the combined 
effect of compound V and OHCbl could be a good approach for those mutants less responsive 
to isolated compound V. The combination of compounds for treatment of inherited metabolic 
disorders, or even the combination of different approaches, has been described for lysosomal 
storage disorders (Porto et al, 2009; Parenti, 2009) and, hence, could be applied in the 
treatment of cblB type isolated methylmalonic aciduria.  
The results obtained during this work also indicate that, although 40 % of cblB type 
patients are responsive to vitamin B12 treatment, this last compound is not a natural 
chaperone. The positive response to vitamin B12 is not completely understood and it may rely 
on factors such as mRNA stabilization or expression regulation (Linscheid et al, 1998; Erlandsen 
et al, 2004). The mechanism underlying the response to pharmacological doses of vitamin B12 
could also be related to a reduced affinity of the mutant enzyme to hydroxocobalamin, 
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translated in an elevated Michaelis-Menten constant (Km). Nevertheless, p.His183Leu displays 
similar Km values when compared to the wild-type protein (laboratory data) and the 
p.Arg186Trp and Glu193Lys mutants have a complete impaired enzymatic activity (Fan and 
Bobik, 2008). Another possible explanation would be the stabilization of the complex formed 
by ATR, MUT and MMAA proteins in the mitochondrion, which could be affected by ATR 
mutants (Banerjee et al, 2009).  
Toxicity, absorption, distribution and metabolization of compound V was assessed 
using wild-type C57BL/6 mice, since no animal model is available for methylmalonic aciduria 
cblB type. This approach has also been used in other disorders (Pey et al, 2008; Calvo et al, 
2010). No alterations in animal normal behavior (food and water intake, socialization, sleep 
cycles, etc.) were observed, indicating no apparent toxic effects for both concentrations used 
(0.25 mg/kg/d and 5 mg/kg/d) (Sloman and McNeil, 2012). The stabilizing effect was assessed 
in liver and brain, central organs in this disorder, and western blot analysis revealed an 
increase in the relative amount of wild-type ATR protein in both organs. The stabilization of 
this protein in brain extracts is of great importance, since it indicates that compound V could 
be crossing the blood brain barrier. The literature shows conflicting data about methylmalonic 
acid effects in the brain (Kölker and Okun, 2005), but the persistence of neurological effects in 
patients that undergo liver or liver/kidney transplantation suggests that the presence of 
methylmalonic acid or other toxic metabolites, such as 2-methylcytrate or propionic acid, is 
responsible for the neurotoxicity observed in these patients (Kaplan et al, 2006; Kasahara et al, 
2006).  
 The metabolization rate of compound V was analyzed in liver extracts and HPLC-
MS/MS analysis revealed the presence of the compound in the liver, for both concentrations 
used. This indicates that compound V is successfully absorbed and metabolized.  
Experimental evidences show that some pharmacological chaperones can stabilize one 
mutant protein while acting as inhibitors over other proteins (Calvo et al, 2010). Because ATR 
protein interacts in the mitochondrion with the MUT protein, it prompted us to investigate if 
compound V might have any effect upon MUT protein. The same methodological approach 
was used and no apparent stabilizing effect was observed, indicating that compound V acts, 
effectively, as a pharmacological chaperone aiding the folding of ATR protein. 
The analysis of the stabilizing effect of compound V upon p.His183Leu mutant was 
performed in cell cultures of immortalized fibroblasts from patient P8 
(p.His183Leu/p.Arg190dup) and no recovery of the propionate incorporation rate was 
observed. This could be due to the destabilizing effect of the other mutation, p.Arg190dup, 
which, as shown before, is responsible for the complete impairment of ATR protein 
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production. Cells from patient P8 presented the same incorporation profile as the cells bearing 
the p.Ile117_Gln118del, also a very destabilizing mutation. These results are important since 
they indicate that, despite a positive effect upon the isolated missense mutant is observed, for 
patient treatment purposes the complete genotype profile has to be taken into account. In this 
patient P8, the synergistic effect observed for compound V and OHCbl could be beneficial, and 
further assays should be performed to assess if recovery is achieved in those conditions.  
Taken together, our data indicate that compound V is capable of stabilizing different 
missense mutants affecting the ATR protein, both in vitro and ex vivo. In vivo experiments 
indicate that its oral administration is well tolerated and no toxic effects are associated with a 
12 day period of treatment. The successful absorption and metabolization of compound V, 
allied to the stabilizing effect observed upon the wild-type ATR protein in key organs such as 
liver and brain, indicate that this compound is a good candidate for future studies upon other 
missense mutants and also for clinical trials in cblB type patients.  
The second therapeutic approach was the use of antisense therapy for pseudoexon 
exclusion. Mutations affecting the normal splicing process account for about 9 % of all 
mutations described in Human Genome Mutation Database (HGMD® Professional 2013.1), 
although this percentage may vary among the different disorders. One of the effects of 
defective splicing is the inclusion of intronic regions that resemble normal exons. These 
regions are called pseudoexons and the aberrant inclusion of pseudoexons are emerging as a 
common cause of human disorders (Dhir and Buratti, 2010) The use of antisense therapy 
based on antisense oligonucleotides (AON) has become widely accepted as a promising 
treatment strategy (Saonere, 2011), and has been successfully used in disorders such as 
propionic and methylmalonic aciduria (Rincón et al, 2007; Perez et al, 2010), Duchenne 
muscular dystrophy (Wood et al, 2010), and spinal muscular atrophy (SMA)(Hua et al, 2010), 
among others.  
Cell cultures from three PTPS deficient patients (P12, P13 and P14) bearing deep 
intronic splicing mutations were treated with antisense therapy, particularly, antisense 
morpholino oligos (AMOs). Patients P12 and P13 had been previously described (Meili et al, 
2009). P12 is homozygous for the c.84-322A>T mutation that leads to the insertion of a 79 
nucleotides LINE2 (long-interspersed element) sequence between exon 1 and 2 (r.83_84ins79), 
while P13 is heterozygous for the c.163+695_163+751del57 mutation, responsible for the 
insertion of 45 nucleotides between exons 2 and 3 (r.163_164ins45). Patient P14 is also 
heterozygous for the c.164-712A>T mutation that leads to the introduction of the same 45 
nucleotide sequence observed in patient P13 and of another sequence of 45 nucleotides plus 
25 adjacent nucleotides (r.164_165ins45/70). In both patients P13 and P14, the inserted 
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sequences belong to an antisense Alu sequence (Meili et al, 2009). LINEs are transposon or 
transposon-derived elements, which consist of repetitive sequences, and account for more 
than 50 % of the human genome and about 4% of human genes contain repetitive sequences 
in their coding regions (Keren et al, 2010; Poulos et al, 2011). Alu elements are the most 
abundant repetitive element found in the human genome and the inclusion of these repetitive 
elements in the mRNA, as internal exons, has been described in several disorders (Varon et al, 
2003; Keren et al, 2010).  
Mutation c.164-712A>T was found in patient P14 and is responsible for the inclusion of 
a pseudoexon sequence. This mutation affects the coupling of the splice site sequence to the 
U1 snRNA, and it has been observed that the complementarity between the 5’ splice site 
sequence and the last eleven nucleotides of the 5’ U1 snRNA site is one of the most important 
steps in the splicing process. It has also been demonstrated that the higher the 
complementarity between these two sequences, the higher is the splicing efficiency and pre-
mRNA stability (Freund et al, 2005). In higher eukaryotes, consensus 5’ splice site consists of 
nine partially conserved nucleotides, located at the exon-intron boundary: NAG|GTRAGT in 
which N is A or C and R is A or G. These positions are numbered spanning from -3 to +6 (De 
Conti et al, 2012). Most splicing mutations located near the exon-intron junction affect the GT 
dinucleotide. Mutations affecting other nucleotides beside the GT dinucleotide, are mostly 
8located between the +3 and +6 nucleotides of the adjacent intron and the most common 
affect positions +1, +2 and +5 (Krawczak et al, 2007; De Conti et al, 2012). Hence, the effect of 
the mutation c.164-712A>T (position +6) upon the possible U1 snRNA union sequence was 
studied using an ex vivo minigene system. The effect of two additional changes, c.164-714C>A 
(position +4) and c.164-715T>A (position +3), upon U1 snRNA complementarity were also 
studied. The pseudoexon activation was observed for the c.164-712A>T (position + 6), as 
expected, and to a higher extent for the c.164-715T>A (position +3). The c.164-714C>A 
mutation also activated the insertion of the pseudoexon, although to a much lesser extent. 
These results shown that the c.164-712A>T is in fact influencing the U1 snRNA binding and that 
changing the nucleotides that are involved in the interaction with the U1 snRNA binding 
sequence, the complementarity of this protein to the pre-mRNA can be increased or 
decreased.  
For the antisense therapy, three different types of oligonucleotides were used. 
Morpholino oligos (AMOs), VIVO-morpholinos oligos (VIVO-AMOs) and locked nucleic acids 
(LNAs). AMOs have been used successfully for pseudoexon exclusion in other disorders (Rincón 
et al, 2007; Moulton and Jiang, 2009). In this study, morpholino oligos were designed to 
hybridize specifically to each inserted sequence and two different concentrations, 20 µM and 
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30 µM were used. Recovery of the normal splicing profile was obtained in cell cultures of all 
patients and at both concentrations. We have demonstrated AMO specificity, since no 
recovery of the normal splicing profile was observed for any of the patients when the 
experiment was performed with scrambled AMOs.  
The treatment of the patients-derived fibroblasts with AMO also recovered the 
immunoreactive PTPS protein levels and enzymatic activity. The pterin levels, specially the 
neopterin/biopterin ration were also analyzed by HPLC and a significant decrease was 
observed, indicating a restoration of the normal metabolic pathway.  
Although the efficiency of morpholino oligonucleotides has been extensively proven, 
its use on in vivo systems has only been successful with leaky tissues, such as muscle. To 
increase transport and delivery efficiency, VIVO-morpholinos (VIVO-AMOs) were designed 
(Morcos et al, 2008). These oligonucleotides are AMOs coupled to an eight guanidinium head 
group in a dendrimer scaffold, and this structure enables the oligonucleotide entry into the cell 
without any type of aid (Li and Morcos, 2008; Morcos et al, 2008; Moulton and Jiang, 2009). It 
has been demonstrated that these oligonucleotides can cross the blood brain barrier, although 
to a minor extent when compared with organs like liver, kidney or small intestine (Morcos et 
al, 2008). Since PTPS deficient patients usually present neurological symptoms and because 
AMOs enter the cells by aid of a transfection agent, which molecules do not cross the blood 
brain barrier, the antisense effect of VIVO-morpholinos was analyzed. These oligonucleotides 
are specifically designed for in vivo experiments, but since an animal model is not available to 
test the effect of antisense therapy in this disorder, patient-derived fibroblasts were used and 
the normal splicing profile was recovered in patients P12 and P14.  
The effect of LNAs was also tested for patients P12 and P14. LNAs are smaller 
oligonucleoties with a locked ribose ring, which confers greater stability (Veedu and Wengel, 
2009; Campbell and Wengel, 2011). The use of LNAs has been reported in several disorders 
and their effect has been tested in different organs (Beane et al, 2007; Gupta et al, 2010; Obad 
et al, 2011; Moschos et al, 2011). 
Specific LNA sequences were designed against the pseudoexon sequence and the 
treatment of the patients-derived fibroblasts was successful, with a dose dependent recovery 
of the normal splicing profile. Although LNAs normally have to enter the cell through a carrier 
system (transfection agent), reports on the positive effect of “naked” LNAs have been 
described using process called gymnosis (Stein et al, 2010; Soifer et al, 2012). This is of great 
importance for disorders like PTPS deficiency where the antisense oligonucleotides must be 
able to reach the brain. Nevertheless, for gymnosis to occur, LNAs have to be chemically 
modified (Soifer et al, 2012). The conjugation of LNAs with nanoparticles has also been 
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described and could be another approach (Preiss and Bothun, 2011; Griveau et al, 2013). 
Future experiments should be performed using chemically modified LNAs to assess the efficacy 
of the treatment without transfection agents.  
The data obtained with these studies indicate that antisense therapy using different 
types of antisense oligonucleotides has successfully eliminated pseudoexon inclusion in three 
different splicing mutations found in PTPS deficient patients.   
The effective targeting of pseudoexon sequences using antisense therapy, and the full 
recovery of the normal splicing profiles, is of great importance since repetitive elements are 
probably the major source of pseudoexon sequences, and the inclusion of such sequences in 
the pre-mRNA is emerging as an important disease-causing effect.  
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This work has contributed to the description and characterization of mutations found 
in isolated methylmalonic mut, cblD and cblB and propionic patients, broadening the 
knowledge of the molecular basis of these disorders, to the elucidation of the 
pathophysiological mechanisms of mitochondrial dysfunction in cblB type patients and, finally, 
represents the proof of concept for the use of two different therapeutical approaches, 
chaperone and antisense therapy, in isolated methylmalonic aciduria and 6-
pyruvoyltetrahydropterin synthase deficiency, respectively. 
First, the identification of the MMADHC gene, responsible for the cblD 
complementation group allowed the characterization, for the first time in our laboratory, of 
four isolated methylmalonic cblD variant 2 type patients who had remained uncharacterized 
until then and, moreover, the identification of three novel mutations, which contributed to the 
expansion of the known mutational spectrum of cblD variant 2 type deficiency. 
Additionally, the characterization of one mut type methylmalonic patient and two 
propionic patients of Portuguese origin revealed the presence of two novel mutations in the 
MUT gene and two already described mutations in PCCB gene, respectively. The two novel 
mutations, c.244dupA and c.1408-10A>G found in the MUT gene are disease causing and the 
functional characterization of the splicing mutation revealed that, due to its effect, antisense 
therapy might be a good therapeutic approach.  
Functional analysis of two novel (p.His183Leu and p.Arg190dup) and three already 
described (p.Ile117_Gln118, p.Arg186Trp, and p.Glu193Lys) mutations affecting the MMAB 
gene (cblB complementation group) revealed that all are destabilizing mutations. Both 
p.Ile117_Gln118 and p.Arg190dup are highly destabilizing mutations and are probably 
responsible for a complete lack of ATR protein, while the p.His183Leu, p.Arg186Trp, and 
p.Glu193Lys mutants affect the ATR folding and produce an unstable protein. These results 
indicate that these three mutants are probable candidates for chaperone therapy.  
The two novel mutations (p.His183Leu and p.Arg190dup) were described in two 
siblings (patients P8 and P9) who presented phenotypic differences, in spite of the same 
genotype. Analysis of the propionate incorporation rates revealed a decrease in protein 
activity for one of the siblings, only in a stress situation. This is important because 
asymptomatic patients can manifest a disease phenotype in stress situations, such as fever 
episodes, possibly leading to neurological affectations. Moreover, it indicates that the 
phenotypical differences between the siblings could be explained by differential expression of 
proteins implicated in the protein quality control system, since they bear folding mutants.  
The analysis of mitochondrial dysfunction in both siblings and two other mut type 
patients confirmed that isolated methylmalonic patients present mitochondrial impairment. 
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Moreover, a correlation between the mitochondrial dysfunction and the phenotypic 
differences between the cblB type siblings was observed, since the sibling with the worst 
phenotype (patient P8) presented higher mitochondrial impairment.  
We can also conclude that for the cblB type patients, mitochondrial dysfunction could 
be a phenotype modifier. Furthermore, it could be considered as a future therapeutical target. 
This opens the door to further studies using specific pharmacological strategies targeting the 
mitochondria and also to the administration of antioxidants (vitamin C, vitamin E and MitoQ), 
as a complementary treatment option.  
Moreover, in organic acidurias, mitochondrial impairment has been related with high 
methylmalonic acid levels but, in this work, that correlation was not observed. This suggests 
that although methylmalonic acid is a hallmark of methylmalonic aciduria and may be 
responsible for mitochondrial impairment, other factors like other toxic metabolites, 
differences in control systems, such as the mtPQC, but also mutations affecting genes 
encoding free radicals scavengers, can contribute to mitochondrial dysfunction.  
The in vitro and in vivo analysis of compound V confirmed its effect as a 
pharmacological chaperone upon different missense mutations and, its effective 
metabolization and delivery to key organs in these disorders, such as liver and brain, with no 
apparent toxic effects. Hence, this work is the proof of concept for the use of pharmacological 
chaperones in methylmalonic aciduria cblB type. 
Most importantly, in this work we have demonstrated that OHCbl is not a natural 
chaperone of the ATR protein. We have also demonstrated that the combination of OHCbl and 
compound V is responsible for a synergistic action and the recovery of protein activity in a 
control cell line. This observation is of great importance since it opens the possibility to other 
treatment strategies in these patients and also to further studies with chaperones. 
This work represents also the proof of concept that antisense oligonucleotide therapy 
can be used to exclude pseudoexon sequences affecting the PTS gene. The use of other 
antisense oligonucleotides, such as LNAs and VIVO-morpholinos has also recovered of the 
normal splicing profile. The successful use of VIVO-morpholinos is of great importance, since 
this type of oligonucleotides allows a higher stability and delivery efficiency of the morpholino 
molecule in vivo. Further studies using nanoparticles should be performed in order to increase 
delivery efficiency in a key organ such as the brain.  
In conclusion, this work allowed the identification and characterization of novel 
mutations identified in isolated methylmalonic patients, the identification of mitochondrial 
dysfunction as a phenotypic modifier in isolated methylmalonic aciduria and, finally, the 
assessment of specific therapeutical strategies in metabolic disorders.  
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Methylmalonic aciduria (MMA) cblB type is caused by mutations in theMMAB gene. This encodes the enzyme
ATP:cob(I)alamin adenosyltransferase (ATR), which converts reduced cob(I)alamin to an active adenosylcobala-
min cofactor. We recently reported the presence of destabilizing pathogenic mutations that retain some residual
ATR activity. The aim of the present studywas to seek pharmacological chaperones as a tailored therapy for sta-
bilizing the ATR protein. High-throughput ligand screening of over 2000 compounds was performed; six were
found to enhance the thermal stability of purified recombinantATR. Further studies using awell-established bac-
terial system in which the recombinant ATR protein was expressed in the presence of these six compounds,
showed them all to increase the stability of the wild-type ATR and the p.Ile96Thr mutant proteins. Compound V
(N-{[(4-chlorophenyl)carbamothioyl]amino}-2-phenylacetamide) significantly increased this stability and did
not act as an inhibitor of the purified protein. Importantly, compound V increased the activity of ATR in patient-
derived fibroblasts harboring the destabilizing p.Ile96Thr mutation in a hemizygous state to within control
range.WhencobalaminwascoadministratedwithcompoundV,mutantATRactivity further improved.Oraladmin-
istration of low doses of compound V to C57BL/6J mice for 12 days, led to increase in steady-state levels of ATR
protein in liver and brain (disease-relevant organs). These results hold promise for the clinical use of pharmaco-
logical chaperones in MMA cblB type patients harboring chaperone-responsive mutations.
INTRODUCTION
Cobalamin, or vitamin B12, is an essential micronutrient that
mammals must obtain from their diet. It is then processed via a
complex pathway for the biosynthesis of methylcobalamin and
adenosylcobalamin (AdoCbl), which, respectively, serve as
cofactors of the cytosolic enzyme methionine synthase (MS,
EC_2.1.1.13) and the mitochondrial enzyme methylmalonyl-
CoA mutase (MUT, EC_5.4.99.2). The study of inborn defects
of cobalamin metabolism has revealed nine complementation
groups: cblA to cblJ and mut (1–4). In particular, defects in
the mitochondrial enzyme methylmalonyl-CoA mutase (mut
group) or in the synthesis of the AdoCbl cofactor (complemen-
tation groups cblA, cblB or cblD variant2) lead to isolated
methylmalonic aciduria (MMA, MIM 251 000) (5).
The synthesis and transfer of AdoCbl to MUT involves
three proteins, ATP:adenosylcobalamin transferase (ATR,
EC_2.5.1.17), the cblA protein and the cblD protein (5–7). ATR
is a homotrimer encoded by theMMABgene (8,9). MUT is respon-
sible for the isomerization of L-methylmalonyl-CoA into succinyl-
CoA, which can enter the Krebs cycle, and MMA cblB type is
caused by mutations in the gene encoding ATR (10).
MMA cblB patients suffer either a severe early-onset form of
the disease, with neonatal ketoacidosis, lethargy, failure to thrive
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and encephalopathy, or a milder late-onset form usually diag-
nosed during infancy that has a less serious neurological
outcome. While there is currently no cure for the disease, thera-
peutic options, including the dietary restriction of substrates, aim
to reduce methylmalonic acid production and improve the clin-
ical outcome. Pharmacological cobalamin supplementation is
part of the usual treatment, although only 40% of patients
show any biochemical response to it, and in many cases neuro-
logical manifestations persist. In those that do respond, signifi-
cant improvements in clinical condition, growth and metabolic
variables have been reported, although the levels of toxic meta-
bolites never normalize (1).
Efforts are now being directed towards exploring alternative
therapies based on identifying new targets in the context of per-
sonalized medicine. Understanding the molecular mechanisms
of pathogenesis underlying genetic defects can help guide the
design and development of new therapeutic approaches.
Several studies have shown that many human diseases are
caused by loss-of-function mutations that impair the correct
folding of affected proteins (11–13). Over the past decade,
pharmacological chaperones have emerged as novel therapeutic
tools for rescuing misfolded proteins by stimulating and preserv-
ing their correct folding (14,15). Pharmacological chaperones
are small, cell-permeable molecules that specifically bind and
stabilize target proteins. Pharmacological chaperones have
been investigated as a potential treatment for many genetic dis-
orders that result from misfolded and/or unstable proteins, and
proof-of-concept studies have been described for several
human diseases such as lysosomal disorders, phenylketonuria
and cystic fibrosis (12,16–19).
In a previous study, we reported the characterization of two
mutations in the MMAB gene, p.Ile96Thr and p.Arg191Trp,
both of which are associated with reduced ATR stability and
residual activity (20). The aim of the present work was to identify
compounds with pharmacological chaperone potential for ATR.
We demonstrate that N-{[(4-chlorophenyl)carbamothioyl]
amino}-2-phenylacetamide, here after referred to as compound
V, enhanced the stability of wild-type and p.Ile96Thr mutant
ATR. It also increased the residual activity of ATR in patient-
derived fibroblasts harboring the latter mutation. The effect of
compound V on the stabilization of recombinant wild-type and
mutant ATR both as isolated recombinant protein and in patient-
derived fibroblasts is further increased when tested simultan-
eously with cobalamin. Finally, oral loading of compound V in
wild-type mice resulted in an increase in ATR stability in the
liver and brain (disease-relevant organs).
RESULTS
High-throughput screening forpharmacological chaperones
Asubsetof2000compounds fromtheMyriaScreenDiversityCol-
lection was screened by differential scanning fluorimetry (DSF).
Data analysis revealed a group of six compounds that shifted the
Tm of ATR between 6.0 and 178C. These six compounds (I–VI)
were selected for further studies (Figs 1 and 2).
Figure 1. Differential scanning fluorimetry profiles for six candidate pharmacological chaperones. Thermal denaturation profiles of purified wild-type ATR
(0.086 mg/ml) (fluorescence at 610 nm vs. temperature [8C]). In grey, curve for ATR incubated with DMSO(final concentration 2%); in black, purified ATR incubated
with 0.04 mg/ml of compounds I–VI. The melting temperature (Tm) was taken as the temperature at which the maximum fluorescence was achieved;DTm was calcu-
lated as the difference between theTm in the presence of a ligand andTm in the presence of DMSO. The lower figure for each graph represents the data without scaling.
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ATR stability and activity in the presence of hit compounds
To determine whether compounds I–VI acted as pharmaco-
logical chaperones, their effect on the stability of wild-type
ATR and the p.IleI96Thr mutant was studied. Table 1 sum-
marizes the quantification of ATR by western blot analysis of
the bacterial lysates grown in the presence of the potential cha-
perones. Compounds I–VI increased or tended to increase the
steady-state levels of expressed wild-type and/or mutant ATR
(Table 1) indicating an increase in ATR stability. Compound
V (80 mM) had the largest effect on the mutant (Table 1). Com-
pound VI was the most effective in stabilizing the wild-type
type ATR (Table 1). Based on these results, compounds V and
VI were selected for further studies.
The effect of compounds V and VI was then analyzed by
measuring the activity of the lysates of bacterial cultures expres-
sing wild-type and mutants (p.Ile96Thr and p.Arg191Trp),
grown in the presence of 100 mM compounds. While no effect
could be observed for compound VI, in either wild-type or
mutant extracts, the activity in the lysates of bacterial cultures
grown with compound V increased 1.5-fold for wild-type and
8-fold for the destabilizing mutation p.Ile96Thr. For the
p.Arg191Trp mutant, which is also unstable, no quantifiable
enzyme activity could be measured in the lysates of cultures
grown without compound V, but some activity could be detected
in its presence (data not shown).
A clear stabilizing effect of the p.Ile96Thr by compound V
was observed in the time-dependent quantification of mutant
Figure2.Chemical structures and IUPAC names of the selected compounds. Six compounds, named I to VI, were found to stabilize ATR protein in a high-throughput
screening of 2000 compounds.
Table 1. Thermal stabilization in the presence of compounds I–VI from DSF screening, and relative stability of wild-type and p.Ile96Thr ATR in the presence of
compounds as measured by quantitative immunoblottinga
DTm (8C) Wild-type p.Ile96Thr
40 mM 80 mM 40 mM 80 mM
DMSOb — 1.0 1.0 1.0 1.0
Compound I 16.1 1.8+0.4 (∗) 1.6+1.2 0.8+0.3 2.3+1.3
Compound II 5.4 2+1 ND 1.3+0.1 ND
Compound III 8.5 0.7 0.9+0.4 1.9+0.5 2.1+0.6(∗∗)
Compound IV 7.4 1.0+0.2 3.4+0.4(∗∗∗∗) 2.0+0.6 2.2+0.1(∗∗∗)
Compound V 13.6 ND 1.4+1.0 1.6+1.2 3+ 1 (∗∗)
Compound VI 15.7 4+2 (∗) 6.2+ 0.5(∗∗∗∗) 2.1+0.1 (∗∗∗∗) 1.7+0.2(∗∗)
Bold figures highlight the most important effect of compounds V and VI.
ND, not determined.
aData obtained with bacterial extracts prepared from cultures grown in the presence of 40 or 80 mM of compounds I–VI, as described in Materials and Methods.
bData represent the mean+SD of at least two independent determinations. In all cases the appropriate DMSO control was used and taken as the reference value
(stability ¼ 1) for the bacterial cultures grown in the presence of the compounds.
∗P, 0.05.
∗∗P, 0.01.
∗∗∗P, 0.005.
∗∗∗∗P , 0.001.
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protein in the bacterial lysates (Fig. 3A and B). Similar time-
course experiments were performed with lysates from bacter-
ial cultures grown in the presence of 1 mg/ml (0.7 mM)
OHCbl, which did not have any stabilizing effect on the
expressed wild-type and only slight on mutant protein
(Fig. 3A and B). Interestingly, the combined addition of com-
pound V and OHCbl showed a slightly increased stabilizing
effect of the mutant p.Ile96Thr compared with compound V
alone (Fig. 3A and B).
The combined effect of compound V and OHCbl was further
analyzed using isolated recombinant wild-type ATR protein. We
first measured the concentration-dependent thermal stabiliza-
tion of ATR by OHcbl using DSF. Concentrations up to 25 mM
OHCbl did not affect the thermal stability of the protein, and
similar unfolding curves as for the controls (shown in Fig. 1)
were obtained. But higher concentrations of OHCbl destabilized
ATR slightly (1.58C) and gave poor curves due to quenching of
fluorescence. Titration with compound V (0–200 mM) in the
absence of OHCbl showed that ATR is thermally stabilized by
the compound at concentrations approximately .2 mM
(Fig. 3C), and by analyzing the effect of the ligand on the Tm
of ATR as described by Cooper and McAuley-Hecht (21), we
estimated aKd ¼ 7.4+ 0.4 mM for compound V. In the presence
of 0.75 mM OHCbl, this Kd was not affected, but higher concen-
trations of the substrate increased the affinity of compound V
(Kd ¼ 5.4+ 0.5 mM with 3 mM OHCbl and Kd ¼ 5.5+ 0.4
with 12 mM), resulting in increased stabilization at similar con-
centrations of the compound (Fig. 3C). Comparatively, ATP,
which had a negligible effect on the Tm for ATR denaturation
up to 200 mM, did not have any effect on the concentration-
dependent stabilization by compound V (Fig. 3C). The affinity
of ATR for compound V appears comparable to the apparent
Km values for ATP (6.4+ 0.4 mM) and 3.7+ 0.5 mM for cobala-
min (22).
Figure3.Effect of compounds V, VI and cobalamin on ATR stability and activity. (A) Effect of compound V on p.Ile96Thr ATR protein stability.Bacteria expressing
wild-type or p.Ile96Thr mutant ATR were incubatedwith 80 mM compoundV (final DMSOconcentration 0.2%) or the equivalent amount of the vehicle (0.2% DMSO)
or with 1 mg/ml (0.7 mM) of OHCbl or both. Crude cell extracts from cultures expressing wild-type or p.Ile96Thr ATR were incubated at 378C, and aliquots were
removed at different times. The aliquots were loaded onto SDS–PAGE gels and the protein was immunodetected by western blotting. Proteins were quantified by
laser densitometry as the percentage density of each protein relative to its density at time 0. Compound-treated samples were compared with the DMSO-treated
sample. (B) Quantification of the effect of compound V and/or OHCbl on stability of wild-type ATR and mutant p.Ile96Thr ATR. (C) Concentration-dependent sta-
bilization of ATR by compound V and effect of OHCbl and ATP. The stabilization of ATR in the presence of compound V (0–200 mM) in the absence of OHcbl (black
solid line, circles) and in the presence of OHCbl at 3 mM (dark grey solid line, triangles) and 12 mM (light grey solid line, squares) or 40 mM ATP (dotted line, squares).
See main text for estimated Kd values for compound V binding. (D) Specific activity was measured using purified wild-type ATR from bacteria with 40 or 80 mM of
either compound V or VI or the equivalent volume of DMSO (final DMSO concentration 0.4 or 0.8%). ∗P , 0.05, ∗∗P , 0.01.
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Given that pharmacological chaperones can act as enzyme
inhibitors if they resemble the natural substrates (23), we
tested the effect of compound V on the activity of recombinant
ATR. The specific activity of purified recombinant human
ATR was 0.23+ 0.04 U/mg at the standard assay conditions.
In the presence of 40 mM of compound V, the activity remained
comparable to that of control samples (0.27+ 0.02 U/mg)
(Fig. 3D). Comparatively, with 40 mM of compound VI,
another of the initial hit compounds, the specific activity
decreased to 0.09+ 0.05 U/mg, suggesting that compound VI,
but not V might be inhibitory. At concentrations of 80 mM, no in-
hibitory effect was again obtained for compound V (specific ac-
tivity of 0.30+ 0.14 U/mg). For compound VI at 80 mM, the
inhibition observed at lower concentration appears reversed,
suggesting a complex pattern of stability and activity effects
for this inhibitory potential pharmacological chaperone.
Given that compound V showed a clear stabilizing effect on
wild-type and mutant ATR and did not seem to be inhibitory,
it was selected for further testing on cellular and animal models.
Recovery of residual activity in a cellular disease model
The therapeutic potential of compound V was further evaluated
by its ability to increase total cellular ATR activity using patient-
derived transformed fibroblasts. Its effect at 40 and 80 mM on the
propionate oxidation metabolic pathway was assessed using
immortalized dermal fibroblasts from a patient bearing the muta-
tions p.Ile96Thr and p.Ser174fs (20) incubated for 48 and 72 h
with the compound. [14C]-propionate uptake was quantified as
an indirect measurement of ATR activity. Incubation with com-
pound V at 80 mM for 48 h induced a slight increase in the re-
sidual activity (data not shown), while 72 h of treatment
significantly increased ATR activity (5.4-fold). Indeed, it
reached control range levels. An effect due to DMSO was
ruled out since residual activity in the presence or absence of
DMSO was comparable. In the same way as described earlier,
the effect of compound V and OHCbl on the activity and stability
of ATR was assessed. According to the results obtained with the
patient-derived fibroblasts, OHCbl increased the incorporation
of 14C propionate (3.5-fold). 14C propionate incorporation was
further stimulated (17-fold) when compound V and OHCbl
(1 mg/ml) were simultaneously present (Fig. 4A). The levels of
mitochondrial ATR protein were also slightly increased when
both compound V and OHcbl were added (Fig. 4B).
Supplementation with compound V to mice: effect on liver
and brain ATR
In addition to in vitro and ex vivo studies, experiments with
whole organisms are pivotal for determining a drug’s pharmaco-
kinetics to assess whether it is adequately absorbed, distributed
and excreted. To this end, the effect of compound V on the sta-
bility of endogenous ATR was examined in a wild-type mouse
strain since a cblB mouse model is currently unavailable. Two
doses (0.25 and 5 mg/kg/day) of compound V were administered
orally every day for 12 days. No secondary effects of compound
exposure (such as weight loss, automutilation, tumors, abnormal
movements, etc.) were observed. The results showed an increase
in the amount of immunoquantified ATR at the 5 mg/kg/day
dose in liver and brain, two disease-relevant organs (Fig. 5), sup-
porting the stabilizing effect of compound V in vivo.
Molecular docking
The molecular docking of compound V (24,25) resulted in 49
clusters being identified in eight different pockets of the
protein. The top-score cluster had a significantly lower FullFit-
ness (26) than the others. This binding site is formed by residues
at the C-terminal end of each subunit in the trimeric ATR (resi-
dues 228–240), and the loop 165–175, close to residue Phe170,
which has been reported as a potential candidate residue for
binding the hydrophobic surfaces of cobalamin (9). The site is
distant from the ATP binding site (Fig. 6A). In this conformation,
compound V could be able to form three hydrogen bonds with the
backbone amide of Ala169 and the carboxyl acid side chain of
Glu235, making it a favorable binding site (Fig. 6B). The loca-
tion of this binding pocket is consistent with the results obtained
by DSF on the synergistic stabilizing effect of OHCbl and com-
pound V and the absence of effect by ATP (Fig. 3C). Thus,
binding of OHCbl and compound V to their respective adjacent
sites might lead to a greater packing and conformational stability
of this part of the protein, and notably the loop 165–175, than
obtained by compound V binding alone.
Figure 4. Effect of compound V and cobalamin in a cellular disease model.
Immortalized patient (harboring the mutations p.Ile96Thr/p.Ser174fs) and
healthy-derived fibroblastswere incubated in the presence of 80 mM of compound
V or the equivalent volume of DMSO (0.1 or 0.2%), and in the presence of 1 mg/
ml of cobalamin. After 72 h, ATR activity was indirectly measured via
[14C]-propionate incorporation into acid-precipitable material in intact cells
grown in basal medium. (B) Western blot analysis for ATR protein using mito-
chondria isolated from healthy and patient-derived fibroblasts. The cells were
treated for 72 h with 80 mM of compound V or 1 mg/ml of OHCbl or both sub-
stances. Mitochondrial Hsp60 was used as a protein control loading.
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DISCUSSION
Research into understanding how missense mutations trigger
protein degradation is a growing field, the goal of which is to
find new therapeutic options for protein misfolding diseases
(27). Particular efforts have been directed towards the use of
drugs that increase the amount of native-state protein (12,15)
through increasing its stability and reducing the degradation of
mutated but biologically active protein. Such research could
lead to new orphan drugs for treating rare diseases within the
context of personalized medicine (12,17,18,28–30). In the
present study, we searched for compounds that enhance ATR
enzyme stability, opening up the possibility of a new therapeutic
strategy for the treatment of MMA cblB, which envisions a
tailored therapy for patients harboring destabilizing mutations
that could be used in combination with MMA conventional
treatment.
Combinations of in vitro, ex vivo and in vivo approaches were
used successfully in the search for compounds capable of stabil-
izing the ATR protein. DSF-based high-throughput screening
Figure 5.Effect of compound V in wild-type mice. Two groups of six wild-type C57BL/6 mice were orally treated for 12 days with 0.25 mg/kg/day or 5 mg/kg/day of
compound V. The control animals (five mice) were treated with 10% DMSO in a 9% glucose solution, i.e. the vehicle for compound V administration. After treatment,
whole liver and whole brain extracts were prepared and ATR protein levels detected by immunoblotting (represented as the mean+SD for each group). ∗P, 0.05.
Figure6.Proposed binding site of compound V. (A) Overview of ATR (PDB ID 2IDX) showing the location of the proposed binding site for compound V in one of the
protein subunits (top score position from SwissDock with highest FullFitness) (26), the location of ATP, and the residues proposed to interact with cobalamin (yellow).
(B) A detailed view of the proposed binding site of compound V (ball-and-stick). The residues Ala169 and Glu235 are shown with sticks and the potential hydrogen
bonds to compound V with dotted lines. Phe170, which is implicated in cobalamin binding, is also shown.
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(HTS) identified compounds that stabilized purified recombin-
ant wild-type ATR and the p.Ile96Thr mutant to different
degrees. One of these compounds, compound V, also stabilized
the p.Ile96Thr protein ex vivo, and was associated with a dose-
dependent increase in ATR activity in the patient-derived cell
line bearing the mutations p.Ile96Thr/-p.Ser174fs (20). No in-
hibitory effects of the compounds on the purified ATR protein
were observed. A broad concentration window for compound
V administration could be used for increasing a patient ATR ac-
tivity up to the therapeutic range and is therefore available for a
future therapeutic trial in selected cblB patients (18,31).
The promising preliminary results obtained with compound V
with the rare destabilizing mutations p.Ile96Thr and p.Arg191
Trp (20) open up the possibility of analyzing the response of
other misfolding mutations of ATR (9,31,32). An in vitro evalu-
ation of compound V effects is needed to determine which
patients it might be beneficial for.
The efficacies of the potential pharmacological chaperones
found by HTS were varied (Table 1) and it is possible that
their co-administration might lead to synergistic effects, increas-
ing the residual activity of mutant ATR, and combinations of the
hit compounds could be tested for each mutation background.
While the threshold for clinical efficiency in MMA is
unknown, small increases in residual activity (5–10%) might
be sufficient to attenuate a severe clinical phenotype
(17,18,32). The synergistic effect of OHCbl and compound V
on the activity and stability of ATR is noteworthy. The results
suggest that vitamin B12 administrated alone is not a natural
chaperone; no increase in protein was detected in any experi-
ment, and the vitamin did not cause any increase in the Tm of re-
combinant wild-type ATR, as seen by DSF. Nevertheless,
wild-type ATR is indeed stabilized in the presence of both sub-
stances, as well as the mutant enzyme in the bacterial and cellular
model. The modeled structure of compound V bound to ATR,
adjacent to the proposed cobalamine site (Fig. 6), appears to
support the synergistic effect of both substances.
The present study suggests a possible clinical application for
pharmacological chaperones in the treatment of MMA cblB
type. However, putative toxic effects of compound V need to
be assessed in an appropriate cblB animal model (33,34). The
proof-of-concept work performed in the present study made
use of wild-type mice since no available ATR-deficient mouse
model carrying missense alleles was available. The results
obtained in these mice in vivo suggest that compound V is effi-
ciently absorbed and transported to tissues that are affected in
MMA and that it crosses the cellular and mitochondrial mem-
branes and increases ATR stability at a relatively low dose
(5 mg/kg/day).
The ultimate goal in MMA treatment research is to prevent, or
slow, the development of symptoms of the disease, including
metabolic instability, strokes and kidney failure. Currently
there is some controversy regarding the source of neurological
dysfunction: it might be caused by methylmalonic acid produced
in the neurons and/or glia in brain, or by it being made elsewhere
in the body and being transported across the blood–brain barrier
(BBB) (35). If the brain is responsible for its production, a
pharmacological chaperone would have to cross the BBB to be
effective. The results obtained with mouse brain extracts are
very encouraging since they suggest that compound V could
cross the BBB.
In conclusion, the present work identifies a potential pharma-
cological chaperone (compound V) with in vitro efficacy in
patient-derived fibroblasts carrying the p.Ile96Thr mutant
protein and in wild-type mice. It is therefore a good candidate
for therapeutic trials in selected cblB patients. Further, the
excellent effects of cobalamin—reported over decades—in the
treatment of cblB MMA patients might be improved by
co-administration of compound V. Compound V might also be
subjected to chemical modification to enhance its effectiveness;
this warrants further investigation.
MATERIALS ANDMETHODS
Compounds tested for pharmacological chaperone potential
The library of small compounds tested in this study was the
commercially available MyriaScreen Diversity Collection
(Sigma-Aldrich, St Louis, MO, USA), where the compounds
are dissolved to a final concentration of 2 mg/ml in 100%
DMSO. The hit compounds from the screening were consecutive-
ly ordered from Sigma-Aldrich, prepared at concentrations of
10 mM in 100% DMSO and stored at 2208C, and their chemical
structure confirmed by HPLC-MS/MS and NMR spectroscopy.
All experiments presented in this study were performed by the
addition of compound dissolved in DMSO to the different assays
and parallel control experiments were carried out maintaining
the same concentration of DMSO (but without compound).
ATR expression, preparation of bacterial crude extracts
and protein purification
Human ATR was expressed in Escherichia coli (BL21StarTM
DE3 One Shot Cells) transformed with the NL173 plasmid.
This plasmid, which is based on the pET41a vector, encoded
either wild-type or mutant (p.Ile96Thr or p.Arg191Trp) ATR
lacking the mitochondrial targeting sequence (20). Protein ex-
pression was induced with 1 mM IPTG; 5 h after induction the
cells were harvested by centrifugation (48C, 6000 rpm for
10 min) and frozen at 2708C until needed. Cell pellets were
resuspended in 50 mM potassium phosphate buffer pH 8,
100 mM NaCl, 1 mM DTT, 1× Complete Mini, EDTA-free Pro-
tease Inhibitor Cocktail (Roche Applied Sciences, Indianapolis,
IN, USA), 1 mM EDTA, 0.05 mg/ml DNAse and 0.3 mg/ml lyso-
zyme. After 1 h, the cell suspension was sonicated and centri-
fuged (48C, 13 000 rpm for 15 min) to obtain the crude soluble
cell extract, which was diluted to 1 mg/ml. This crude extract
was used in protein stabilization studies and in crude bacterial
extract activity assays. For further purification of ATR, the
extract was subjected to ammonium sulfate precipitation and
subsequent anion-exchange chromatography using a HiTrap
Sepharose Q column (GE Healthcare, Buckinghamshire, UK)
as previously described (36). In all purification steps, the
protein concentration was determined by the Bradford assay
(Bio-Rad Laboratories, Munchen, Germany). Fractions eluted
from the Sepharose Q column were subjected to SDS–PAGE
to identify those enriched in ATR. Purified ATR was centrifuged
at 10 000g for 10 min at 48C to precipitate aggregates, and then
loaded onto a Superdex 200 HiLoad 16/60 size-exclusion chro-
matography column (GE Healthcare). The elution peak corre-
sponding to the trimeric ATR form was recovered and used for
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further experiments. Pure protein concentration was estimated
by measuring the absorbance at 280 nm in a Nanodrop spectro-
photometer (Thermo Scientific) using the theoretical molar ex-
tinction coefficient (16 305 M21 cm21) estimated from the
amino acid composition for ATR.
High-throughput screening forpharmacological chaperones
Ligand-induced ATR stabilization was assessed by an HTS
protocol using DSF (37), monitoring the thermal denaturation
of purified ATR in the presence of the extrinsic fluorescent
probe SYPRO Orange (Sigma-Aldrich). Protein solutions con-
taining 0.086 mg/ml of ATR (3.2 mM ATR subunit) in 20 mM
Na-Hepes, pH 7.0, 200 mM NaCl and 5× SYPRO Orange,
were dispensed (49 ml) into 96-well PCR plates (LightCy-
cler480 Multiwell Plate 96, Roche). One microliter of each po-
tential chaperone compound dissolved in DMSO was added to
each well to produce final concentrations of 0.04 mg/ml com-
pound and 2% DMSO. Plates were incubated at room tempera-
ture for 30 min before loading into a Light Cycler 480 (Roche
Applied Science, Indianapolis, IN, USA) for thermal denatur-
ation. Control experiments with 2% DMSO were routinely per-
formed. Unfolding curves were registered from 20 to 998C, at a
scan rate of 28C/min. The increase in SYPRO Orange fluores-
cence intensity associated with protein unfolding (lexcitation ¼
465 nm, lemission ¼ 610 nm) was monitored as a measure of
thermal denaturation. Unfolding curves were recorded from 20
to 958C, at a scan rate of 28C/min. The experimental unfolding
curves were smoothed, normalized and analyzed using
in-house software. The midpoint melting temperature (Tm) was
calculated as the temperature at which half the protein is in the
unfolded state. A compound qualified as a ‘hit’ if it increased
the Tm of the protein by ≥68C.
The concentration-dependent stabilization of ATR 0.15 mg/
ml (6.35 mM ATR subunit) by ATP and hydroxocobalamin
(OHCbl) (0–200 mM) was carried out using DSF at otherwise
similar sample preparation, pre-incubation and scanning condi-
tions as in the HTS protocol. Following this experiment, thermal
stabilization titrations with compound V (0–200 mM) were
carried out in the presence or absence of either 40 mM ATP or
0.75, 3 and 12 mM of OHCbl.
Effect of the compounds on ATR stability in a prokaryotic
expression system
ATR stability was assessed as previously described (20). Basic-
ally, ATR expression was induced with 1 mM IPTG in 10 ml
E. coli LB cultures for 5 h in the presence of 40 or 80 mM com-
pound dissolved in DMSO (final concentration of DMSO 0.1
or 0.2%, respectively) or the corresponding concentration of
DMSO. To determine a possible synergistic effect of compound
V and OHCbl on ATR stability, the same experiment was
performed in the presence of 1 mg/ml (0.7 mM), of OHcbl a con-
centration commonly used to stimulate cells to incorporate 14C
propionate. Additionally, E. coli were cultured for 5 h in the
presence of 80 mM of compound V dissolved in DMSO added
together with OHCbl dissolved in water. The crude extracts,
prepared as described earlier, were diluted to 1 mg protein/ml.
Aliquots of equal amounts of total protein were incubated at
378C, and equal sample volumes were removed at different
times for immediate analysis by SDS–PAGE or frozen until
gel loading.
Enzyme activity assays
ATR activity was measured as described by Johnson et al. (38)
with minor modifications. Briefly, 1 ml of reaction mixture
(200 mM Tris–HCl pH 8.0, 1.6 mM KH2PO4, 2.8 mM MgCl2
and 100 mM KCl) was dispensed into cuvettes and kept at 378C.
Specific activity was measured with 40 mM ATP and 60 mM
OHCbl (Sigma-Aldrich). In indicated experiments, 0–100 mM
of compound V or VI were added to the reaction mixture. After
titanium (III) citrate (30 mL) was added, the reaction was started
by the addition of 10 mg of purified wild-type ATR. Alternatively,
50–100 mg of crude extracts from bacterial cultures expressing
wild-type, p.Ile96Thr or p.Arg191Trp, grown in the presence of
0–100 mM of compound V or VI, were used to start the reaction.
Anaerobic procedures were followed in the preparation of the re-
action mix, the protein solution, compound solutionsand the titan-
ium (III) citrate solution. The reduction in absorbance at 388 nm
was monitored to calculate the concentration of AdoCbl, with
DA388 taken as 24.9 cm
21 mM21, and specific activity was
expressed asmmol of product generated per minute and milligram
of protein (U/mg). Experiments were performed in triplicate.
Biochemical data on the p.Ile96Thr-bearing patient and
biochemical chaperone analysis in patient fibroblasts
The patient with the genotype c.287T.C/c.584G.A (p.Ile96
Thr/p.Ser174fs) has been described earlier (20). This patient
was placed under protein restriction, carnitine supplementation
and oral OHCbl administration (5 ml/day). During therapy, the
patient showed .1000 mmol/mol creatinine, plasma C3 levels
of 10 mM and normal plasma odd-chain fatty-acid levels
(,0.4%). Urine methylmalonic acid varied (,200–800 mmol/
mol creatinine). A dermal fibroblast cell line from this patient
and healthy control fibroblasts were stably transformed with
pBabe retroviral vector (kindly provided by Dr J.A. Enriquez,
Centro Nacional de Enfermedades Cardiovasculares, Madrid).
5 × 105 transformed cells were plated and grown at 378C for
24 h in MEM medium supplemented with 2 mM glutamine,
10% fetal bovine serum and antibiotics. After treatment, the
culture medium was discarded and replaced with fresh medium
containing 40 or 80 mM of compound V for 48 or 72 h, or the
equivalent volume of DMSO for controls. After this time, cell
lines were grown for 18 h in the presence of [14C]-propionate,
and were harvested by trypsinization, followed by centrifugation,
and were used to determine ATR activity, which was
indirectly measured by [14C]-propionate incorporation into acid-
precipitable material in intact cells grown in basal medium (39).
Assays were performed in triplicate and results were examined
statistically using anF-test analysis of variance followed by a one-
tailed, paired t-test. Significance was set at P, 0.05.
Alternatively, mitochondrial isolation from cell pellets was
performed using anti-TOM22 MicroBeads (Mitochondrial Iso-
lation Kit, Miltenyi Biotec, Bergisch Gladbach, Germany).
Briefly, 8.0 × 105 cells from a healthy control and patient
immortalized fibroblasts were seeded in T75 flasks and incu-
bated overnight at 378C, and then for 72 h with 80 mM of com-
pound V, 1 mg/ml of OHCbl or both. The cells were harvested
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by trypsinization and the mitochondria isolated following the
manufacturer’s protocol. Mitochondrial pellets were resus-
pended in 50 mL of storage buffer.
Animal studies
Seventeen female 12-week-old wild-type mice (C57BL/6J) were
purchased from Harlan Laboratories (Harlan Laboratories Inc.,
Indianapolis, IN, USA). These were housed under standard condi-
tions in compliance with European Community Guidelines (Dir-
ective 86/609/EEC) at the Centro de Biologı´a Molecular Severo
Ochoa, and maintained at a temperature of 22+18C under a
12 h/12 h light/dark cycle. All had ad libitum access to food and
water and were handled in strict accordance with national and in-
stitutional animal welfare guidelines. Two groups of six animals
(23–25 g) were orally loaded with a 25 ml suspension containing
either 0.25 or 5 mg/ml/day of compound V in 10% DMSO plus
9% glucose for 12 days. The control group was treated only
with the 10% DMSO and 9% glucose. Approximately, 30 min
after the last dose, the animals were sacrificed using CO2. The
livers and brains were rapidly removed and divided into two
equal parts, one of which was frozen in liquid nitrogen for
further studies. Fresh liver extracts were prepared in phosphate
buffered saline with protease inhibitors; fresh brain extracts
were prepared in RIPPA buffer [50 mM Tris–HCl, pH 7.4, 1%
Triton, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1 mM Na3VO4,
1× Complete Mini EDTA-free Protease Inhibitor Cocktail
(Roche Applied Sciences) and 0.25% Na-deoxycholate]. These
samples were homogenized using a Tissue Lyser II (QIAGEN,
Hilden, Germany) and the extracts clarified by centrifugation at
13 000 rpm for 30 min at 48C. The supernatants were stored at
2708C prior to SDS–PAGE and immunoblotting analyses.
SDS–PAGE and immunoblotting
Samples were loaded onto pre-cast polyacrylamide NuPAGE
SDS–PAGE Bis–Tris 10% gels in the case of bacterial crude
extract or 4–12% gels for the murine tissue extracts (75 mg of
liver or 150 mg of total brain extract) and separated using
NuPAGE SDS MES running buffer (Life Technologies, Grand
Island, NY, USA). Proteins were transferred to a nitrocellulose
transfer membrane using the iBLOT gel Device System (Life
Technologies). Poinceau staining was used to monitor equal
protein loading. Immunodetection was performed using com-
mercially available anti-ATR antibodies (ProteinTech Group,
Inc., Chicago, IL, USA) as primary antibodies (diluted 1:1000
for the bacterial crude extracts, and 1:500 for the mouse tissue
extracts). The secondary antibody used was conjugated
goat-anti-mouse IgG-horseradish peroxidase (1:10 000 for bac-
terial extracts and 1:5000 for mouse tissue extracts) (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA). The mouse tissue
extract membranes were also immune stained with a polyclonal
antibody against mitochondrial Hsp60 (1:10 000). Signals were
visualized using the Enhanced Chemiluminescence System (GE
Healthcare, Munich, Germany) and the relative amount of
protein determined using a GS-800 calibrated densitometer
running Quantity One software (BioRad, Hercules, CA, USA).
The prokaryotic stability experiments were performed in tripli-
cate and were statistically examined using the F-test analysis
of variance followed by a one-tailed paired t-test. Significance
was set at P , 0.05.
Molecular docking
To identify potential binding sites of compound V, we performed
an automated molecular-docking procedure using the web-
based SwissDock program (24,25). The docking was performed
using the ‘Accurate’ parameter at otherwise default parameters,
with no region of interest defined (blind docking).
WEB RESOURCES
http://www.ncbi.nlm.nih.gov/omim.
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ABSTRACT: Antisense oligonucleotide therapy to modulate
splicing mutations in inherited diseases is emerging as a
treatment option also for metabolic defects. In this article,
we report the effect of cellular antisense therapy to
suppress pseudoexon activation in primary dermal fibro-
blasts from patients with mutations in the PTS gene
encoding 6-pyruvoyltetrahydropterin synthase (PTPS),
which leads to tetrahydrobiopterin and monoamine
neurotransmitter deficiency. Pathogenic inclusion of SINE
or LINE-derived cryptic exons in different PTPS patients
due to the intronic mutations c.84322A4T, c.1631
695_1631751del57, or c.164712A4T was demon-
strated by transcript analysis in fibroblasts and minigene
ex vivo assays. Antisense morpholino oligonucleotides
(AMOs) directed to the pseudoexons 30 or 50 splice sites
were designed with the aim of preventing the pathological
pseudoexon inclusion. At the time of AMO transfection,
we investigated patients’ cells for correct PTS-mRNA
splicing and functional recovery of the PTPS protein.
Transcriptional profiling after 24hr posttransfection
revealed a dose- and sequence-specific recovery of normal
splicing. Furthermore, PTPS enzyme activity in all three
patients’ fibroblasts and the pterin profile were close to
normal values after antisense treatment. Our results
demonstrate proof-of-concept for pseudoexon exclusion
therapy using AMO in inherited metabolic disease.
Hum Mutat 32:1019–1027, 2011. & 2011
Wiley-Liss, Inc.
KEY WORDS: alternative splicing; antisense oligonucleo-
tides; pseudoexons; splicing therapy; tetrahydrobiopterin
deficiency
Introduction
Pseudoexon inclusion is emerging as a common disease-causing
mechanism in many human disorders. Most pathological pseu-
doexon inclusion events are originated from intronic mutations
creating a new 50 or 30 splice site followed by the subsequent
selection of weaker opportunistic acceptor or donor site sequences
[Dhir and Buratti, 2010]. In addition, other common mechanisms
for intronic insertion activation involve the creation/deletion of
splicing regulatory sequences or genomic rearrangements, that is,
gross deletions or genomic inversions. Many of these new exons in
our genome are transposable sequence elements derived from short
or long interspersed nuclear elements (SINEs or LINES, respec-
tively), with primarily SINE-Alu sequences as a prominent source of
new exons in the eukaryotic transcriptome [Vorechovsky, 2010].
Several examples of this pathogenic mechanism have been reported
in human genetic disorders such as cystic fibrosis, ataxia
telangiestasia, and several inherited metabolic disorders, including
organic acidemias, phosphomanomutase deficiency, and 6-pyru-
voyltetrahydropterin synthase deficiency [Perez et al., 2010].
Previously, we described two new disease-causing mutations that
improve the branch site of a LINE-2 element or the polypyrimidine
tract of an antisense Alu sequence in the PTS gene encoding
6-pyruvoyltetrahydropterin synthase (PTPS; MIM] 261640) [Meili
et al., 2009]. PTPS catalyzes the second reaction in the three-step
biosynthesis of tetrahydrobiopterin (BH4) from GTP and is encoded
by the PTS gene located in chromosome 11q22.3–q23.3. BH4 is the
natural cofactor for aromatic amino acid hydroxylases, nitric oxide
synthases, and glycerol ether monooxygenase [Werner et al., 2011].
The most common form of BH4 deficiency is due to the autosomal
recessive PTPS deficiency. Patients present with elevated levels of
neopterin, low levels of biopterin, hyperphenylalaninemia, and
monoamine neurotransmitter deficiency in the central nervous system
(CNS) [Tho¨ny and Blau, 2006]. Early diagnosis and treatment to
control hyperphenylalaninemia and also correction of neurotransmit-
ter deficiency in the CNS is associated with better outcome of the
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disease [Jaggi et al., 2008]. Oral administration of BH4 is effective to
control peripheral hyperphenylalaninemia, but BH4 passes ineffectively
through the blood–brain barrier. Thus, L-dopa and 5-hydroxytrypto-
phan, the precursors for the catecholamines and serotonin,
respectively, also have to be administrated to normalize monoamine
neurotransmitters in the CNS. Patients can have the typical/severe
form with hyperphenylalaninemia and abnormal CSF neurotransmit-
ters or the less common atypical/peripheral form with minor or no
changes in neurotransmitter levels and less significant or transient
hyperphenylalaninemia [Jaggi et al., 2008; Longo, 2009; Shintaku,
2002]. More than 64 different mutations have been reported to date
(HGMDs professional release 2010) associated with the severe or the
milder forms of PTPS deficiency [Tho¨ny and Blau, 2006]. Although
this treatment is effective in most cases, it is believed that alternative
strategies to improve the current life-long dependency from BH4 and
monoamine neurotransmitter precursors should be pursued.
Splice modulation therapy by manipulation of premessenger RNA
splicing is a promising therapy for genetic diseases [Wood et al., 2007].
Therapeutic strategies based on antisense oligonucleotide (AON)
chemistry have been employed in Duchenne muscular dystrophy
(DMD) to induce mutant exon skipping to avoid aberrant pseudoexon
inclusion [Wood et al., 2010]. Mutations causing exonization of deep
intronic sequences are more common than previously thought, and
antisense strategies have been employed to rescue the splicing process
[Dhir and Buratti, 2010; Perez et al., 2010]. AONs bind by
complementarity to the pre-mRNA, and steric hindrance, which
inhibits the recruitment of splicing factors to the targeted splicing cis-
elements, forces the spliceosomal machinery to use the natural splicing
sites [Wood et al., 2007]. Based on the pioneering work with antisense-
mediated modulation in the CTFR and b-globin genes [Friedman
et al., 1999a; Suwanmanee et al., 2002], several aberrant splicing
processes have been successfully restored in various cellular disease
models [Friedman et al., 1999b; Lacerra et al., 2000; Perez et al., 2009].
Some of these antisense approaches for splicing intervention have been
tested already in animal models [Alter et al., 2006], and a human
clinical phase III trial for DMD has been launched as well [Kinali et al.,
2009; van Deutekom et al., 2007]. The induction of skipping a specific
exon bearing a nonsense change in DMD in an attempt to rescue a
internally shorter but partially functional dystrophin, has been shown
to be promising and safe both in The Netherlands and the United
Kingdom [Aartsma-Rus et al., 2009].
This work aims at developing a cellular splice-modulation
antisense therapy to suppress pseudoexon activation in primary
dermal fibroblasts from PTPS-deficient patients who have been
identified with intronic mutations causing exonization. Whereas
two PTS mutations were reported before (c.84322A4T and
c.1631695_1631751del57; the latter originally reported as
c.163_164ins45) [Meili et al., 2009] we included identification
and functional analysis as well as ex vivo minigene assays of a new
intronic sequence variant (c.164712A4T), which activates
insertion of the antisense Alu exon located in intron 2. Although
antisense therapy using AMO for BH4-deficient patients with
intronic exonization mutations in the PTS gene is far from clinical
application, our results demonstrate proof of concept for
pseudoexon exclusion therapy in inherited metabolic disease.
Materials and Methods
Metabolic Analysis of PTPS-Deficient Patients
The study includes primary dermal fibroblasts from the three
PTPS patients: MD96, MD130, and MD335. MD96 with the mild
form, and MD130 with the severe form of PTPS deficiency were
described elsewhere [Meili et al., 2009] (with ID363 and ID503 in
the International Database of tetrahydrobiopterin deficiencies
BIODEF, http://www.bh4.org). Patient MD335 was identified
recently with the severe form of PTPS deficiency and had
an elevated blood Phe value (668 mmol/l), elevated neopterin
(50mmol/mol creatinin), and no detectable biopterin
(o0.01mmol/l) in urine, and PTPS enzyme activity of 0.22mU/mg
protein in primary dermal fibroblasts. Analysis of biogenic amines
in the cerebral spinal fluid (CSF) of patient MD335 (ID622 in
BIODEF) revealed very low homovanillic acid (56 nmol/l) and
5-hydroxyindolacetic acid (85.1 nmol/l; for reference values see
[Blau et al., 2002; Bonafe et al., 2001]).
Mutation Analysis of the PTS Gene
Mutation analysis was carried out with cDNA and genomic
DNA samples prepared from primary fibroblasts and/or whole
blood. Total RNAwas isolated using the RNeasy Mini Kit (Qiagen,
Chatsworth, CA) and the first-strand cDNA was synthesized with
the AMV Reverse Transcription System (Promega, Madison, WI)
and primer PTPS-53 (50-TTT CAA TAA ATA GGC ACT CC-30).
Amplification of the PTS cDNA was carried out with primers
PTPS-53 and PTPS-54 (50-ATG AGC ACG GAA GGT GGT G-30).
Primers and polymerase chain reaction (PCR) conditions for
amplification and DNA sequence analysis of exons 1–6 and intron
2 are available upon request. Mutation designation is according to
the official mutation nomenclature (http://www.hgvs.org/mutnomen/).
Reference accession numbers for normal alleles: L76259.1 for
human genomic DNA; M97655.1 for human cDNA (cDNA
numbering starts with 1 at A at the ATG start codon). To validate
nomenclature of mutations we used the program Mutalyzer 2.0
b-2 (http://www.mutalyzer.nl/2.0).
Patient MD96 was found to be homozygous for the nucleotide
change c.84322A4T (g.2666A4T), and MD130 is compound
heterozygous for the changes c.393delA (g.7901delA) and c.1631
695_1631751del57 (originally reported as c.163_164ins45;
g.3762_3818del57.
In primary dermal fibroblasts we found for MD96 an insertion of
a LINE2 sequence of 79 bp between exon 1 and 2 (r.83_84ins79).
Fibroblasts from MD130 presented a larger cDNA fragment
containing a 45-nucleotide insertion (r.163_164ins45) resulting
from a maternal deletion located 20nt upstream of an antisense Alu
sequence (c.1631695_1631751del57) [Meili et al., 2009]. Splice
scores of the natural and cryptic donor and acceptor sites were
determined using the analysis tools from Berkeley Drosophila
Genome Project (BDGP server: http://www.fruitfly.org/).
Transcriptional Profile and Ex Vivo Minigene Analysis
Splicing reporter plasmid encompassing PTS exons 2 to 4
(described in [Meili et al., 2009]) was used as a template. Mutation
c.164712A4T from patient MD335 was introduced with the
QuikChange II XL Kit (Agilent Technologies, Santa Clara, CA)
using primer 50-CCT CCC AGG TTC GTG CGA TTC TCC AGC-
30 and its reverse complement. Variant minigenes containing
mutations c.164714C4A and c.164715T4A were generated
by site-directed mutagenesis using primers 50-CTC CAC CTC
CCA GGT ACG AGC GAT TCT CC-30 and 50-CTC CAC CTC
CCA GGTACG TAG AGC GAT TCT CC-30, respectively, and their
reverse complement. COS-1 cells were transfected in triplicates
using 2.25-mg plasmid DNA and 8.5ml lipofectamine LTX
according to the manufacturer’s instructions (Invitrogen,
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Carlsbad, CA). Cells were harvested by trypsinization after 24 hr.
Total RNA was extracted using the QIAamp RNA Blood Mini Kit
(Qiagen, Hilden, Germany). RNA was reverse transcribed and
amplified using vector-specific primers PL3 (50-GGG AGA CCC
AAG CTG GCT A-30) and PL4b (50-AGT CGA GGC TGA TCA
GCG G-30) and OneStep RT-PCR Kit (Qiagen) with the following
cycling conditions: 30min at 501C, 15min at 951C, 40 cycles of
30 sec at 951C, 30 sec at 551C, 1min at 721C, followed by 10min at
721C. PCR products were separated on agarose and sequenced to
confirm their identity.
Antisense Morpholino Oligonucleotide Treatment
Patients and control dermal fibroblasts were cultured in MEM
containing 10% fetal bovine serum, 100U/ml penicillin, 100mg/ml
streptomycin, and 2mM glutamine. Cells were passaged by
trypsinization and studied at a passage number ranging from 6–23.
Cultures were kept at 371C in humidified air containing 5% CO2.
The 25-mer AMO were designed, synthesized, and purified by
Gene Tools (Philomath, OR) and were targeted to donor or
acceptor cryptic splice sites in the pre-mRNA. The sequences of
the three AMOs are: PTS-AMO1 50- AGT GCC TAC AAT GTA
ACA GGC AAG T-30, PTS-AMO2 50-AGG CTG GAG AAT CGC
TCG AAC CTG G-30, and PTS-AMO3 50-AGG CTG GAG AAT
CGC ACG AAC CTG G-30. As a negative control, a standard
25-mer Morpholino control oligonucleotide provided by Gene
Tools was used (50-CCT CTTACC TCA GTTACA ATT TATA-30).
As a delivery reagent, Endo-Porter was used following the
manufacturer’s recommendations as previously described (Gene
Tools; www.gene-tools.com) [Ugarte et al., 2007]. After transfec-
tion with 20 and 30 mM of the corresponding AMO, cells were
harvested at 24 hr and mRNA was isolated using the MagnaPure
system following the manufacturer’s protocol (Roche Applied
Sciences, Indianapolis, IN). The cell lines were incubated with
cycloheximide 0.75–1mg/ml 4–6 hr prior to cell harvest. For PCR
amplification of transcript from MD96 and MD130 cell lines
50-TAT GGA GGA GGC GAT TAT GC-30 and 50-TTT CAA TAA
ATA GGC ACT CC-30 were used as forward and reverse primer,
respectively. To exclude amplification from the allele bearing the
c.16312T4G mutation in the mRNA from MD335, a forward
specific primer located in the exon 1 and exon 2 junction was used
(50-CCG ATT GTA CAG TAA ATT TCT AA-30).
Different amounts of antisense Morpholinos, PTS-AMO1, and
PTS-AMO3, that were covalently linked to Vivo-Porter (also
supplied by Gene Tools) were added directly to the cultured
primary dermal fibroblast cells (VIVO-AMO1 and VIVO-AMO3).
Conventional RT-PCR for splice analysis was performed as
described above.
PTPS Activity, Pterin Quantification, and Protein
Immunodetection
The patients’ fibroblast cells were treated with 30mM of AMOs
during 48 and 72 hr, and the activity levels were determined as
described elsewhere [Bonafe et al., 2001]. To induce expression of
the GTPCH enzyme, a confluent cell monolayer in 75-cm2 plates
was stimulated with a cytokine cocktail containing 1,250U of
recombinant human interferon-g (IFN-g) and 500U of tumor
necrosis factor a (TNF-a), and incubated for 24–96 hr. At the same
time the cells were treated with 30mM of the corresponding AMO
and harvested 48, 72, and 96 hs after transfection. Cells grown for
96 hr were transfected twice with the AMOs. After incubation, cells
were harvested by trypsinization, counted to determine the cell
number, washed with phosphate-buffered saline, and kept at
701C until analyzed for neopterin and biopterin.
Cytokine-stimulated cells from a confluent 75-cm2 plate were
lysed in 150ml of lysis buffer (100mM Tris-HCl, pH 8.0, 2.5mM
EDTA, 300mM KCl, and 10% glycerin) by freezing and thawing six
times. Lysate was centrifuged at 15,000 g for 15min at 41C.
A volume of 100ml of supernatant was oxidized with 6ml of 1M
HCl and 20ml of a 10 g/l iodine solution for 30min at room
temperature in the dark. The remaining supernatant was used for
determination of protein concentration using the Bradford reagent
(Bio-Rad, Munich, Germany). The oxidation reaction was stopped
by the addition of 20ml of 10 g/l ascorbic acid (freshly prepared). To
adjust the pH to 8.0–9.0, 10ml of dephosphorylation buffer (1M
Tris-HCl pH 9.6 containing 80mM MgCl2) was added to the
sample with alkaline phosphatase (20U) to desphosphorylate the
neopterin triphosphate. The sample was incubated at 371C for
60min. The reaction was stopped by acidification to pH 2.0 with
7ml of 2M HCl. The sample was deproteinized using a low protein
binding centrifugal filter (VWR, West Chester, PA) and analyzed by
high-performance liquid chromatography (HPLC). The intracellu-
lar concentrations of neopterin and biopterin after cytokine
stimulation are expressed as pmol per mg of protein [Bonafe
et al., 2001; Werner et al., 1996].
For Western blot analysis patient’s fibroblasts from one
confluent 75-cm2 plate were treated with the corresponding
AMO. After 48 hr cells were harvested by trypsinization and
protein concentration was determined using the Bradford reagent
(Bio-Rad, Munich, Germany). Equal amounts of protein crude
extracts were loaded on a 4–12% NuPAGEs Novexs Bis-Tris
precast gel (Invitrogen, Carlsbad, CA). After electrophoresis,
proteins were transferred to a nitrocellulose membrane (iBlots
Gel Transfer Stacks, Regular) in an iBlots Gel transfer device
(Invitrogen) for 7min. Poinceau staining was used to monitor
equal loading of protein. Immunodetection was carried out using
antihuman PTPS polyclonal antibody SZ28 (1:500 diluted)
[Elzaouk et al., 2004] followed by a second antibody (conjugated
goat antirabbit IgG horseradish peroxidase, diluted 1:10,000;
Santa Cruz Biotechnology Inc., Santa Cruz, CA). The detection
was made using the Enhanced Chemiluminescence System (GE
Healthcare, Buckinghamshire, UK).
Results
Identification of a Novel Exonization Mutation Leading to
Inclusion of the Antisense Alu Sequence in Intron 2 of the
PTS Gene
Patient MD335 was identified by newborn screening for
hyperphenylalaninemia and later diagnosed for the severe form
of PTPS deficiency based on urinary pterins, monoamine
neurotransmitter deficiency in CSF, and PTPS enzyme activity
in primary fibroblasts (see also Materials and Methods; ID622 in
BIODEF, http://www.bh4.org). Subsequent fibroblast-cDNA and
genomic DNA analyses revealed two compound heterozygous
mutations in the PTS gene intron 2, a T4G transversion at c.163
12T4G (g.3069T74G), and an A4T transversion at position
c.164712A4T (g.3887A4T). The transcriptional profile in
primary dermal fibroblasts from patient MD335 and his parents
is shown in Figure 1A. The intronic c.16312T4G mutation,
which was inherited from the mother (MD336), is located in the
50 splice site of intron 2 (IVS212T4G) and generates three
distinct shorter PTS-mRNA transcripts or cDNA-fragments
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corresponding to skipping of exon 2, exons 2–3, and exons 2–4.
The deep intronic mutation c.164712A4T, inherited from the
father (MD337), was identified based on computation methods to
be located in the ‘‘putative exonic splicing silencer’’ site, or PESS,
50 from the antisense Alu sequence in intron 2 of the PTS gene
[Meili et al., 2009]. As shown below, this intronic A4T
transversion leads to the inclusion of a similar antisense Alu
exon, which was retained in the PTS-mRNA from patient MD130.
However, in MD335 we found besides the known 45-nt
pseudoexon, a longer 70-nt fragment, that is, the 45-nt fragment
from MD130 extended at the 50 side by 25 nt. The 30 splice
acceptor site contains at least two conserved 30 AG dinucleotides,
the more upstream being the predicted ‘‘natural’’ Alu exon and
70-nt downstream the corresponding 50 GT splice site, which is
identical to the pseudoexon 50 site in MD130 [Meili et al., 2009].
Using minigene assays with COS1 cells that were transfected with
corresponding splicing reporter plasmids, the c.164712A4T
mutation is responsible for exonization and inclusion of primarily
the 70 nt antisense Alu sequence (see Fig. 1B).
In the following, the 50 GT splice site was analyzed in more
detail, as mutation c.164712A4T located in a putative splicing
silencer element might effect at the same time complementarity to
U1 snRNA, and it was reported that extensive complementarity to
U1 snRNA exerts to some extend a dominant effect for 50 splice
site selection [Roca et al., 2005]. A schematic representation of
base pairing between the 50 splice site of the pseudoexon and the
U1 sequence is shown in Figure 2A. In an attempt to address this
point and by taking into account that the 50 splice site motif
consists of nine partially conserved nucleotides at the exon–intron
boundary, the last three nucleotides of the upstream exon and the
first six nucleotides of the intron, we tested the two additional
mutations c.164714C4A and c.164715T4A in our minigene
assay. As shown in Figure 2B, mutation c.164–715T4A appeared
to be even more efficient in splicing of the 70-bp pseudoexon
compared to mutation c.164712A4T. On the other hand, the
minigene construct containing the c.164714C4A alteration was
similar to the wild-type control and did not lead to pseudoexon
inclusion. In addition, a shorter band corresponding to insertion
of the 45-bp pseudoexon was weakly detectable also for construct
c.164715T4A. In conclusion, changing positions 13 or 16
downstream of the pseudoexon not only improved complemen-
tary to U1 snRNA but also strengthened the 50 splice site.
Reversion of the Splicing Defect and Restoration of PTPS
Enzymatic Activity Using Antisense Therapy
In the following, we investigated three deep intronic changes
c.84322A4T, c.1631695_1631751del57, and c.164712A4T,
which are responsible for splicing defects and exonization in the
PTS gene found in patients MD96, MD130, and MD335,
respectively. Whereas the heterozygous mutation c.164712A4T
in patient MD335 was newly identified (plus mutation c.1631
2T4G), the homozygous c.84322A4T transversion in MD96
and the heterozygous deletion c.1631695_1631751del57 in
Figure 1. Transcriptional profiling of fibroblasts derived from patient MD335 and functional analysis of the splicing mutation c.164712A4T
using a minigene assay. A: RT-PCR pattern and subsequent sequence analysis of the amplified products obtained from patient’s fibroblast.
Individual bands were validated by DNA sequence analysis. As shown from analyzing the parents’ expression profile for the PTS-mRNA, the two
larger bands correspond to the insertion of the longer (70 nt) or shorter (45 nt) version of the antisense Alu sequence using the identical 50 splice
donor, but two different 30 splice acceptor sites (for details, see also [Meili et al., 2009]). The paternal mutation c.164712A4T was identified
based on computation methods to be located in the ‘‘putative exonic splicing silencer,’’ or PESS, 50 from the antisense Alu sequence in intron 2
of the PTS gene. The shorter bands correspond to skipping of different exons due to the maternal mutation c.16312T4G, located in the 50 splice
site of intron 2. B: Result of the ex vivo splicing assay for minigene constructs with wild-type and the corresponding c.164712A4T mutation
from patient MD355. The A4T transversion produces in the minigene vector produces in our assay an additional and very prominent upper
band, which turns out to contain the 70-bp antisense Alu sequence with or without exon 3. Furthermore, we could not rule out that a low
percentage of this upper band contained in addition the shorter 45-bp version of the antisense Alu fragment. [Color figures can be viewed in the
online issue, which is available at www.wiley.com/humanmutation.]
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MD130 (plus c.393delA) were described previously, and lead to the
insertion of a LINE-2 element in exon 1 and exonization of a
shortened, 45-nt version, of the antisense Alu sequence in exon 2,
respectively [Meili et al., 2009]. To determine if either the pathological
insertions of a LINE-2 fragment in MD96, or the two variants of the
antisense Alu in MD130 and MD335 can be suppressed to rescue
PTPS activity in patients’ fibroblasts, the possibility of redirecting
transcript processing by AMOs was explored. AMOs were targeted to
the 30 (PTS-AMO1) and 50 cryptic splice sites (PTS-AMO2 and PTS-
AMO3) to block access of the splicing machinery to the
pseudoexonic regions in the pre-mRNA. Because the mutation
c.164712A4T in MD335 leads to the use of the same 50 splice
donor site as for the mutation c.1631695_1631751del57 in MD130,
the same AMO was used for treatment (PTS-AMO2). Fibroblasts
were transfected with two different concentrations of AMOs 20 and
30mM for a 24-hr period, followed by transcriptional profiling
analysis. The results showed that the splicing process was restored in
all three cases (Fig. 3), even when MD335 fibroblasts were transfected
with AMO2 (MD130), which differ in a single nucleotide (data not
shown). Correctly spliced mRNA was obtained 24hr after transfec-
tion in a dose-dependent fashion. In all three cases, the upper band
containing the intronic insertion disappeared even though the cells
were cultured with cycloheximide to avoid mRNA degradation. The
identity of the cDNA fragments obtained was confirmed by sequence
analysis, and for MD130 we were able to confirm the presence of
mutation c.393delA in heterozygous state after AMO treatment.
When all three patient cells were transfected with a scrambled
morpholino, the splicing process did neither influence nor rescue the
erroneous splicing pattern (see Supp. Fig. S1).
A recent development of a new transporter structure that is
thought to provide effective in vivo delivery of morpholino
antisense oligomers into a wide variety of tissues are the Vivo-
Morpholino complexes, conjugates of an octa-guanidine dendri-
mer covalently linked to the morpholino oligo [Li and Morcos,
2008]. In a set of parallel experiments we wanted to test such
Vivo-Morpholinos to confirm whether the splicing correction is
comparable to AMO treatment under cell culture conditions. As
shown in Figure 4, the AMO transporter-conjugates VIVO-AMO1
and VIVO-AMO3 corrected the erroneous splicing in MD96 and
MD335 cells, respectively. Due to the poor growth behavior of the
primary dermal fibroblasts from MD130, we were not able to
include results from this patient. In conclusion, we found no
significant differences under cell culture conditions between the
use of AMO and the transporter-conjugated Vivo-Morpholinos as
the delivery reagent.
To test whether suppression of missplicing resulted not only in
the production of a normal PTS-mRNA, but also in functional
PTPS protein, we analyzed enzyme activity and recovery of the
pterin profile. Patients’ fibroblasts were treated with 30mM of
AMO during 48 and 72 hr, and activity levels were determined. As
shown in Figure 5A, PTPS activity was rescued in all three
fibroblast cell lines after AMO treatment for 48 and 72 hr. We
observed recovery of the activity in the range of normal levels for
primary dermal fibroblasts, which is between 0.4 and 1.6 mU/mg
[Bonafe et al., 2001]. Although PTPS activity increased to control
levels 48 hr after transfection, enzyme activities in all three cases
were somewhat lowered 72 hr after treatment (Fig. 5A). Using the
specific antibody SZ28 against PTPS protein [Elzaouk et al., 2004],
Figure 2. Result of the ex vivo splicing in the minigene assay using constructs with wild-type sequences, the mutation c.164712A4T from
patient MD355, and the changes c.164714C4A and c.164715T4A. A: Schematic representation of base pairing between the 50 splice site of
the pseudoexon and the U1 snRNA sequence, plus the different minigene constructions tested. The 50 splice motive consists of nine partially
conserved nucleotides at the exon–inton boundary, and differences between the PTS gene sequence and the ‘‘perfect match’’ to the U1
sequence are underlined; also underlined and in red/gray are the changes to match the ‘‘perfect’’ sequence. B: RT-PCR profile of the ex vivo
splicing assay from the different minigene constructs. The mutations c.164712A4T and c.164715T4A produced in our assay an additional
and very prominent upper band, which turns out to contain the 70-bp antisense Alu sequence with or without exon 3. Construct c.164715T4A
generated a shorter but very faint band corresponding the 45 bp pseudoexon. [Color figures can be viewed in the online issue, which is available
at www.wiley.com/humanmutation.]
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we were able to detect protein recovery in all three primary
patients’ cells after 48 hr of treatment in (Fig. 5B).
Quantification of pterin levels in the patients’ fibroblasts was
performed after cells were treated with 30 mM of the correspond-
ing AMO. Because GTPCH is not expressed in dermal fibroblasts
but can be induced upon cotreatment with TNF-a and INF-g,
AMO therapy was done simultaneously with cytokine stimulation
[Bonafe et al., 2001]. After 48, 72, or 96 hr of in the presence of the
AMOs, neopterin levels decreased and biopterin increased to
variable degrees, depending on the cell line, but all fibroblast cells
normalized their pterin profile in a time and cell-dependent
manner (Table 1). The best recovery was obtained in cells from
patient MD96 after 96 hr posttreatment and following two
consecutive transfections. As mentioned above, MD96 is homo-
zygous for the splicing mutation, whereas MD130 and MD335 are
both carrying a second mutant allele that cannot be corrected by
the pseudoexon exclusion approach. Therefore, it is not
unexpected the AMO correction of cells from MD96 resulted in
a better recovery due to this dosage effect.
Discussion
Extensive RNA-based diagnosing in addition to genomic DNA
mutation analysis of human genetic disorders allows identification
of several deep intronic mutations that may cause splicing
mutations including exonization of pseudoexon sequences. In
addition, treating patient’s cells with nonsense-mediated mRNA
decay (NMD) inhibitors and subsequent transcript profiling
analysis allows comprehensive diagnosis and identification of
these elusive mutations. Such a strategy not only improves genetic
diagnosis but may also provide the rationale to tailor a specific
genetic treatment.
Figure 3. Splicing therapy using antisense AMOs to avoid pseudoexon inclusion in primary dermal fibroblast from PTPS-deficient patients. The
left panels show the schematics of the splicing patterns with the regions of the PTS gene where the splicing mutations were found in patients MD96,
MD130, and MD335. The numbers indicate the splicing scores calculated with BDGP software (http://www.fruitfly.org/). The sequence of the three
different AMOs used are depicted. The right panels show transcriptional profiling analyses by conventional RT-PCR of fibroblasts derived from
patients MD96, MD130, and MD335, treated (20 and 30mM) or untreated (0mM) with the corresponding AMOs (PTS-AMO1, PTS-AMO2, PTS-AMO3).
Figure 4. RT-PCR pattern of fibroblasts derived from patients MD96 (A)
and MD335 (B) untreated (0mM) and treated (20mM and 30mM) with two
different concentrations of Vivo-Morpholinos (VIVO-AMOs). To identify the
PCR fragments indicated, DNA sequence analysis was performed.
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Transposable sequences are prone to have nucleotide changes
activating the creation of new exons in the genome [Vorechovsky,
2010]. These sequences in addition to playing an essential role in
gene evolution are associated to Mendelian diseases, and to date,
several examples have been described with pathological effect
[Dhir and Buratti, 2010]. In the PTS gene two different changes
have been reported previously [Meili et al., 2009], and herein we
present one additional case of pseudoexon inclusion in intron 2.
All three mutations, which are deep intronic DNA alterations,
activate the insertion of transposable elements present in the PTS
gene, an antisense Alu sequence in exon 2 or a LINE-2 in exon 1.
Knowing that pseudoexon sequences are present in an intron, one
should take into account that deep intronic alterations in such a
region have the potential to be pathogenic mutations, and they
must be included in the genetic diagnosis of the disease.
An interesting observation of the mutation analysis is the
identification of two different deep intronic mutations, c.1631
695_1631751del57 (MD130) and c.164712A4T (MD335),
resulting in exonization of the same peudoexon but with different
30 splice sites, resulting in inclusion of either a 45- or 70-bp
fragment. As discussed before, the deletion mutation introduced a
favorable branch point sequence in the optimal distance from the
pseudoexon 30 splice site, and at the same time removed an
upstream AG dinucleotide required for the 30 splice site repression
on normal alleles [Meili et al., 2009]. Furthermore, this intronic
deletion lacks the most upstream pseudoexon 30 splice site, thus
Table 1. Neopterin and Biopterin Levels in Antisense AMO-Treated Fibroblasts Derived from Three Different PTPS-Deficient
Patients
Patient
Time of
treatment (hr)
Neopterin
(pmol/mg)
Biopterin
(pmol/mg)
Neopterin fold
activation
Biopterin fold
activation N/B ratio
MD-96 0 281.16 0.40 – – 703
48 75.88 14.17 3.71 35.05 5.35
72 57.84 32.91 1.31 2.32 1.76
96 15.61 26.86 3.71 0.82 0.58
MD-130a 0 378.23 0.51 – – 741.60
48 243.32 5.53 1.55 10.84 44.00
MD-335 0 235.37 1.48 – – 159.49
48 123.23 8.98 1.91 6.09 13.72
72 38.46 9.52 3.20 1.06 4.04
96 6.50 2.09 5.92 0.22 3.12
Controlb 48–72 11.42 45.85 – – 0.25
Patient (U)c Untreated 45 nmol/l 0 nmol/l – – –
Treated 34 nmol/l 25 nmol/l – – 1.36
aThe assay was performed only 48 hr posttransfection due to the poor growth behavior of the primary fibroblasts.
bNeopterin and biopterin in control fibroblasts.
cNeopterin and biopterin in patient’s urine before and 24 hr after an oral loading test with 20mg/kg synthetic BH4. Neopterin and biopterin in control urine are 5–22mmol/l
and 4–10mmol/l, respectively; ratio 1.25–2.2 [Blau et al., 2003].
Figure 5. Restoration of PTPS enzyme activity and protein expression in primary patients’ fibroblasts. A: Functional correction of PTPS
activity after treatment. The activity was assayed in primary dermal fibroblasts derived from a healthy control subject and from patients MD96,
MD130, and MD335, treated for 48 or 72 hr. B: PTPS protein expression in control and in MD96, MD130, and MD335-derived fibroblasts treated
(30 mM) or untreated with corresponding AMOs.
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leading to the shorter 45-bp pseudoexon insertion. A different
mechanism is responsible for exoniziation of the same AluSq
sequence by the intronic mutation c.164712A4T. Here a change
at position 16, but also at position 13 as shown by in vitro
minigene assay with mutation c.164715T4A, seems to strength-
en the pseudoexon 50 splice site, thus improving complementarity
to U1 snRNA (see Fig. 2). Both mutations, c.164712A4T and
c.164715T4A, predominantly activate the inclusion of the 70-bp
pseudoexon and to a much lesser extent inclusion of the 45-bp
pseudoexon even though this internal 30 splice site has a higher
splice score than the selected one. It is clear that the consensus
motifs are by themselves insufficient to completely define the splice
site, and other parameters such as splicing regulatory-elements
may modulate the alternative splicing process, determining which
30 splice site should be used [Andresen and Krainer, 2009].
Considering the increasing knowledge at the molecular level of
the diseases, treatment is moving toward an increasing personalized
therapy. It is well known that this kind of mutation represents an
excellent example for mutation-specific therapies. Recently, anti-
sense therapy has been applied successfully in several inherited
metabolic disease cellular models [Dhir and Buratti, 2010; Perez
et al., 2010] and in view of this, we report new examples of
successful rescue of an aberrant splicing process by pseudoexon
insertions. Specifically, we could demonstrate in cells derived from
three individual PTPS deficient patients carrying three different
mutations that two short antisense oligonucleotides can suppress
the aberrant splicing process of the PTS pre-mRNA. Moreover,
normal mRNA processing and recovery of the PTPS enzyme
activity was achieved. Although the amount of PTPS protein was
not comparable to control levels based on Western blot quantifica-
tion, enzyme activity was in the normal range even for the
compound heterozygous PTPS-deficient cells from MD335 and
MD130. In any case, the results suggest that moderate increases in
PTPS enzyme are sufficient to achieve a therapeutic effect in a
recessive disorder, as has been described in other genetic disorders
such as methylmalonic aciduria, propionic acidemia, and phos-
phomannomutase deficiency [Perez et al., 2009; Ugarte et al., 2007;
Vega et al., 2009]. This finding has also been described in the PCCA
knock-out animal model treated with a liver-specific transgene,
which allowed prolonged survival of the animal even though PCCA
protein activity was rather low [Miyazaki et al., 2001].
The recovery appears to be sequence-, dose-, as well as cell-
specific. The fact that pterin levels after treatment are different in
the three individual primary dermal fibroblasts may reflect subtle
variations in the levels of pseudoexon insertion and could also
contribute to patient’s phenotype. It can be envisaged that some
levels of normal transcript might exist depending on the deep
intronic mutations as described in patient MD96 [Meili et al.,
2009], but also for other disorders [Gurvich et al., 2008], resulting
in a milder phenotype. It is worth noting that the best functional
recovery was obtained after extended treatment for 96 hr in either
cell derived from MD96 and from MD335, whereas the result
obtained in the severely effected patient MD130-derived cells was
less efficient. In any case, in all three PTPS fibroblasts, the
neopterin/biopterin ratio was improved significantly, even though
the pterin profile was not completely normalized.
All functional results presented here establish a proof of
principle for the application of AMO treatment in the PTPS-
affected patients as has been demonstrated in other inherited
metabolic disorders [Perez et al., 2010]. In any case, the clinical
exploitation of antisense therapy as well as interfering-based
therapies will depend on safe and effective in vivo delivery to
target tissue that should be assayed using animal models, such as
mice or zebra fish, to check the biodistribution of antisense
oligonucleotides [Alter et al., 2006; Madsen et al., 2008]. An
Interesting approach would also be the generation of induced
pluripotent stem (iPS) cells as they will provide a valuable
experimental platform with potential value for cell therapy
application [Raya et al., 2009].
In addition to all other complications in developing a new drug,
within neurological disorders one must consider the blood–brain
barrier (BBB). Interesting, attempts to cross the barrier by large
polar structures have been reported with successful recovery of the
function assessed [Aouadi et al., 2009; Ivanova et al., 2008; Kumar
et al., 2007]. Using polymeric nanoparticles, as has been used in
the present studies and also in Li and Morcos [2008], cell-
penetrating peptides, or PEGylated immunoliposomes [Pardridge,
2010] to encapsulate the nucleic acid cargo, a modest delivery of
siRNA into the adult mice brain [Li and Morcos, 2008] has been
achieved as well as phosphorothiolate oligonucleotide by intrave-
nous administration in an Alzheimer’s model [Banks, 2008; Banks
et al., 2001]. These encouraging results should stimulate
investigations on the development of a safe and effective vehicle
to deliver antisense therapeutic molecules.
In conclusion, this work represents an example of a genetic
splicing disorder with the potential to be treated with antisense
therapy. Furthermore, the future novel methods—such as, for
instance, the use of Vivo-Morpholinos, which show great promise
for optimal delivery of antisense drugs to the brain or other
organs—should be investigated in an attempt to improve splice
correction therapy for a broad range of genetic disorders.
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